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ABSTRACT OF THE DISSERTATION 
The Role of RNA Interference in the Control of  
Leishmania RNA virus 1 Infection 
By 
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Doctor of Philosophy in Biology and Biomedical Sciences 
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Washington University in St. Louis, 2017 
Professor Stephen M Beverley, Chair 
 
The presence of Leishmania RNA virus 1 (LRV1) in parasites of the Leishmania (Viannia) 
subgenus increases the virulence of the parasite in mouse models of leishmaniasis and is 
correlated with treatment failure, relapse, and the development of mucocutaneous disease in 
humans. LRV1 is not shed or infectious; rather, the infection is persistent, and as yet it is 
unknown how the parasite controls virus levels. Many eukaryotic organisms use RNA 
interference (RNAi) to limit virus replication, and Leishmania (Viannia) parasites have an active 
RNAi pathway. To determine whether Leishmania are capable of using RNAi to control LRV1, 
we sequenced sRNAs from LRV1-containing L. braziliensis and L. guyanensis and found that 
these cells have abundant LRV1-derived sRNAs. Further, I targeted LRV1 using an RNAi 
transgene in these species, which resulted in a loss of virus. Together, these data suggest that 
RNAi can limit LRV1 replication. In contrast, knockout of the RNAi effector protein gene 
Argonaute1 resulted in only a small increase in LRV1 levels, as opposed to the expected 
dramatic increase. While we did not find evidence of a role for Dicer1/2 or Piwi in control of 
xiii 
 
LRV1, we cannot rule out that such a role exists. These studies suggest that RNAi may play a 
role in control of LRV1, but that other mechanisms may contribute more or be redundant. In 
addition to these studies, I also developed a new genetic tool for the manipulation of Leishmania 
in the laboratory. These “popout constructs” use GFP expression to facilitate the removal of the 
construct after it has been integrated into the parasite genome, and will allow short-term 
expression of genes and RNAi transgenes in Leishmania (Viannia) species. Finally, I present 
investigations into the effect of RNAi transgenes on parasite biology and virulence. I found that 
the presence of an RNAi transgene impairs knockdown of an unrelated target, results in an 
accumulation of stable dsRNA and transposable element transcripts, and may increase parasite 
virulence. These findings suggest that caution is warranted when using these constructs. 
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Chapter 1: Introduction 
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Preface 
The first draft of this chapter was written by EAB. Comments from SMB were incorporated into 
the final version, presented here. 
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1.1 – Leishmaniasis: a global health threat 
Leishmaniasis is a group of diseases caused by the protozoan parasite Leishmania and 
spread by sand flies that occurs in tropical and sub-tropical regions around the world (1), with 
nearly a billion (2) to 1.7 billion (1) people at risk for infection. Official figures compiled by the 
World Health Organization total nearly 300,000 new infections every year and 20,000-40,000 
deaths (3). Underreporting is rampant, however, and true case numbers are likely to be much 
higher (3, 4). Further, large numbers of asymptomatic infections go unrecognized and untreated 
(5, 6). While strategies such as indoor spraying and insecticide-treated bed nets show promise in 
limiting cases of leishmaniasis (7, 8), they require a high rate of compliance (9), and resistance 
of the sand flies to insecticides is increasing (10). Situations of mass displacement, such as the 
civil war in Sudan and current Syrian refugee crisis, frequently result in outbreaks of 
leishmaniasis (11), sometimes with huge loss of life (12). Infections are likely to increase in the 
future as urban sprawl and deforestation increase contact of people to infected sand flies (13–15). 
Further, climate change is likely to increase the range of the sand fly vector and reservoir hosts 
into areas that previously had no known transmission (16), including the United States (17). 
Indeed, while cases are still rare, there are increasing reports of autochthonous transmission of 
leishmaniasis in Texas and Oklahoma (18).  
Leishmaniasis has three main disease phenotypes, which correlate largely with infecting 
species. In the relatively mild cutaneous disease (CL), ulcerating skin lesions ultimately heal, 
leaving significant scarring. In mucocutaneous disease (MCL), parasites metastasize to and cause 
destruction of the mucous membranes of the nose, throat, and mouth (19). MCL can occur 
simultaneously with a cutaneous lesion, or can present years to decades later, even after 
apparently-successful treatment of the cutaneous lesion (20). In both CL and MCL, the resulting 
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disfigurement can have substantial social repercussions (21). In visceral disease, parasites 
metastasize to the lymphatic and vascular systems and cause hepatosplenomegaly, anemia, and 
ultimately death when left untreated (22). 
While attempts to create a vaccine to prevent leishmaniasis are underway (23, 24), there 
is not one currently available. Chemotherapies for the treatment of leishmaniasis leave much to 
be desired: they are expensive, cannot be delivered orally, have significant toxicities, and/or 
require cold storage, all of which serve to limit their usefulness in the healthcare settings where 
they are most needed (reviewed in (25–27)). Additionally, more severe cases of MCL appear to 
be refractory to standard treatment (20), and recurrence is common (28). As metastasis of 
parasites from the site of the sand fly bite is required for the progression to MCL, it is possible 
that prevention of metastasis could improve cure rates and prevent the necessity of further or 
more intense treatment regimens. 
1.2 – Leishmania life cycle and infection of the mammalian host 
Leishmania parasites are digenetic, with cycles of replication in two hosts: the sand fly 
midgut and the mammalian macrophage. When a sand fly bites an infected mammal, parasites 
are ingested with the bloodmeal and differentiate into the replicative procyclic promastigote 
stage (reviewed in (29, 30)). Over time, these differentiate into non-dividing, infectious 
metacyclic promastigotes. When the infected sand fly bites another mammal, the metacyclic 
promastigotes are regurgitated into the wound (31). They are phagocytosed by endocytic 
immune cells such as macrophages, neutrophils, and dendritic cells, where they differentiate into 
the amastigote stage, replicate within the phagolysosome, and infect neighboring cells (32, 33). 
The mammalian host immune response to Leishmania infection plays a large role in 
disease progression and parasite clearance. For example, increasing levels of TNF-α and IFN-γ 
5 
 
production are correlated with increasing disease severity. Patients with subclinical infections 
have very low IFN-γ and TNF-α production compared to patients with CL disease (34), while 
patients with MCL have elevated levels of these cytokines compared to patients with CL. 
Modulation of this response could serve as a therapeutic tool for the treatment of leishmaniasis 
or the prevention of disease progression to MCL. One parasite factor that modulates the host 
immune response is Leishmania RNA virus, which will be explored in further detail through this 
work. 
1.3 – Viruses of microbes – Leishmania RNA virus and the Totiviridae 
Leishmania parasites can be infected with a virus of the Totiviridae family, Leishmania 
RNA virus (LRV) (35). Within the Leishmaniavirus genus, LRV1 occurs in New World parasites 
of the Leishmania (Viannia) subgenus (36–38), including L. braziliensis and L. guyanensis, 
while LRV2 occurs in Old World Leishmania (Leishmania) parasites (39–41), including L. 
major and L. aethiopica. This work will focus on LRV1 infecting L. braziliensis and L. 
guyanensis.  
LRV1 consists of a dsRNA genome (42) approximately 5.3 kb in length that encodes 
only two proteins, a capsid protein and an RNA-dependent RNA polymerase (RDRP), in 
overlapping open reading frames (43). It is located in the parasite cytoplasm (35) and assembles 
into ~30nm viral particles that can be purified by sucrose (35) or CsCl (44) gradient . A related 
virus from the family Totiviridae found in Saccharomyces cerevisiae, L-A virus, is the type 
species of the Totiviridae family, and has been characterized much more extensively than has 
LRV.  Due to the similarities between the two, it is assumed that the replication cycle of LRV 
matches that of L-A (reviewed in (45)) (Figure 1). Where direct evidence exists for LRV, I have 
noted it. Briefly, the RDRP transcribes a plus-strand transcript from the dsRNA genome 
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contained within the capsid and extrudes it into the cytoplasm (42, 46), where its genes are 
translated by host translational machinery. This single transcript encodes both the capsid and 
RDRP, and the RDRP is likely translated via frameshift as a fusion protein (39, 43, 47). Finally, 
the plus-strand transcript is encapsidated (48, 49) and used by the RDRP as a template for 
synthesis of the minus-strand (42), regenerating the dsRNA genome. Importantly, the dsRNA 
genome remains enclosed within and protected by the protein capsid, and only (+)-strand mRNA 
is exposed to the contents of the cytoplasm. 
Like most viruses of the Totiviridae family, LRV is not shed in culture, nor are viral 
particles infectious (48). Only a select few viruses of this family, such as Giardiavirus (50) and 
piscine myocarditis virus (51) have extracellular routes of infection. Fungal totiviruses, such as 
L-A, can be transmitted by cytoplasmic fusion, as during mating (52). Leishmania genetic 
exchange can occur at low frequency during sand fly passage (53, 54). Crosses done in 
collaboration with David Sacks between L. major strains 5-ASKH (containing LRV2) and Sd 
resulted in hybrid progeny containing LRV2, suggesting that LRV2 can likewise be transmitted 
by mating (Owens, Lye, Inbar, Akopyants, Sacks, Beverley, unpublished data). Attempts to 
super-infect parasites with LRV1 or to introduce LRV1 into parasites not naturally containing 
the virus, however, have not produced persistent virus infections (48, 55). Prior to this work, 
there had been one report in the literature of loss of LRV1 from an infected L. guyanensis strain 
(56); however, the mechanism by which this occurred is unclear, and it could not be replicated 
by the same or other laboratories. Because LRV1 cannot be introduced into uninfected parasites, 
and cannot be reliably “cured” from strains that contain it, research on its biological effects has 
relied on either non-isogenic, naturally-occurring isolates or on the single isogenic L. guyanensis 
strain that arose cryptically. The field would benefit from a reliable method with which to 
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generate LRV1+ lines from an LRV-negative strain, or LRV-negative lines from a strain 
containing LRV1.  I address this topic in Chapter 2 of this dissertation. 
1.4 – The role of LRV1 in parasite biology & virulence 
Despite its long history in the literature, very little was known about the effect of LRV1 
on parasite biology. Recently, it has become clear that LRV affects the pathogenesis of 
Leishmania, and therefore has large implications for human disease. Much of the mechanistic 
work has been done in mouse models of infection using the single isogenic pair of L. guyanensis 
lines. Experiments were either in vitro infections of murine bone marrow-derived macrophages 
or in vivo injection of parasites into hind footpad of mice.  
L. guyanensis parasites that contain LRV1 produce larger lesions with higher parasite 
burdens than do LR1-negative strains in WT C57BL/6 mice (57). Similarly, LRV1+ parasites 
induce higher pathology and parasite burden in IFN-γ knockout mice, and metastasize earlier in 
the course of infection than do LRV1-negative parasites (58). LRV1+ parasites also stimulate the 
release of a number of proinflammatory cytokines, including TNF-α, CXCL-10, IL-6 (57), and 
IL-17A (58). Recent work by Eren et al. found that the presence of LRV1 induced the expression 
of miR155, which led to phosphorylation of Akt and promoted the survival of macrophages (59). 
The induction of cytokine release, miR155 expression, and Akt phosphorylation all depended on 
Toll-like receptor 3 (TLR3) in the mouse (57–59), which senses dsRNA. Induction of miR155 
appears to occur via a separate downstream pathway than the LRV1-induced hyperinflammatory 
response, however, as ΔmiR155 macrophages display a cytokine profile similar to that of WT 
macrophages upon infection with LRV1+ parasites (59). These findings provide direct 
mechanistic links between LRV1 and increased virulence of the LRV1-containing parasites.  
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Research into the implications of LRV on human disease relies on correlative 
associations in clinical samples. The impact of LRV1 on the progression of disease to MCL is 
not black-and-white, as many factors, both in the parasite and in the human host, contribute to 
metastasis (60). In some regions, MCL is relatively common, but LRV is absent (61, 62); in 
these cases, MCL is clearly triggered by other factors. Surveys in other regions have given 
conflicting results, with one finding no correlation between the presence of LRV1 and MCL 
(63), and another finding LRV1 in a higher percentage of cases of MCL than cases of CL (64). 
Consistently, though, studies have found that the presence of LRV1 correlates with treatment 
failure (63, 65) and relapse (65). Some of these correlative studies show similar immune 
responses to LRV1 in patients as were seen in mice. In one study, patients infected with LRV1+ 
L. guyanensis had higher levels of IL-17A and lower IFN- γ in lesion tissue than patients 
infected with LRV1-negative L. guyanensis, as occurred in mice (59). In another, patients 
infected with LRV1+ L. guyanensis had higher levels of intralesional cytokines (65), including 
IL-6 and CXCL-10. 
While the role of LRV1 in promoting MCL disease in humans is unclear, the evidence 
from mouse studies supporting LRV1’s effect on parasite virulence is strong, and has real-world 
implications for the treatment of leishmaniasis. There are a number of open questions on the 
subject, however, that could improve patient treatment. First, we need a diagnostic tool that can 
identify LRV1 in patient samples at high accuracy and low cost. This would enable us to identify 
patients that might be at high risk of treatment failure, relapse, or metastasis. Second, we need to 
understand the mechanisms by which LRV1 is maintained within LRV1. By understanding these 
mechanisms, we may be able to develop ways to eliminate the virus from the infection and 
improve treatment outcomes. Third, we need drug treatment regimens that are optimized for 
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infections containing LRV1. This would decrease the incidence of treatment failure and relapse, 
and improve quality of life for affected patients. This work focuses on the second need, 
understanding the mechanisms by which LRV1 is maintained, and uses as its basis an antiviral 
mechanism common within eukaryotic life, RNA interference (RNAi). 
1.5 – RNA interference – RNA-based gene regulation 
The RNAi pathway is an RNA-directed posttranscriptional regulation mechanism that is 
ubiquitous across eukaryotic life, with only isolated instances of loss. It can be divided into three 
main branches: the short interfering RNA (siRNA)-, micro RNA (miRNA)-, and piwi-interacting 
RNA (piRNA)-mediated pathways. Each pathway uses a characteristic small RNA to direct the 
regulation of another RNA. The piRNA pathway is found in the germline of multicellular 
animals and primarily restricts the mobilization of transposable elements (66). The miRNA 
pathway is found in both plants and animals, and regulates the translation of mRNAs (67). The 
siRNA pathway is the most evolutionarily widespread pathway, and uses dsRNA to trigger the 
cleavage and degradation of a complementary ssRNA (68). The remainder of this work will 
focus on the siRNA-mediated RNAi pathway, and all references to “RNAi” will refer to this 
mechanism, unless otherwise specified. siRNA-mediated RNAi begins with the production of 
siRNAs from long dsRNA by the RNaseIII protein Dicer, which bind to the RNaseH nuclease 
protein Argonaute (Figure 2). Perfectly-complementary base pairing between the siRNA and a 
target RNA causes Argonaute to cleave the target RNA, triggering its degradation. 
1.6 – RNAi as an antiviral defense 
Many organisms, including fungi (69), plants (70), and insects (71), use RNAi as an 
antiviral defense pathway. Upon infection with an RNA virus, Dicer cleaves viral dsRNA into 
10 
 
viral siRNAs (vsiRNAs) which are loaded onto Argonaute. Base pairing between the vsiRNAs 
and the viral mRNA guides Argonaute to the transcript, which is cleaved and subsequently 
degraded. RNAi is well-suited to the task of defense against viruses for two main reasons: 1) it is 
sequence independent – any dsRNA will trigger a response, and mutation of the virus does not 
enable it to evade the RNAi pathway; and 2) it is specific – vsiRNAs only target perfectly 
complementary sequences for degradation, leaving host genes unaffected. Mutations in RNAi 
pathway genes in these organisms result in increased susceptibility to viruses, virus titers, and/or 
lethality (72–75), demonstrating their importance in the control of viruses. The role of RNAi in 
the control of viruses in mammalian somatic cells is not settled; some studies have found RNAi 
to not be antiviral in mammalian somatic cells (76), while others have found evidence suggesting 
mammalian RNAi may serve an antiviral function (77–79). 
In response to the pressure by the RNAi pathway, most, if not all, RNA viruses infecting 
organisms with an antiviral RNAi pathway encode an RNA Silencing Suppressor (RSS). These 
suppressors operate through diverse mechanisms: some bind to viral RNA or siRNA, preventing 
cleavage by Dicer or Argonaute (80, 81); others directly interact with and inhibit RNAi pathway 
proteins (82, 83); other viruses produce high levels of subgenomic transcripts that suppress 
RNAi (84).  
1.7 – RNAi in Leishmania and the trypanosomatids 
RNAi is highly conserved throughout eukaryotic life, with only infrequent instances of 
loss. Some of these losses occurred in the trypanosomatid lineage, and include Trypansosma 
cruzi and the Leishmania (Leishmania) subgenus of parasites. Other trypanosomatids, including 
T. brucei and Leishmania (Viannia) species, have active RNAi pathways (85, 86) (Figure 3). 
RNAi was first identified within the trypanosomatid lineage by the Ullu and Tschudi laboratories 
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when the introduction of an inverted repeat containing sequence from the alpha-tubulin transcript 
resulted in a “FAT” cell phenotype and marked reduction in alpha-tubulin mRNA (86). They 
identified a protein in the T. brucei genome with the PAZ and Piwi domains indicative of 
Argonaute, which they showed to bind siRNAs and to be required for RNAi, and which they 
named Argonaute1 (AGO1) (87). It was soon clear that T. cruzi and L. major did not have 
functional RNAi pathways (88, 89), and these organisms also lacked the AGO1 gene (90). 
Further database mining from the Ullu and Tschudi labs identified two RNaseIII domain genes 
present in T. brucei but not T. cruzi or L. major and showed that these genes encoded Dicer 
proteins (91, 92). Peacock et al. identified an AGO1 and Dicer gene in the completed L. 
braziliensis genome sequence (93), and our lab showed that L. braziliensis and L. guyanensis 
both have functional RNAi pathways (85). A final attempt to identify new RNAi pathway genes 
in trypanosomatids by comparative genomics returned only the three previously-identified 
components and two additional genes, RNA Interference Factor (RIF) 4 and RIF5, an 
exonuclease required for loading of siRNAs onto Argonaute and a Dicer 1 cofactor, respectively 
(94). Interestingly, while AGO1, Dicer1, Dicer2, RIF4, and RIF5 are found only in RNAi-
proficient species, a second Argonaute protein containing a readily-identifiable PIWI domain and 
a highly divergent PAZ domain (95) is also present in the RNAi-null T. cruzi and L. 
(Leishmania) species (90). This protein was termed “Piwi” because it was initially thought to 
lack the PAZ domain (90). It is evolutionarily distinct from the mammalian Piwi protein (95), 
and its role in the RNAi pathway is unclear. It is not essential in the RNAi-null L. major (96), but 
attempts in our lab to knock PIWI out in L. braziliensis were unsuccessful (Tsang, Anderson, and 
Beverley, unpublished data).  If this result can be shown to be meaningful (rather than technical), 
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this suggests that Piwi may serve an additional, essential function in RNAi-competent species. 
The distribution of known RNAi components in trypanosomatids is summarized in Table 1.  
Attempts in the Beverley lab to reconstitute the RNAi pathway in L. major by 
introduction of the missing pathway components were unsuccessful (Lye and Beverley, 
unpublished data). While technical issues may contribute to this, it also suggests that more 
pathway machinery has yet to be identified. It is possible that there are additional RNAi 
components that serve dual functions in RNAi-proficient species. These proteins would still be 
present in RNAi-null species, but have lost their RNAi functionality, such as may be the case 
with Piwi. In trypanosomatids, RNAi appears to function in the silencing of active transposable 
elements and repeats (97–99) which are not present in Leishmania (Leishmania) species (93). 
The lack of active transposable elements in Leishmania (Leishmania) species likely removed the 
selective pressure maintaining the activity of the RNAi pathway in these species. Until now, the 
role of the parasite RNAi pathway in control of viruses has not been investigated. 
1.8 – Toolkit for the study of Leishmania biology and virulence 
Leishmania is a genetically-tractable organism amenable to many manipulations both in 
vitro and in vivo. Procyclic promastigote parasites can be grown in suspension in the laboratory 
using media supplemented with components for which they are auxotrophic. The L. guyanensis 
and L. braziliensis strains used in this work have doubling times of 7-8 hours and reach densities 
of 107 – 108 cells/mL in culture, enabling large amounts of cells to be obtained in a short period 
of time and small culture volume.  
The Beverley lab pioneered the transfection and genetic manipulation of Leishmania 
parasites (100, 101). Leishmania can be plated on semisolid media (i.e. agarose plates) to obtain 
clonal lines, and antibiotics are available for selection of desired mutants. Experiments in this 
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work utilize the following drug/gene pairs: nourseothricin/SAT, hygromycin B/HYG, blasticidin 
S/BSD, and puromycin/PAC. Because of these capabilities, a number of genetic manipulations 
are possible, and will be used in this work. 
Leishmania parasites do not appear to repair double-stranded break via non-homologous 
repair to any significant extent (102); instead, homologous recombination is the default DNA 
repair pathway (103). The field has taken advantage of this feature to stably integrate transfected 
linear DNA into the parasite genome using regions of homology ranging from 250-1,000 bp. 
This method allows for two manipulations that will be used extensively in this work: allelic 
replacement to generate gene knockouts and ectopic expression from the ribosomal small subunit 
(SSU) locus.  
Non-essential genes can be readily knocked out by replacement with gene knockout 
cassettes (101), which are targeted to the appropriate gene using regions of homology 5’ and 3’ 
of the gene of interest (GOI). The regions of homology flank a drug resistance gene (Figure 4A), 
allowing the desired replacement mutants to be selected. Leishmania are “diploid-ish” – most 
chromosomes are disomic, but cells display substantial aneuploidy of individual 
chromosomesome, leading to trisomic and even tetrasomic tetrasomic chromosomes (104, 105). 
Most gene knockouts require two rounds of replacement with separate drug resistance genes, but 
some genes require further replacements. In addition, since gene regulation occurs post-
transcriptionally in Leishmania (106, 107), entire chromosomes can be duplicated in response to 
stress, such as antibiotic pressure (108, 109). Some attempts at gene knockout result in 
chromosome or whole genome amplification (110–112), which can be a sign that the GOI is 
essential. Even for non-essential genes, there are factors that can make proper targeting a 
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challenge, including poorly assembled flanking regions and flanking regions containing repeats. 
These factors come into play in this work, and will be addressed in Appendix A. 
Many species of cultured promastigotes can be transfected with circular plasmid DNAs 
(episomes), which are maintained extrachromosomally (100, 113, 114) and drive expression of 
exogenous genes. This is particularly useful for tests of essentiality when attempts to replace a 
gene fail to yield viable null mutants. In these cases, an episome encoding GFP and the gene to 
be knocked out (GOI) is transfected into cells under selection conferred by a drug resistance 
cassette (Figure 4B). The GOI is expressed from the episome while the chromosomal alleles are 
replaced by homologous recombination, and once a chromosomal null mutant is obtained the 
drug selection maintaining the episome is removed. The cells are cultured for a time to allow the 
episome to be lost and then sorted on the basis of GFP expression. If the GOI is not essential, 
this process will yield viable GFP-dim clones that have lost the episome; if the GOI is essential 
any GFP-dim cells will not survive or will still contain low levels of episome (115).  
The parasites used in this work, L. braziliensis and L. guyanensis, do not support the 
maintenance of episomes, likely due to the presence of an active RNAi pathway (85). In these 
species, a gene is assumed to be essential if repeated attempts to knock it out fail, but succeed 
when the gene is integrated into (and expressed from) the ribosomal small subunit locus. While 
this assumption is sound, it has two major drawbacks. First, transfection efficiency is low and 
homologous recombination is a relatively rare event, and therefore it is possible that too few cells 
were examined to obtain the desired mutant. Second, there have been instances where genes 
appeared to be essential by this criteria, but the episome segregation test revealed them to be not 
essential (116, 117). Therefore, it would be advantageous to have an analogous system for the 
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Viannia subgenus species to facilitate genetic manipulations, which will be discussed further in 
Chapter Four. 
Another tool that utilizes homologous recombination is the pIR expression system, in 
which a construct is integrated into the ribosomal SSU locus, which is transcribed at high levels 
by RNA polymerase I. These constructs contain a drug resistance gene for selection of mutants, 
sequences enabling proper splicing and translation of genes, and two cloning sites that can each 
carry a gene to be expressed (Figure 4C). This system was originally developed for the 
expression of genes, such as luciferase, at high levels, with little clone-to-clone variation. More 
recently, it is also used to drive transgenic RNAi in Leishmania (Viannia) species. 
As described above, species of the Viannia subgenus have an active RNAi pathway that 
can be harnessed to knock down parasite genes (85). To do this, sequence from the GOI is 
cloned as an inverted repeat into one of the expression sites of an IR vector (Figure 4D). The 
sequence is transcribed at high levels by RNA polymerase I, and it is believed that the inverted 
repeat folds into a long hairpin structure (“stem-loop,” StL). Dicer cleaves this dsRNA StL into 
siRNAs, which are incorporated into Argonaute and guide cleavage and degradation of the 
GOI’s transcript. Reduction in target mRNA scales approximately linearly with the length of the 
sequence in the stem (Lye, unpublished data), but the stem requires a minimum length of 
approximately 250 nt for appreciable reductions. The caveat of knockdown using StL vectors, as 
with all RNAi experiments, is that reductions in mRNA do not always generate equivalent (or 
any) reductions in protein level and therefore do not always result in an observable phenotype. 
After the desired mutant parasites have been generated, the effects of the manipulation on 
parasite virulence can be investigated by infection of laboratory mice. To achieve infection, 
luciferase-expressing procyclic promastigote parasites are grown to stationary phase in vitro, 
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which causes them to differentiate into metacyclic promastigotes (118, 119), and injected into 
the hind footpad of mice. The mice are monitored over the course of infection for luciferase 
activity, which correlates with the number of parasites present at the site of infection, and the 
thickness of the footpad, which is a measure of the host immune response. The L. guyanensis 
parasites used in this work cause a self-limiting infection in wild-type C57B6 mice that does not 
metastasize and ultimately resolves. In contrast, the same parasites in IFN-γ knockout mice cause 
chronic infections with a relatively high rate of metastasis (58). 
1.9 – Aims and Scope 
LRV1 plays a substantial role in the virulence of Leishmania parasites, and a deeper 
understanding of the mechanisms by which it is maintained and controlled within Leishmania 
could provide targets for the improvement of patient treatment outcomes. As LRV1 is a dsRNA 
virus and Leishmania (Viannia) species have active RNAi pathways, it is logical to suspect that 
the RNAi plays a major role in control of LRV1. The primary aim of this work is to investigate 
the relationship between LRV1 and the Leishmania RNAi pathway and determine to what extent 
it functions in control of LRV1. 
For RNAi to serve an antiviral purpose, siRNAs must be generated from LRV1 sequence 
and competent for the targeting and degradation of the LRV1 transcript. In Chapter 2, I 
investigated whether siRNAs with LRV1 sequence can reduce LRV1 levels in both L. 
braziliensis and L. guyanensis, and show that LRV1 can indeed be targeted and eliminated by 
transgenic RNAi, suggesting that the parasite RNAi pathway may well be antiviral. Further, 
targeting by RNAi provides a mechanism by which LRV1-negative lines can be generated at will 
from Leishmania isolates. In Chapter 3 I disrupted the L. guyanensis RNAi pathway by knocking 
out Argonaute 1 (AGO1) and show that, contrary to predictions, there was little change in the 
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level of LRV1, suggesting that AGO1-dependent RNAi is not the major mechanism by which 
LRV1 levels are regulated in Leishmania. In Appendix A I describe experiments to map the 
region immediately 3’ of Argonaute 1 in L. guyanensis, facilitating the experiments described in 
Chapter 3. In Appendix B, I describe a protocol that I developed to isolate genomic DNA from 
small numbers of Leishmania cells, facilitating the validation of transfectants in situations where 
transfection efficiency was predicted to be particularly low. In Appendices C and D, I describe 
preliminary attempts to investigate the roles of additional RNAi pathway components and their 
roles in the control of LRV1. 
Investigation of gene function in Leishmania (Viannia) species is made more difficult by 
the inability of these species to support extrachromosomal circular DNAs (85), which are used in 
Leishmania (Leishmania) species in tests of essentiality. In Chapter 4 I present a plasmid system 
analogous to the above-described episome sort, which I term “pop-outs.” Further, I harness the 
pop-out system to investigate whether transgenic RNAi has previously-unrecognized 
consequences to Leishmania biology that should be considered during further use of transgenic 
RNAi. Finally, in Appendix E, I describe experiments investigating the knockdown of flagellar 
genes in Leishmania braziliensis, which occupied my earliest work in the laboratory.  
The experiments described in this dissertation add to our understanding of the 
interactions between Leishmania parasites and the RNAi pathway, as well as to our 
understanding of the possible interactions between viruses and their hosts, more generally. 
Further, they provide new tools for the future investigations of Leishmania biology and gene 
function. 
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1.10 – Table Legends 
Table 1-1: Summary of known RNAi components in the trypanosomatid parasites.  
Components present in a given species are denoted by a “+” while absent components are 
denoted by a “-“. L. major is representative of Leishmania subgenus species, while L. 
braziliensis is representative of Viannia subgenus species, as indicated in Figure 3. 
1.11 – Figure Legends 
Figure 1-1: Replication cycle of LRV1.  
The dsRNA genome is enclosed within the protein capsid (circle), where the RDRP 
(arrow shape) synthesizes a plus-strand transcript. The transcript is extruded into the 
cytoplasm, where it is translated into protein. The transcript in encapsidated, and the 
RDRP generates a minus strand, yielding dsRNA. Figure modified from (45). 
Figure 1-2: Biogenesis of siRNAs.  
Long dsRNA is cleaved by Dicer into duplex siRNAs. The siRNA duplex is loaded onto 
Argonaute, and the passenger strand is ejected. Base pairing between the siRNA and a 
ssRNA target causes cleavage of the target by Argonaute and subsequent degradation. 
Figure from (120). 
Figure 1-3: Presence and absence of RNAi and LRV1 in select species of Leishmania and 
Trypanosoma.  
Species are marked with a + when RNAi or LRV1 is consistently present and a – when 
consistently absent. +/- indicates that isolated occurrences have been identified. For LRV, 
the species present is indicated. 
Figure 1-4: Schematics of constructs used in the genetic manipulation of Leishmania parasites. 
A) Gene of interest (GOI) knockout by homologous recombination. An allele is replaced 
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with a gene conferring resistance to a selective antibiotic (here, HYGR confers resistance 
to hygromycin B).  
B) Episomes encode a GOI, GFP, and resistance to a selective antibiotic. When cells 
containing the episome are grown without selection, a portion of cells lose the episome, 
and can be recovered by single cell sorting on GFP expression.  
C) IR constructs integrate into the 18S rRNA small subunit (SSU) locus by homologous 
recombination. Two sites (A and B) are available for cloning of genes to be expressed. 
Splice acceptor (SA) sequences enable proper trans-splicing of transcripts. A drug 
resistance cassette (here, mediating resistance to hygromycin B) enables positive 
selection of transfectants.  
D) Stem-loop (StL) constructs use the pIR backbone to drive RNAi knockdown of a GOI. 
Sequence from the GOI is cloned into an inverted repeat in the A cloning site using 
Gateway technology (Invitrogen, Thermo Fisher). 
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Table 1-1 
 T. brucei T. cruzi L. braziliensis L. major 
Argonaute 1 (Ago1) + - + - 
Dicer 1 (Dcl1) + - + - 
Dicer 2 (Dcl2) + - + - 
RIF4 + - + - 
RIF5 + - + - 
Piwi + + + + 
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+
+
+
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2.1 – Abstract   
Many Leishmania (Viannia) parasites harbor the double-stranded RNA virus Leishmania RNA 
virus 1 (LRV1), which has been associated with increased disease severity in animal models and 
humans, and drug treatment failures in humans. Remarkably, LRV1 survives in the presence of 
an active RNAi pathway, which in many organisms controls RNA viruses. We found significant 
levels (0.4-2.5%) of small RNAs derived from LRV1 in both L. braziliensis and L. guyanensis, 
mapping across both strands and with properties consistent with Dicer-mediated cleavage of the 
dsRNA genome. LRV1 lacks cis or trans-acting RNAi inhibitory activities, suggesting that virus 
retention must be maintained by a balance between RNAi activity and LRV1 replication. To tilt 
this towards elimination, we targeted LRV1 using long-hairpin/stem-loop constructs similar to 
those effective against chromosomal genes. LRV1 was completely eliminated, at high efficiency, 
accompanied by a massive overproduction of LRV1-specific siRNAs, representing as much as 
87% of the total. For both L. braziliensis and L. guyanensis, RNAi-derived LRV1-negative lines 
were no longer able to induce a Toll-like receptor 3-dependent hyper-inflammatory cytokine 
response in infected macrophages. This is the first demonstration of a role for LRV1 in L. 
braziliensis virulence in vitro, the Leishmania species responsible for the vast majority of 
mucocutaneous leishmaniasis cases. These findings establish the first targeted method for 
elimination of LRV1, and potentially of other Leishmania viruses, which will facilitate 
mechanistic dissection of the role of LRV1-mediated virulence. Moreover, our data establish a 
third paradigm for RNAi-viral relationships in evolution, one of balance rather than elimination. 
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2.2 – Introduction  
Leishmania is a genus of early-diverging protozoan parasites that cause leishmaniasis in 
many regions of the world, with an estimated 12 million symptomatic cases, at least 120 million 
asymptomatic cases, and nearly 1.7 billion at risk (1-5). The disease has three predominant 
clinical manifestations, ranging from the relatively mild cutaneous form to mucocutaneous 
disease, where parasites metastasize to and cause destruction of mucous membranes of the nose, 
mouth, and throat, and fatal visceral disease. Disease phenotypes segregate primarily with the 
infecting species; however, it is not fully understood which parasite factors affect severity and 
disease manifestations. 
One recently identified parasite factor contributing to disease severity in L. guyanensis is 
the RNA virus Leishmaniavirus (6, 7). This virus is a member of the Totiviridae family, and 
consists of a single-segmented dsRNA genome that encodes only a capsid protein and an RNA-
dependent RNA polymerase (RDRP) (8, 9). It is most frequently found (as LRV1) in New World 
parasite species in the subgenus Viannia such as L. braziliensis (Lbr) and L. guyanensis (Lgy), 
which cause both cutaneous and mucocutaneous disease (6), but it has also been found 
sporadically in Old World subgenus Leishmania species (as LRV2) (10, 11). Like most 
totiviruses, LRV1 is neither shed nor infectious, and thus can be viewed as a long-term 
evolutionary endosymbiont whose activities on the mammalian host arise indirectly through the 
parasite, rather than by direct infection of the mammalian host by the virus (6). Previous work 
has shown that mice infected with LRV1-bearing strains of Lgy exhibit greater footpad swelling 
and higher parasitemia than mice infected with LRV1-negative Lgy (7). Similarly, macrophages 
infected in vitro with LRV1+ Lgy or LRV2+ L.aethiopica release higher levels of cytokines, 
phenotypes that were dependent on Toll-like receptor 3 (7, 10). The assignment of the LRV1 
40 
 
specificity of these phenotypes benefited greatly from the availability of a single isogenic LRV1-
free line of Lgy (12). Importantly, recent studies have shown that disease severity is increased in 
patients infected with LRV1+ Lgy, relative to LRV1-negative parasites (13).  
In humans, Lbr is associated with cutaneous leishmaniasis, as well as the larger share of 
the more debilitating mucocutaneous leishmaniasis (MCL) (14, 15). While in some studies 
LRV1 was not correlated with MCL (16, 17), in others there was a strong association (6, 18, 19). 
Recent studies show that LRV1 in Lbr and Lgy clinical isolates correlates with drug treatment 
failure (16, 20). Thus, while other parasite or host factors may play a significant role in the 
development of MCL (21, 22), current data support a role for LRV1 in exacerbating the 
pathogenesis of human leishmaniasis caused by Lbr and Lgy.  A similar role in pathogenicity has 
been proposed for the Trichomonas vaginalis  totiviruses (23).   In contrast, endobiont viruses in 
other systems more often impair the host or have no known effect on disease.  Hypoviruses of 
Cryphonectria parasitica are associated with decreased virulence of their fungal host whereas 
the L-A totivirus of Saccharomyces cerevisiae is not thought to affect  pathogenicity, instead 
contributing to intermicrobial competition (24-27) . 
Research into the role of LRV1 in Lbr disease is hampered by the fact that animal models 
are less well developed than for other Leishmania (28) and by the absence of isogenic lines 
bearing or lacking LRV1. Since reverse genetic systems for Totiviridae do not exist and attempts 
to stably transfer LRV1 have proven unsuccessful (29), we asked whether RNA-interference 
(RNAi) could be used to generate LRV1-free isogenic isolates. Unlike Old World Leishmania, 
species of the Viannia subgenus, including Lbr and Lgy, retain an active endogenous RNAi 
pathway (30). The RNAi pathway converts double-stranded RNA into siRNAs, which trigger the 
degradation of an mRNA with complementary sequence (31). Importantly, the RNAi pathway 
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acts as a defense against RNA viruses in plants and some animals, leading to great reductions or 
complete elimination (32, 33). Further, introduction of RNAi pathway proteins from 
Saccharomyces castellii into the naturally RNAi-null S. cerevisiae resulted in greatly decreased 
levels of persistently-infecting L-A totivirus (26). In mammals, siRNA-mediated RNAi activity 
appears to play a smaller direct role in antiviral responses in adult mice (34, 35), although 
evidence of a direct response has been found in embryonic stem cells and young animals (36, 
37). 
Here we explore further the interactions of the RNAi pathway with LRV1 in both Lbr 
and Lgy, and show first that LRV1 is indeed seen by the endogenous RNAi pathway, as judged 
by the presence of significant levels of antiviral sRNAs. Thus and different than other systems, 
RNAi and viral replication appear to be balanced. However, by increased siRNA expression 
RNAi could be used to efficiently eliminate the virus. Importantly, these LRV1 negative 
transfectants recapitulate the in vitro macrophage cytokine release defect seen in naturally-
occurring LRV1-negative lines, suggesting that the engineered LRV1-negative isogenic lines 
will be valuable in studying the role of LRV1-mediated biology and virulence. 
2.3 – Results  
2.3.1 – Naturally abundant siRNAs directed against LRV1 of L. braziliensis and L. guyanensis 
Previous siRNA studies in Leishmania analyzed RNAs using a tagged Argonaute inserted 
into an ago1- knockout of Lbr M2903, which lacks LRV1 (9, 29, 38, 39). Because the lines 
bearing LRV1 studied here had not been similarly modified, we sequenced total small RNAs 
(sRNAs) as an alternative. Lbr siRNAs bear a 5’-P and 3’-OH, reflecting their origin through the 
action of cellular Dicer nucleases (39), and we used these properties to make siRNA-focused 
sRNA (<42 nt) libraries for next-generation sequencing (Table S1). For Lgy we chose the 
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established LRV1+ Lgy M4147 strain (7), and three different Lbr shown to bear LRV1 by PCR 
and/or anti-dsRNA antibody tests (40).  
For sRNAs from Lbr M2903 mapping to the Lbr reference genome, read length displayed 
a biphasic distribution, with a major peak centered around 23 nt (20-26 nt, 77.9% of total 
mapped reads) and a minor one around 33 nt (30-36nt, 9.4% of total mapped reads) (Fig. 1A, 
Table S1,S2). The 33 nt peak reads mapped primarily to structural RNA loci (62% of mapped 
reads; Table S2) similar to a sRNA class described in many eukaryotes including trypanosomes 
and Leishmania lacking the RNAi pathway (41-44). In contrast, reads from the 23 nt peak 
showed properties similar to AGO1-bound siRNAs (39), including their size and the presence of 
1-2 untemplated nucleotides at the 3’ end in about 21% of the reads (Fig. 1A; Table S1). The 3’ 
untemplated bases likely arise from the action of cellular terminal transferases, as Leishmania sp. 
lack the HEN1 methyltransferase that normally blocks their action (39). When both AGO1-
bound siRNAs and the 23 nt sRNA peak reads were mapped to the Lbr genome their 
distributions were very similar, with the vast majority mapping to transposable elements (Figs. 
1B, S2; Table S2) (39). We concluded that the 23 nt peak sRNAs (23 nt sRNAs) provides a 
reasonable proxy for siRNAs.  
The properties of sRNAs from the LRV1-bearing Lgy M4147 and Lbr LEM2700, 
LEM2780 and LEM3874 mapping to the Lgy or Lbr reference genomes were similar to those of 
Lbr M2903, including the 23 and 33 nt sRNA peaks, genomic mappings, and the presence and 
level of 3’ nt extensions in the 23nt sRNAs (Figs. 1, S1; Tables S1 & S2). Importantly, a 
substantial fraction of sRNA reads obtained from the LRV1+ Lgy and Lbr lines mapped to the 
LRV1 genomes, ranging from 0.4-2.5% of the 23nt mapped reads (Fig. 1B, Table S1). Unlike 
those aligned to the nuclear genome, LRV1-mapped reads showed a single size distribution 
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centered around 23 nt (Fig. 1A), with about 20% again showing short 3’ extensions (Table S1), 
typical of Lbr siRNAs and 23 nt sRNAs (39). LRV1-mapping 23 nt sRNAs showed no consistent 
strand- or region-specific biases in all four strains (Fig. S2), suggesting that they likely originated 
from the action of DICERs on the viral dsRNA genome. 
We previously showed that LRV1 does not encode a trans-acting inhibitor of RNAi 
activity (30), and the presence of high levels of LRV1-directed sRNAs similarly suggests that it 
does not encode a strong cis-acting inhibitor. Importantly, the levels of 23 nt sRNAs mapping to 
LRV1s were in the same range as siRNAs mapping to an efficiently silenced Luciferase reporter 
(0.4–2.5% vs. 0.8% targeted by long hairpin/stem loop transgene) (30, 39). Thus, LRV1 is able 
to persist in the face of a significant RNAi response, as judged by 23 nt sRNA levels.  
2.3.2 – LRV1 can be efficiently targeted by transgenic RNAi 
These data are consistent with a model where RNAi activity and LRV1 replication has 
achieved a ‘balance’ between viral synthesis and degradation, which might be shifted by 
increasing or decreasing RNAi activity. With an eye towards virus elimination, we focused on 
increasing LRV1-targeting siRNA levels through the use of transgenic RNAi methods developed 
previously (30), in which long hairpin RNA is expressed at high levels from a stem-loop (StL) 
construct containing LRV1 sequences integrated into the ribosomal RNA locus (Fig. 2A). We 
targeted regions of LRV1 from the capsid or RDRP ORFs (Lgy M4147, Lbr LEM2700 and 
LEM2780), or a region that spanned them (Lbr LEM3874), ranging in length from 794 to 1,143 
bp (Fig. 2B & Table S3); since the two viral genes reside within the same RNA segment, 
targeting either should lead to degradation of the entire LRV1 RNA. Since LRV1 sequences 
diverge substantially between parasite strains (69-90% nt identity), ‘stems’ specific for each 
species/strain were used. To assess non-specific effects, we integrated an StL construct for an 
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AT-rich GFP (GFP65 StL), which efficiently silences expression of GFP65 (30). The 
untransfected parental lines served as LRV1+ controls, and Lbr M2903 or Lgy M4147/HYG (12) 
served as LRV1-negative controls.  
To screen for loss of LRV1, StL transfectants were analyzed by flow cytometry of fixed, 
permeabilized cells using an antibody raised against the Lgy M4147 LRV1 capsid (45), which 
cross reacts with Lbr LRV1. For both Lgy M4147 (Fig. 3, top) and Lbr LEM2780 (Fig. 3, 
bottom), there was a clear separation in capsid staining between the LRV1-positive (red) and 
LRV1-negative controls (green). While control GFP65 StL lines (purple) had capsid protein 
levels similar to WT, capsid protein was undetectable in LRV1-targeted StL lines (Fig. 3, light & 
dark blue), indistinguishable from the LRV1-negative control. This was observed whether the 
capsid or RDRP was targeted (Fig. 3). Similar results were obtained with LRV1 StL transfectants 
from Lbr LEM2700 and Lbr LEM3874 (data not shown). In support of the flow cytometry data, 
western blot analysis with an anti-capsid antibody showed high LRV1 levels in the Lgy parental 
line and GFP65 StL transfectants, while capsid protein was undetectable in the capsid StL 
transfectants (Fig. S3).  
2.3.3 – StL constructs result in high levels of siRNAs mapping to the LRV1 stem 
 Despite the insensitivity of LRV1 to ‘natural’ levels of RNAi, as judged by the 
abundance of 23nt sRNAs, introduction of StL constructs targeting LRV1 resulted in great 
reduction in LRV1 levels. To understand the basis for this reduction, we analyzed 23 nt sRNA 
peak reads mapping to the nuclear and LRV1 genomes, for one LRV1 StL transfectant of each 
species (Fig. 4). Remarkably, the percentage of total 23 nt sRNAs mapping to LRV1 had 
increased greatly from that seen in the WT parent, from 2.5% to 86.7% for Lgy and from 1.8% to 
73.0% for Lbr LEM3874 (Figs. 4A, S1B). Concomitantly, the percentages of 23 nt sRNAs 
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mapping to the nuclear genome was proportionately reduced, with some variability amongst loci 
and/or lines (for example, rRNA reads were unchanged in both species, while tRNA reads 
decreased in Lgy; Figs. 4A, S1B). While we did not measure the absolute levels of sRNAs, 
previous studies show these are tightly controlled by the level of Argonaute 1 and thus are 
unlikely to differ significantly (39). Essentially all LRV1-mapping sRNAs in LRV1 StL lines 
now mapped only to the RNAi-targeted ‘stem’ region (Fig. 4B, dark grey), as expected since 
LRV1 had been eliminated (below). This also argues against the occurrence of ‘transitive’ 
siRNA formation (46, 47). 
 The levels of LRV1 23 nt sRNAs (76-87%) in LRV1 StL-transfectants were much 
greater than seen with siRNAs mapping to the LUC ORF/stem targeted using the same StL 
transfection construct (0.8%) (39). To rule out the possibility that this arose from reliance on 
23nt sRNAs, we analyzed these from a line bearing the LUC StL RNAi reporter used in the 
siRNA studies (IR2-LUCStL(b)-LUC(a)). For this, 1.14% of the 23nt sRNA peak reads mapped 
to the LUC ORF/stem, suggesting that use of 23nt sRNAs vs siRNAs did not significantly 
impact quantitation. To assess the target-specific effects, we compared the results here with those 
obtained in other studies, quantitating 23 nt peak sRNAs after RNAi StL targeting of a panel of 
10 chromosomal genes. For these, 1.5-34% of 23 nt sRNAs mapped to the RNAi-targeted gene, 
compared to less than 0.02% basally (unpublished data). Thus, the StL-bearing IR vectors 
generate a high but variable level of sRNAs for all genes tested, with the LUC reporter being at 
the low end and LRV1 at the high end. This may reflect the fact that while the LRV1 target is 
typically eliminated by RNAi (Fig. 3 and below), chromosomal RNAi targets continuously 
transcribe mRNAs. In other organisms, studies have shown that the presence of a cognate target 
facilitates the turnover of sRNAs; thus, the absence of LRV1 target may lead to higher levels of 
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siRNAs (48, 49). Future studies may address the factors contributing to the differences in sRNA 
levels amongst genes and to the very high steady-state levels of LRV1-directed 23 nt sRNAs 
seen here. 
2.3.4 – Complete virus elimination following RNAi of LRV1 
RNAi-mediated LRV1 knockdown would be most useful as a tool if it resulted in a 
complete elimination of LRV1. To achieve a sensitivity beyond that of flow cytometry (~20 
fold) or western blotting (~100 fold), we validated a sensitive quantitative RT-PCR assay (qRT-
PCR) for LRV1, using strain- and LRV1-specific primers to amplify a region located outside the 
‘stem’ regions (Table S4; Fig. 2B). Since the melting temperatures of PCR amplicons are 
sequence- and length-dependent, comparison of dissociation (melt) curves facilitated 
discrimination between specific and non-specific amplification. 
Because LRV1 copy number was estimated to be ~100/cell (50), a cutoff for 
classification as LRV1-negative was set at 104-fold below WT. Analysis of Lbr qPCR data by 
the ΔΔCt method (51) showed that most LRV1 StL transfectants had LRV1 RNA levels more 
than 105-fold lower than WT (Figs. 5A, S5A,B). Raw Ct values for LRV1 StL lines with LRV1-
specific primers were indistinguishable from mock cDNA preparations, and ΔCt values were 
indistinguishable from those of negative controls. Melt curves show that products seen at Ct 
arose from non-specific amplification (Figs. 5A, S5A,B; white bars). As expected for control 
GFP65 StL lines, LRV1 RNA levels were similar to those in WT (Figs. 5A, S5A,B; black bars).  
Similar results were obtained with RNAi of LRV1 in Lgy M4147, with most transfectants 
showing reductions below the 104-fold cutoff (Fig. 5B). However, low levels of LRV1 remained 
in two lines where the RDRP was targeted, approximately 300- to 500-fold less than the parent 
line (Fig. 5B, black bars); here melt curve analysis suggested these products were LRV1-specific 
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(not shown). Alternate primers targeting other regions across the virus gave similar results (data 
not shown), suggesting the presence of intact LRV1. We hypothesized that this was due to 
heterogeneity in viral load, with most but not all cells lacking LRV1. In support of this, we 
generated and showed that all clonal lines arising from one of the “weakly positive” lines were 
negative for LRV1 by flow cytometry (data not shown) and satisfied the 104-fold cutoff by qPCR 
(Fig. S5C). The occasionally incomplete LRV1 elimination is consistent with our prior 
observation that RNAi was somewhat less efficient in Lgy than in Lbr (30). Nonetheless, even 
for “weakly positive” Lgy transfectants, RNAi was sufficiently efficient for the ready isolation of 
LRV1-negative lines (Fig. 3, top; 5B; S3).  
2.3.5 – LRV1 knockdowns induce less cytokine production in in vitro macrophage infection 
assays 
Previous reports showed that LRV1+ Lgy stimulated the TLR3-dependent release of 
higher levels of cytokines from bone marrow-derived macrophages (BMDMs) than LRV1-
negative strains (7). The availability of defined RNAi-derived LRV1-negative lines now allowed 
tests of this in Lbr for the first time as well as confirmation of prior results obtained with a single 
isogenic LRV1- Lgy. Briefly, BMDMs were infected in vitro with LRV1 StL and GFP65 StL 
Lbr and Lgy transfectants, as well as positive and negative control lines, and the levels of two 
cytokines known to be induced by LRV1 (TNF-α and IL-6) (7, 10) were measured. 
Capsid StL and RDRP StL LRV1-negative lines of both Lbr and Lgy induced 
significantly lower levels of cytokine production than did the LRV1-positive lines (both parental 
and GFP65 STL) (Fig. 6, Fig. S5). Additionally, when macrophages from TLR3-deficient mice 
were infected with Lbr LEM2700, the LRV1-positive parasites no longer elicited higher levels of 
cytokine release (Fig. S5). Of note, all Lgy LRV1 StL lines induced background levels of 
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cytokine release, including the two lines that retained low levels of LRV1 (Fig. 5B & 6B, Fig. 
S5), consistent with the observation that high levels of LRV1 were necessary for cytokine 
stimulation (7, 10). 
2.4 – Discussion  
In this study we have characterized the endogenous RNAi response in Leishmania 
bearing the dsRNA virus LRV1, and used these insights to generate virus-negative lines that 
facilitate the study of the role of LRV1 in parasite biology and host-parasite interactions.  
Leishmania LRV1 and the endogenous RNAi pathway  
We identified two populations of sRNA in Lbr and Lgy. The less abundant 33 nt sRNAs 
mapped primarily to genes encoding structural RNAs (Table S2), as seen in other organisms 
including trypanosomatids (41-44). In contrast, the more abundant 23 nt sRNA fraction exhibited 
properties similar to authentic, AGO1-bound Lbr siRNAs (39), including size, the presence of 3’ 
untemplated bases at the same frequency (~20%), and mapping primarily to transposable 
elements and repetitive sequences (Fig 1; Tables S1 & S2). Only 23 nt sRNA reads mapped to 
the LRV1 dsRNA genome (Fig. 1A), and these also bore 3’ nucleotide extensions at the same 
frequency, again consistent with an origin via the RNAi pathway (Table S1). Importantly, the 
levels of 23 nt sRNAs mapping to LRV1 constituted a substantial fraction of total aligned 23nt 
sRNAs (Fig 1B, Table S1), comparable to those targeting an efficiently-silenced LUC reporter 
gene (30, 39). Thus, LRV1 can persist in the face of RNAi pressure that gives rise to sRNA 
levels comparable to that which efficiently silences a chromosomal target gene. 
In other organisms, sRNA/siRNA levels provide a gauge of RNAi pathway recognition 
and targeting of viruses: when RNAi controls virus replication, as in plants, fungi, and insects 
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(26, 32, 33), high levels of siRNAs accompany viral infections, leading to eradication of the 
virus. In mammals, quantitatively fewer siRNAs are present, which do not effectively control 
virus levels, at least in adult somatic tissues (34, 36, 37). In contrast, high levels of siRNA-like 
23 nt sRNAs in Leishmania suggest an attack on LRV1 by the RNAi pathway, but the virus 
persists. While many viruses encode trans-acting RNAi suppressors mediating their survival 
(52), this seems unlikely for LRV1. There is no obvious coding potential for this in the compact 
LRV1 genome, our studies here suggest there is no strong cis-acting inhibitory activity, and we 
showed previously that a luciferase reporter was equally silenced in the LRV1+ and LRV1-
negative Lgy studied here (30). This suggests a third model where LRV1 is targeted strongly by 
the RNAi pathway, but the RNAi-mediated degradation is ‘balanced’ by virus replication or 
other factors. We are currently working to identify which component(s) of the RNAi machinery 
mediate this balance. While the slicer activity of Argonaute is perhaps the most likely agent, 
previous studies examining the role of RNAi in control of viruses frequently raise the possibility 
of Dicer-mediated control as well (53-55).  It is likely that the sequestration of the LRV1 dsRNA 
genome within the capsid may also contribute by limiting the exposure of the LRV1 dsRNA to 
the RNAi machinery and other degradative pathways.   In yeast, SKI genes act to prevent 
deleterious effects of L-A viruses towards its fungal host through alterations in mRNA 
degradation and/or surveillance (27), and homologous genes for several of these are evident in 
the Leishmania genome. 
In other organisms, persistent viruses can also be maintained in the face of an active 
RNAi pathway, but at considerably reduced levels (26, 56). Over evolutionary time, this strong 
pressure likely accounts for the inverse relationship in fungi between virus levels and the activity 
and/or presence of the RNAi pathway, especially when associated with a selective advantage for 
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viral retention, as seen with the yeast killer factors which are dependent on the L-A virus (26, 
57). Similarly, in Leishmania we had originally proposed that RNAi pressure would be 
sufficiently strong as to in some cases provide a driving force for loss of RNAi, in order to 
maintain LRV1-dependent increases in pathogenicity (30). Given the greater ability of LRV1 to 
survive in the presence of an active RNAi pathway, our data suggest that the magnitude of this 
effect may be considerably less than envisioned. However, even small pressure could prove a 
significant force towards down-regulating pathways impacting on LRV1 levels during evolution. 
RNAi as a tool for generating LRV1-negative lines for biology 
Following the predictions of the ‘balance’ hypothesis, we aimed to increase activity 
against LRV1 through the increased synthesis of siRNAs targeting LRV1. This proved quite 
successful; the fraction of 23 nt sRNAs targeting LRV1 rose dramatically in lines expressing StL 
constructs targeting LRV1 (Figs. 1B & 4A). Correspondingly, the fraction of 23 nt sRNAs 
mapping to the Leishmania genome dropped proportionately, most of which again mapped to 
TEs and repeats (Fig. 4A). Importantly, LRV1 levels were dramatically reduced for all LRV1 
StL transfectants, and in most cases the virus eliminated, as judged by protein and RNA methods 
(Figs. 3, 5, S3, S5). Targeting of either the capsid or RDRP gene eliminated LRV1, as was 
expected given that both are encoded by the same RNA (Fig. 2A). Only in Lgy were some 
transfectants found that retained low levels of LRV1, which could reflect less RNAi activity in 
this species, as was seen with reporter genes (30). However, most transfectants had completely 
lost LRV1.  
Viral infection has been reported for Giardiavirus (58), and stable viral transfer for 
several fungal Totiviruses (59). However, de novo infection and stable viral transfer have been 
unsuccessful with Lgy (29), and reverse genetic systems have yet to be reported for any 
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Totivirus. Therefore, the ability to reproducibly mediate viral cure by RNAi is of great value for 
biological studies of LRV1. Previous work used an LRV1-negative Lgy which was obtained 
following transfection with an episomal Leishmania vector expressing resistance to hygromycin 
B, followed by a long period of growth under selection (12); however, this method seems to have 
been successful only once. Neither have we succeeded with several ‘stress-related’ treatments 
that have proven effective in curing mycoviruses, such as yeast L-A (60) (F.M. Kuhlmann and 
S.M. Beverley, unpublished data). Our studies establish RNAi as a viable strategy for cure of 
LRV1 and perhaps other viruses in RNAi-competent Leishmania species.  
LRV1+ but not LRV1-negative Lgy induce a ‘hyperinflammatory’ cytokine response in 
infections of BMDMs in vitro, which is TLR3-dependent <sup>2</sup><sup>2</sup>(Ives et 
al. 2011)(6, 7). Infectivity tests of mouse BMDMs in vitro showed that RNAi-generated LRV1-
negative Lgy lines likewise failed to induce a substantial cytokine response, as shown for two 
cytokines (TNF-α and IL-6) known to be diagnostic for an LRV1-driven innate immune 
response. Interestingly, this occurred with RNAi-derived lines where LRV1 loss was substantial 
but incomplete (RDRP StL c3 & 4; 500- and 300-fold below parental levels, respectively; Fig 
5B, 6B, S7), consistent with data from natural Lgy showing low LRV1 levels (7). Thus, a partial 
reduction in LRV1 levels is sufficient to ameliorate LRV1-dependent virulence, which may 
facilitate future efforts targeting LRV1 in human disease. Importantly, the continued presence of 
the integrated StL constructs appeared to have no ‘off target’ effect in the BMDM infections, 
despite the high levels of transgene-derived 23 nt sRNAs present in these lines; the LRV1 StL 
“cured” lines induced the release of cytokines at a level similar to that of StL-negative, LRV1-
negative controls (Fig. 4), and control GFP65 StL lines that maintained LRV1 induced the 
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release of cytokines at a level similar to the StL-negative, LRV1+ parent (Fig. 3, 5, 6). Future 
studies will assess whether this also pertains to other cell types or host infections. 
LRV1-dependent virulence in Leishmania braziliensis 
Previous studies of LRV1-dependent virulence focused primarily on Lgy; however, in 
humans, Lbr is associated with the larger share of MCL (14, 15). Our studies extend the 
generality of LRV1-dependent virulence to Lbr, as LRV1+ Lbr likewise induce strong TLR3-
dependent cytokine responses. These findings are especially important in light of published work 
on the association of LRV1 with MCL, with mixed results depending on the geographic region 
and methods used (6, 16-19). Our data show that in in vitro infections, LRV1 contributes 
strongly to the pro-inflammatory phenotype associated with elevated pathogenicity, as seen in 
Lgy. This suggests that in human infections it may be informative to seek for correlations 
between LRV1 and the severity of CL in Lbr infections in future studies. Indeed, recent studies 
show that LRV1 in Lbr clinical isolates correlates with drug treatment failure (16), as was also 
seen in Lgy (20). Thus, while other parasite or host factors may play a significant role in the 
development of MCL (21, 22), current data now bolstered by our studies of isogenic 
LRV1+/negative lines support a role for LRV1 in severity of human leishmaniasis caused by 
Lbr.  
2.5 – Materials and Methods 
Parasites and in vitro culture 
Lbr LEM2700 (MHOM/BO/90/AN), LEM2780 (MHOM/BO/90/CS) and LEM3874 
(MHOM/BO/99/IMT252 n°3) were from Patrick Bastien (Université de Montpellier), Lbr 
M2903 (MHOM/BR/75/M2903) was from Diane McMahon Pratt (Yale School of Public 
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Health), and Lgy M4147 (MHOM/BR/78/M4147) and its derivative Lgy M4147/HYG was from 
Jean Patterson (Southwest Foundation for Biomedical Research, San Antonio, Texas). Prior to 
introduction of StL constructs, parasites were transfected with the linear SSU-targeting SwaI 
fragment from B6367 pIR2SAT-LUC(B) (30), and clonal lines were derived, validated, and 
used. The luciferase-expressing clone of Lbr LEM2780 contained only LRV1-LbrLEM2780(b). 
Parasites were grown in fresh Schneider’s Insect Medium supplemented with 10% heat-
inactivated fetal bovine serum, 100 μM adenine, 10 μg/mL hemin, 2 μg/mL biopterin, 2 mM L-
glutamine, 500 units/ml penicillin and 50 ug/mL streptomycin, and selective drugs as indicated 
below. 
RNAi Stem-loop Constructs 
Regions of interest from LRV1 were screened using the RNAit target selection tool to ensure 
that there was no homologous sequence in the parasite genome (61), amplified from cDNA by 
PCR using KlenTaq-LA polymerase, and cloned into the pCR8/GW/TOPO cloning vector 
(Thermo Fisher Scientific, Waltham, Massachusetts) using the protocol recommended by the 
manufacturer and a 20 min ligation. The ‘stem’ segments and PCR primer sequences can be 
found in Table S3. The ‘stems’ were transferred from the pCR8/GW/TOPO donor vector to the 
pIR2HYG-GW(A) (B6365) destination vector (which contains sequence from the parasite rRNA 
locus to enable integration into the genome and inverted LR recombinase sites for the generation 
of inverted repeat through Gateway© technology) using LR Clonase II (Thermo Fisher) in an 
overnight reaction at room temperature. Reactions were terminated by incubating with proteinase 
K for 1 hour at 37°C. Constructs were verified by restriction digest. 
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Transfections 
Stable transfections were performed as previously described (30, 62). Clonal lines were obtained 
by plating on semisolid media with 50 µg/mL hygromycin B. After colonies formed, cells were 
grown to stationary phase in 1 mL media and passaged thereafter in 10 mL media with 30 µg/mL 
hygromycin B.  
RNA preparation and quantitative real-time PCR (qPCR) 
Total RNA was prepared from log-phase cells dissolved in Trizol reagent (Thermo Fisher) at 3 x 
108 cells/mL using the Direct-zol kit (Zymo Research, Irvine, California) and eluted in 50 µL of 
nuclease-free water. The RNA was DNAseI-treated (Thermo Fisher) in a 200 µL reaction using 
the provided buffer and 20 Units of enzyme for 1 hour at 37 °C, purified using the RNA Clean & 
Concentrator - 25 kit (Zymo Research), and eluted in 50 µL of nuclease-free water. Reverse 
transcription was performed using the Superscript III first-strand synthesis kit (Thermo Fisher) 
according to the manufacturer instructions in a 20 µL reaction containing 0.25 ug purified RNA. 
Control reactions contained the same amount of RNA but lacked reverse transcriptase enzyme. 
For qRT-PCR, primers were designed to amplify ~100 bp regions of the LRV1 genome that lie 
outside the stem regions (Table S4). qPCR reactions were performed with cDNA templates in 20 
µL total reaction volume using the Power SYBR Green Master Mix (Thermo Fisher), 5 µL of 
ten-fold diluted cDNA, and final primer concentrations of 0.2 µM. Reactions were run on the 
ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Thermo Fisher). PCR 
amplification conditions were as follows: 50 °C for 2 min and 95 °C for 10 sec followed by 40 
cycles of 95 °C for 15 sec and 60 °C for 1 min. PCR products were confirmed to be specific by 
melt curve analysis. All experiments were performed in triplicate. Amplification of KMP-11 was 
used as an internal control to normalize parallel reactions. 
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Small RNA (sRNA) sequencing 
sRNA libraries were generated from total RNA as described (39); briefly, a primer (5'-
rApppATCTCGTATGCCGTCTTCTGCTTG/ddC for all samples except Lgy M4147, which 
used primer rApppTGGAATTCTCGGGTGCCAAGG/ddC) was ligated first to the 3’ end using 
truncated mutant T4 RNA Ligase (New England Biolabs), and then a second riboprimer (5'-
GUUCAGAGUUCUACAGUCCGACGAUC) to the 5’ end with T4 RNA Ligase. cDNA was 
generated using reverse transcriptase and primer 5'-CAAGCAGAAGACGGCATACGA, and 
then PCR was performed with this in conjunction with primer 5'-
AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAGTCCGA. Products 
corresponding to inserts of 10-50 nt were purified, and taken for sequencing with Illumina 
HiSeq2500 technology. Sequences have been deposited in the NCBI Short Read Archive 
(accession SRP082553). 
Bioinformatic analysis of sRNAs 
The 5′ and 3′ adapter sequences were removed from the sRNA reads, those less than 15 
nt removed, and the trimmed reads were mapped to homologous LRV1 or Leishmania genomes 
(Lbr M2904 (63) or a draft Lgy M4147 genome (Bioproject PRJEB82; accession 
CALQ01000001 – CALQ01004013)) using Novoalign software http://www.novocraft.com; 
parameters were set as -F ILMFQ; -H; -g 40; -x 6; -R 5; -r; and -e 1000). A random strategy was 
employed to align reads mapping to multiple regions and hard clipping of low coverage bases at 
3’ end was performed. sRNA abundance was assessed directly, or after ‘collapsing’ to remove 
duplicate reads using algorithms within the fastx toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/index.html ). To annotate transposable or repeated 
elements, we used RepeatMasker ( http://www.repeatmasker.org) to identify known elements 
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and/or BLAST to identify regions corresponding to Leishmania specific elements (SLACS, TAS, 
and TATE (63)) . The annotations were collected in .bed file format for further use. Coverage 
was calculated by counting the number of reads that align to each strand of the LRV1 genome. 
LRV1 sequences  
From the sRNA sequences we assembled whole or partial LRV1 contigs, which were confirmed 
and completed by PCR amplification and sequencing. The sequences for LRV1-LbrLEM2700, 
LRV1-LbrLEM2780(a) and (b), LRV1-LbrLEM3874, and a revision of the LRV1-LgyM4147 
(formerly LRV1-4; (64)) genome sequences were deposited in GenBank (accession numbers 
KX808483-KX808487). 
LRV1 capsid flow cytometry.  
 The development and optimization of this protocol will be described elsewhere (F.M. Kuhlmann 
et al. in preparation). Briefly, 1 x 107 cells were fixed at room temperature (RT) using 2% 
paraformaldehyde (Thermo Fisher) in PBS for 2 min, and then then incubated in 
blocking/permeabilization buffer (BPB) (10% normal goat serum(Vector Laboratories) and 0.2% 
Triton X-100 in PBS) for 30 min, at RT. Anti-Lgy LRV1 capsid antibody (45) was added 
(1:20,000 dilution) and incubated at RT for 1 hr. After two washes with PBS, cells were 
resuspended in 200 μl BPB with Alexa488-labeled goat-anti-rabbit antibody (Thermo Fisher) 
(1:2,000 dilution) and incubated 1 hr at RT. After two additional washes with PBS, cells were 
subjected to flow cytometry and the data analyzed using CellQuest© software (BD Bioscience). 
Western blot, macrophage infections and cytokine assays. 
After an initial wash with PBS, 5x107 parasites were resuspended in 100 µL of 1x PBS. 1x107 
cells (20 µL) were lysed with 7 µL of 4x Laemmli’s gel sample buffer. After heating for 5 min at 
57 
 
95 °C, cell lysates were loaded and separated on a 10% polyacrylamide denaturing gel, 
transferred to a nitrocellulose membrane and visualized by Ponceau Red staining. The membrane 
was blocked for 1h in 5% powdered milk diluted in TBS + 0.05% Tween20, incubated overnight 
at 4 °C with the g018d53 anti-capsid polyclonal antibody (1:5000 in 1% milk TBS-Tween20), 
washed 4x 15 min at RT, incubated for 1h with an anti-rabbit IgG antibody coupled to 
peroxidase (Promega) (1:2500 in 1% milk TBS-Tween20), washed again 4x and finally revealed 
by ECL chemiluminescence (Amersham). Infections of BL6 mouse BMDM and cytokine assays 
were performed as previously described (7, 10). 
Statement identifying institutional and/or licensing committee approving animal experiments.  
Animal handling and experimental procedures were undertaken with strict adherence to ethical 
guidelines relevant in both host countries. These are set out by the SFVO and under inspection 
by the Department of Security and Environment of the State of Vaud, Switzerland. Experiments 
were carried out in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the United States National Institutes of Health. Animal studies 
were approved by the Animal Studies Committee at Washington University (protocol 
#20090086) in accordance with the Office of Laboratory Animal Welfare's guidelines and the 
Association for Assessment and Accreditation of Laboratory Animal Care International. 
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2.7 – Figure Legends 
Figure 2-1: Properties of Lbr siRNAs and sRNAs from Lbr and Lgy.  
A) Distributions of read lengths of siRNAs or sRNAs mapping to Leishmania genomes 
or LRV1s. Shown are 1) AGO1-bound siRNAs (black, solid) or sRNAs (black, dashed) 
from WT Lbr M2903 mapping to the Lbr genome, 2) Lgy M4147 sRNAs mapped to the 
Lg genome (blue, solid) or LRV1-LgyM4147 (blue, dashed), and 3) Lbr LEM2780 
sRNAs mapped to the Lbr genome (green, solid) or LRV1-LbrLEM2780 (green, dashed). 
B) Percentage of 23 nt sRNA reads (20-26nt) mapping to transposable elements (TEs, 
white), rRNA (red), tRNAs (black), genomic repeat regions (yellow), LRV1 (purple), and 
other Leishmania genomic regions (other, gray).  
Figure 2-2: RNAi constructs for LRV1 elimination. 
A) Schematic of an RNAi “stem-loop” (StL) construct. Each construct includes an 
inverted repeated sequence containing 800-1200 bp of the target gene (gene of interest, 
GOI) and a hygromycin drug resistance marker (HYGR). The construct is flanked with 
sequence of the small subunit ribosomal RNA gene, which allows it to integrate into this 
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locus, where it is transcribed at high levels. Splice acceptor (SA) signals within the 
construct allow for polyadenylylation and processing.  
B) Schematic showing LRV1 genome organization and regions targeted for RNAi StL 
constructions (thick bars) from Lbr LEM2700, LEM2780, and LEM3874, and Lgy 
M4147 targeted by RNAi (white, capsid; gray, RDRP). The locations of qPCR amplicons 
for quantification of LRV1 levels are shown (thin black bars).  
Figure 2-3: Loss of LRV1 induced by RNAi  
Anti-capsid flow cytometry analysis of LRV1-knockdown lines in Lgy M4147 and Lbr 
LEM2780 (top and bottom panels respectively). LRV1 capsid protein levels are 
unchanged in GFP65 StL lines, while LRV1 StL lines have undetectable capsid protein. 
Red, parent lines; purple, GFP65 StLs (off target control); green, LRV1-negative 
controls; light blue, Capsid StL; dark blue, RDRP StL. 
Figure 2-4. Overexpression of LRV1-mapping 23 nt sRNAs in LRV1 StL transfectants. 
A) Genomic mapping of 23 nt sRNA reads from sRNA sequencing of parental or capsid 
StL Lgy M4147 (left) or capsid-RDRP StL Lbr LEM3874 (right) mapping to transposable 
elements (TEs, white), rRNA (red), tRNAs (black), genomic repeat regions (yellow), 
LRV1 (purple), and other Leishmania genomic regions (other, gray). B) LRV1 mapping 
of 23 nt sRNA reads from LRV1StL lines described in panel A (Lgy M4147, top; Lbr 
LEM3874, bottom). Light gray trace indicates parental read distributions; dark gray trace 
indicates LRV1 StL read distributions. The dark box indicates the region targeted by the 
StL stems. 
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Figure 2-5: The LRV1 genome is completely lost in most LRV1-StL transfectants  
qPCR analysis of LRV1 RNA levels in LRV1 StL transfectant clones of Lbr LEM2700 
(A) and Lgy M4147 (B), along with positive and negative controls (+ and – respectively) 
and control GFP65 StL transfectants. White bars denote a non-specific qPCR product, 
while black bars denote an LRV1-specific amplicons (melt curve analysis). Dashed line 
indicates cutoff for designating a clone as LRV1-negative. Error bars are the standard 
deviation of three technical replicates for each line. 
Figure 2-6: LRV1 elimination results in decreased release of cytokines from infected 
macrophages. 
TNF-α or IL-6 levels were quantified 24h after infection of macrophages with Lbr 
LEM2780 (A) or Lg M4147 (B) parent, GFP65 knockdown control, or LRV1-StL 
transfectants. In both studies the LRV1- control was Lgy M4147. For A, results are 
averages of two-three technical replicates for two clones of each line. For B, results are 
the averages of two technical replicates for three to six clones of each line. NS, not 
significant; ** p < 0.01; *** p < 0.0001 by t-test.  
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2.9 – Supplemental Table Legends 
Supplemental Table 2-1: 23 nt siRNA analysis to Leishmania genome and LRV1.  
For Lbr, Lbr M2904 reference genome was used, and for Lgy, a M4147 draft genome (in 
preparation) was used. References for viral genomes are sequences reported in this work. 
Supplemental Table 2-2: Distributions of reads mapped to Lbr and Lgy genomes for Ago1-bound 
siRNAs, 23 nt (20-26 nt) and 33 nt (30-36 nt ) sRNAs.  
Supplemental Table 2-3: Primer sequences used to amplify regions of LRV1 for cloning into 
stem-loop constructs. 
Supplemental Table 2-4:  Primer sequences used to measure LRV1 RNA levels by qPCR. 
2.10 – Supplemental Figure Legends 
Supplemental Figure 2-1: Properties of Lbr siRNAs and 23 nt sRNAs from Lbr and Lgy.  
This figure shows mapping of the indicated small RNAs after ‘collapsing’ the data to 
remove duplicate reads. Shown are the percentages of 23 nt sRNA reads (20-26nt) 
mapping to transposable elements (TEs, white), rRNA (red), tRNAs (black), genomic 
repeat regions (yellow), LRV1 (purple), and other Leishmania genomic regions (other, 
gray). A) As in Figure 1B, mappings in WT parent lines. B) As in Figure 4A, comparing 
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parental lines with capsid StL Lgy M4147 (left) or capsid-RDRP StL Lbr LEM3874 
(right). 
Supplemental Figure 2-2: Mapping of 23nt sRNA reads (20-26 nt) from the respective parasite 
lines to LRV1-LbrLEM2700 (A), LRV1-LbrLEM2780(b) (B), LRV1-LbrLEM3874 (C), and 
LRV1-LgyM4147 (D).  
Reads mapping to the positive strand, (light gray); negative strand, (dark gray). 
Supplemental Figure 2-3: Capsid protein is lost in Lgy M4147 capsid StL transfectants.  
Three GFP65 StL control clones and six Capsid StL clones were evaluated. Top panel: 
Western blot analysis was performed using g018d53 anti-capsid polyclonal antibody 
(35). The arrow marks the location of the capsid protein band. Bottom panel: Ponceau S 
stain of protein gel.   
Supplemental Figure 2-4:  qPCR analysis of LRV1 RNA levels in LRV1 StL clones of L. 
braziliensis strain LEM2780 (A), L. braziliensis strain LEM3874 (B), and re-cloned L. 
guyanensis M4147 RDRP StL c3 (C).  
White bars denote a non-specific product; black bars denote an LRV1-specific product 
(melt curve analysis). Dashed line indicates cutoff for designating a clone as LRV1-
negative. Error bars are the standard deviation of three technical replicates for each line. 
Supplemental Figure 2-5: Infection of macrophages by Lbr LEM2700 (A) and Lgy M4147 (B).  
TNF-α or IL-6 levels were quantified 24h after infection of macrophages with Lbr (A) or 
Lgy (B) parasites. NI, not infected; LRV1+ or LRV1-, infected with Lgy M4147 LRV1+ 
or LRV1-negative cells; GFP65 StL transfectants; and RDRP StL or capsid StL 
transfectants. A) Results are the averages of two technical replicates of two clones per 
67 
 
line. Dark gray bars, experiment performed using WT macrophages; light gray bars, 
experiment performed using TLR3 knockout macrophages. B) Results are the averages of 
two technical replicates for each representative clone indicated. Lines found to be LRV1+ 
by qPCR are denoted by black bars; white bars are lines found to be LRV1-negative by 
qPCR. 
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Supplemental Table 2-1 
A.  Total Reads. 
Sample Total reads (raw) 
Total Trimmed 
Reads aligned to 
the Leish. 
genomes + 
viruses 
(Percent total) 
Aligned  
33 nt peak 
reads to 
Leishmania 
(% 
alignable 
reads) 
Aligned 23 
nt peak reads 
to 
Leishmania 
(% alignable 
reads) 
Aligned 
23 nt 
peak 
reads to 
LRV1 
(% 
alignable 
reads) 
Percent with 
3’ extension 
(Leishmania) 
Percent 
with 3’ 
extension 
(LRV1) 
Genome-
mapping 
reads 3' 
extension 
base A-T-
C-G (%) 
Lbr 
M2903a 29,391,347 
19,447,509  
(66.2%) 
1,827,623 
(9.40 %) 
15,147,603 
(77.9 %) n/a 21 n/a 43-41-8-8 
Lbr 
LEM2700 40,384,483 
29,473,443  
(73.0%) 
8,055,506 
(27.3%) 
15,540,670 
(52.7%) 
59,287 
(0.20%) 19 20 
43-41-7.9-
8.1 
Lbr 
LEM2780b 48,615,815 
34,959,518 
(71.9%) 
5,121,894 
(14.7%) 
25,361,713 
(72.5%) 
326,021 
(0.93%) 20 20 
43-40-7.8-
8.2 
Lbr 
LEM3874 36,543,649 
25,591,362 
(70.0%) 
4,052,707 
(15.8%) 
16,756,188 
(65.5%) 
347,022 
(1.36%) 19 19 
44-41-6.6-
7.4 
Lgy 
M4147 55,220,664 
 37,159,548  
(67.3%) 
1,261,927 
(3.40 %) 
25,489,186 
(68.6 %) 
660,143 
(1.78%) 15 13 
32-33-19-
15 
B. Collapsed Reads 
Sample 
Total 
reads 
(raw) 
Total Trimmed 
Reads aligned 
to the Leish. 
genomes + 
viruses 
Aligned  
33 nt peak 
reads to 
Leishmania 
(% 
alignable 
reads) 
Aligned 23 
nt peak reads 
to 
Leishmania 
(% alignable 
reads) 
Aligned 
23 nt peak 
reads to 
LRV1 
(% 23 nt 
reads) 
Percent with 
3’ extension 
(Leishmania) 
Percent 
with 3’ 
extension 
(LRV1) 
Genome-
mapping 
reads 3' 
extension 
base A-T-
C-G (%) 
Lbr 2,327,188 1,038,131 68,895 776,204 n/a 37 n/a 35-35-15-
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M2903a (44.6%) (6.64%) (74.8 %) 15 
Lbr 
LEM2700 2,948,017 
1,206,587 
(40.9%) 
127,998 
(10.6%) 
758,664 
(62.9 %) 
18,642 
(1.54%) 35 36 
34-34-16-
16 
Lbr 
LEM2780b 3,439,169 
1,777,142 
(51.7%) 
150,229 
(8.45%) 
1,050,094 
(59.1 %) 
61,753 
(3.47%) 33 34 
34-34-16-
16 
Lbr 
LEM3874 2,379,761 
1,224,741 
(51.5%) 
105,696 
(8.63%) 
632,961 
(51.7%) 
48,287 
(3.94%) 31 32 
35-35-15-
15 
Lgy 
M4147 1,437,673 
752,464 
(52.3%) 
152,059 
(20.2%) 
358,039 
(47.6%) 
43,099 
(5.73%) 22 22 
30-28-22-
20 
a Lbr M2903 SSU:IR2-LUCSR.   b The sum of reads mapping to LRV1-LbrLEM2780(a) and (b) are shown, which map quantitatively 
to similar levels. 
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Supplemental Table 2-2 
 Lbr M2903 Lgy M4147 
 AGO1-
bound 
siRNAs 
23 nt  
(20-26 nt) 
sRNAs 
33 nt  
(30-36 nt)  
sRNAs 
23 nt  
(20-26 nt)  
sRNAs 
33 nt  
(30-36 nt)  
sRNAs 
 
Alignable reads 
 
20,029,304 
 
19,447,509 
 
1,827,623 
 
37,159,548 
 
1,261,927 
 
Percent mapping 
to: 
     
 
Transposable 
elements 
     
SLACS      33.9 26.9 1.2 59.8 0.25 
TATE   45.1 53.1 5.2 10.7 0.32 
 
Repeats 
     
Misc.   5.8 5.0 7.7 1.1 2.4 
TAR   4.7 4.2 0.08 4.0 0.38 
TAS   4.2 5.1 20.3 4.8 6.5 
CIR   5.1 4.6 0.09 0.0 0.0 
 
Structural RNAs 
     
tRNAs   0.12 0.75 32.1 9.9 75.4 
rRNAs   
 
0.42 0.47 29.4 5.5 14.6 
       
Transposable elements, repeats and structural RNAs were classified as defined in the Methods 
and by Atayede et al (26) 
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Supplemental Table 2-3 
Parasite 
strain Target 
Construct 
ID Name 
Stem 
length Sequence 
Lbr 
LEM2700 
Capsid 
B6910  pIR2HYG-
LRV1_LbrLEM2700_CapsidStL(A) 
943 
bp 
5’-CGCTAGTCTAGAATACTACAGCAAACATGTTTCG 
  5’-CGCTAGTCTAGACAAGGTGTCTGTTGGGTTCGAT 
RDRP 
B6908  pIR2HYG-
LRV1_LbrLEM2700_RDRPStL(A) 
1143 
bp 
5’-CGCTAGTCTAGAATGTGCTTCAAACTTGAAGATG 
  5’-CGCTAGTCTAGATAGCAGCAATCTAACGACCTGC 
Lbr 
LEM2780 
Capsid 
B7061  pIR2HYG-
LRV1_LbrLEM2780_CapsidStL(A) 
835 
bp 
5’-CCAGCTTGGGATCAATTTGCGG 
  5’-GGACATCTCCATCAGCCGATGA 
RDRP 
B7062  pIR2HYG-
LRV1_LbrLEM2780_RDRPStL(A) 
794 
bp 
5’-GTGAGGATGAGTTGCGCGCTGC 
  5’-ATTGCTAAGTAGACTGTTTGCG 
Lbr 
LEM3874 
Capsid 
/ 
RDRP 
B7268  pIR2HYG-
LRV1_LbrLEM3874_StL(A) 
1000 
bp 
5’-GGCTAGTCTAGA GTCGTGCGATCTATTCCATCCT 
  5’-GGCTAGTCTAGATTAGTGCTTATGTTAGGATCAG 
Lgy 
M4147 
Capsid 
B7066  pIR2HYG-
LRV1_LgyM4147_CapsidStL(A) 
926 
bp 
5’-CTTCTCCTTTACGTGCCAGC 
  5’-GCGCATTGTTGTCCACTCAA 
RDRP 
B7063  pIR2HYG-
LRV1_LgyM4147_RDRPStL(A) 
829 
bp 
5’-CTTGCTAGGTCGTGGGGTGA 
  5’-ACCAACATGCATAGACGTGG 
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Supplemental Table 2-4 
 
 
 
 
 
 
KMP-11 F 5’-GCCTGGATGAGGAGTTCAACA 
R 5’-GTGCTCCTTCATCTCGGG 
L. braziliensis 
LEM2700 
F 5’-
CATCCTGCTGAGTTGACTTCATAC 
R 5’-
GTCACACCTTGTGATGACATTGC 
L. braziliensis 
LEM2780 
F 5’-
GTCATTACGAGGTGTGATGGAAT 
R 5’-GGTAACGCGCCATCACACAGT 
L. braziliensis 
LEM3874 
F 5’-GAATATGCTCTCCGACCGGTTG 
R 5’-
AATTCTCGCAGCCACCCCACAG 
L. guyanensis 
M4147 
Set 1 
F 
5’-CTGACTGGACGGGGGGTAAT 
Set 1 
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5’-CAAAACACTCCCTTACGC 
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CACGCTAGATGAGTACATCTGG 
Set 2 
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5’-GACACCACCTCTAAGACACG 
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Chapter 3: Knockout of Leishmania guyanensis Argonaute1 has little effect on LRV1 levels 
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Preface 
The majority of experiments in this chapter were designed, performed, and analyzed by EAB. 
SMB supervised the work and contributed to study design. Suzanne Hickerson assisted with 
mouse virulence experiments. The first draft of this chapter was written by EAB and the final 
version presented here incorporates comments from SMB. This chapter is being prepared for 
publication. 
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3.1 – Abstract  
Many isolates of Leishmania (Viannia) parasites harbor the dsRNA virus Leishmania 
RNA Virus 1 (LRV1), which is associated with increased disease severity in animal models and 
humans, and with drug resistance and treatment failure in humans. Interestingly, LRV1 survives 
in the face of an active RNAi pathway, which many organisms use as an antiviral mechanism. To 
determine whether the Leishmania RNAi pathway functions in control of LRV1, we knocked out 
the Argonaute1 (AGO1) gene from the LRV1-containing L. guyanensis strain M4147. Loss of 
AGO1 resulted in a 3.8-fold increase in transposable element transcripts and loss of transgene-
driven RNAi, indicating that the mutant parasites are RNAi-deficient. While in many organisms 
loss of RNAi results in dramatic increases in virus levels, there was only a 35% increase in 
LRV1 RNA after loss of AGO1. Virulence experiments in a mouse model of infection indicate 
that, while loss of AGO1 had no effect on virulence in the absence of LRV1, Δago1 lines with 
LRV1 had 2-fold higher parasitemia and induced lesions 25% larger than WT at the peak of 
infection. These experiments suggest that AGO1-dependent RNAi is likely not the main 
mechanism by which LRV1 levels are controlled, and further experiments are needed to identify 
antiviral pathways in Leishmania. Further, they suggest that even small changes in LRV1 level 
can result in changes in virulence.  
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3.2 – Introduction  
Leishmania are single-celled eukaryotes spread by sand flies that cause the disease 
leishmaniasis. These parasites are endemic to tropical and sub-tropical regions around the world, 
with an estimated 1-1.5 million infections and 20,000-40,000 deaths per year (1), many of which 
go unreported. Leishmania parasites can harbor a dsRNA virus, Leishmania RNA Virus (LRV) 
(2, 3). This genus of viruses has been found in both New World and Old World Leishmania 
species (4–6), but is most frequently reported as the virus species LRV1 in Leishmania (Viannia) 
subgenus parasites, including L. braziliensis and L. guyanensis. Infection with LRV1 is 
persistent, and virus particles are not infectious (7); rather, the virus is transmitted vertically 
through cell division, and virus strains have in fact co-evolved with their parasite hosts (8). The 
presence of LRV1 has been shown to increase parasite virulence in mice (9), and to correlate 
with treatment failure (10, 11), disease recurrence (11, 12), and the development of 
mucocutaneous disease (13, 14) in humans. Because of the potential for LRV1 to contribute to 
disease severity, a greater understanding of the interaction between parasite and virus, including 
mechanisms by which the virus is maintained and controlled, would be beneficial. Disruption or 
exploitation of these interactions could provide therapeutic benefit in leishmaniasis cases where 
LRV1 is present. 
In many organisms, including insects, fungi, and plants, the RNA interference (RNAi) 
pathway is known to be antiviral (15–17). RNAi is a conserved pathway found throughout 
eukaryotes that uses dsRNA to degrade a complementary ssRNA. The RNaseIII family protein 
Dicer cleaves long dsRNA into short interfering RNAs (siRNAs), which are loaded into the 
RNA-Induced Silencing Complex (RISC), which contains an Argonaute family protein. Perfect 
complementarity between the siRNA and a target ssRNA results in cleavage of the target by 
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Argonaute, and ultimately degradation of the target RNA. RNA viruses have dsRNA stages of 
their replication cycles, either in the form of a dsRNA genome or replication intermediates, 
which can serve as a substrate for Dicer. The resulting siRNAs can then target the viral mRNA 
for degradation. In organisms with antiviral RNAi, mutations to Dicer and/or Argonaute result in 
increased virus titers and pathology upon virus infection (18–20). Similarly, introduction of 
Dicer and Argonaute from Saccharomyces castellii into the RNAi-null S. cerevisiae results in the 
loss of L-A virus infection in the majority of cells (21). 
The role of RNAi in control of viruses in protozoa, however, has not been extensively 
studied. While many Leishmania species have lost the genes required for RNAi, Viannia 
subgenus parasites have retained an active RNAi pathway (22). Previous work from our lab 
found small RNAs with LRV1 sequence in LRV1-infected L. guyanensis and L. braziliensis 
parasites (23), and we further showed that LRV1 is eradicated from L. braziliensis and L. 
guyanensis parasites when additional pressure is placed on the virus using transgene-driven 
RNAi (23). Together, these results suggest that the LRV1 genome serves as a substrate for the 
RNAi pathway to generate siRNAs; further, it suggests that the LRV1 transcript is a target for 
the RNAi pathway, resulting in siRNA-directed cleavage by AGO1. This RNAi-mediated 
downregulation of LRV1 levels could be a mechanism by which Leishmania (Viannia) parasites 
control LRV1 replication. 
To further probe the role of the RNAi pathway in LRV1 infection, we knocked out 
Argonaute 1 (AGO1), which previous work from our lab and others has shown to be required for 
RNAi activity (22, 24), from LRV1-containing L. guyanensis. Ago1-deficient parasites were 
viable and lacked active RNAi. These parasites exhibited a small but significant increase in 
LRV1 levels; concurrently, Δago1 parasites were more virulent in mice when LRV1 was present, 
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but not in its absence. Therefore, Argonaute 1-dependent RNAi is unlikely to be the primary 
method of control of LRV1 in Leishmania guyanensis parasites. 
3.3 – Results  
3.3.1 – Generation of Δago1 parasites 
We began by knocking out the AGO1 gene in a luciferase (LUC)-expressing clone of L. 
guyanensis (Lgy) strain M4147 (hereafter referred to as “WT”) by successive homologous 
recombination, replacing each copy of AGO1 with an antibiotic resistance gene (Figure 1A). 
Confirmation of proper integrations by PCR is shown in Figure 1B & C. Three double 
replacement clones were obtained that lacked detectable AGO1 sequence by PCR in isolated 
genomic DNA (Figure 2A). Two clones were selected for further experimentation. Both Δago1 
clones lacked detectable AGO1 protein by Western blot using an anti-AGO1 antibody raised 
against L. braziliensis AGO1 (Figure 2B, lanes 2 and 5).  
To complement the knockout, we integrated an N-terminal Ty1-tagged LgyAGO1 into the 
18S ribosomal RNA locus of L. guyanensis Δago1 cells. This tag has been used successfully with 
LbrAGO1 in L. braziliensis and results in functional protein (24). Complemented lines 
(+AGO1c) expressed AGO1 protein near wild-type levels (Figure 2B, lanes 3, 4, 6, 7). As genes 
are transcribed at high levels from the 18S rRNA locus (25, 26), one might expect AGO1 protein 
levels to be increased above WT. Instead, this is evidence of the post-transcriptional gene 
regulation that is common in Leishmania parasites (27, 28). It also suggests that AGO1 cannot be 
easily over-expressed in L. guyanensis. 
 
 
90 
 
3.3.2 – Δago1 parasites are insensitive to RNAi driven by a transgene 
Previous work has shown that loss of AGO1 in L. braziliensis and the related parasite 
species Trypanosoma brucei results in a loss of RNAi activity (24, 29). In Leishmania (Viannia) 
species, transgene-driven RNAi is achieved by engineering an inverted repeat that contains 
sequence of the gene to be knocked down (stem-loop, StL) and integrating it into the small 
subunit (18S) ribosomal RNA locus of the parasite genome (22). To verify the loss of transgene-
driven RNAi activity in the Δago1 lines, we transfected a StL construct targeting the luciferase 
ORF (LUCStL), which was present in the WT prior to knockout of AGO1. In WT parasites, 
luciferase activity of the LUCStL-transfected line was 97% lower than that of the untransfected 
luciferase-expressing line (Figure 3A). This is less than the 300-fold reduction in luciferase 
activity we have previously shown in L. braziliensis, but in line with results in L. guyanensis that 
showed a 96% reduction in luciferase activity (22). This further supports our previous 
conclusions that the RNAi pathway is somewhat less efficient in L. guyanensis than in L. 
braziliensis. In contrast, luciferase activity was unchanged in Δago1 parasites (Figure 3A), 
indicating that transgene-driven RNAi activity is lost in these lines.  
3.3.3 – Δago1 parasites accumulate transposable element RNA 
Previous work in T. brucei (29) and L. braziliensis (24) showed that loss of AGO1 results 
in the loss of siRNAs derived from transposable elements (TEs) and increased TE transcript 
levels. To confirm loss of RNAi activity on endogenous targets in our L. guyanensis AGO1 
knockout, we evaluated SLACS and TATE transcript levels by sequencing and qPCR.  
We depleted ribosomal RNA from total RNA isolated from WT, Δago1, and +AGO1c 
parasites and subjected these to Illumina sequencing. The fraction of reads mapping to two 
control genes, glucose-6-phosphate dehydrogenase and the large subunit of RNA polymerase II, 
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were the same across the three genotypes. The proportion of reads mapping to SLACS was not 
affected by the loss of AGO1, but the proportion of reads mapping to TATE significantly 
increased in the Δago1 line and returned to the level of the WT line upon complementation 
(Figure 3B). To further confirm these findings, we prepared cDNA from total RNA for the WT 
line, Δago1, and +AGO1c and performed qPCR using primers specific for SLACS and TATE. 
As with RNAseq, SLACS levels were unaffected by the loss of AGO1, but TATE levels more 
than tripled in the Δago1 samples compared to the WT line and returned to the level of the WT 
line with complementation (Figure 3C). Reasons for the discrepancy between SLACS and TATE 
will be explored in the Discussion. 
Because the Δago1 parasites lack AGO1 proteins, have increased transposon levels, and 
are insensitive to transgene-driven RNAi, we conclude that they are functionally RNAi-deficient. 
Likewise, because AGO1 protein is expressed at WT levels and TATE RNA returns to WT 
levels in the +AGO1c complemented line, we conclude that the complemented line is RNAi-
proficient. 
3.3.4 – Knockout of AGO1 did not deregulate other Leishmania genes 
Previous work in L. braziliensis and L. guyanensis found that very few siRNAs originate 
from protein-coding genes (23, 24), suggesting that RNAi does not regulate these RNAs. We 
compared the number of RNAseq reads mapping to Leishmania genes for WT and Δago1 lines to 
determine if any were affected by the loss of AGO1. In this comparison, any data points that 
diverge from the best fit line are differentially expressed between the two samples. Because the 
RNA we sequenced was depleted of rRNA, we anticipated that levels would be somewhat 
variable; therefore, we omitted rRNA genes from our analysis. Further, we omitted LUC from 
the analysis due to its high expression (data not shown). As expected, AGO1 levels were 
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dramatically reduced in the Δago1 cells (Figure 4, arrow). While a number of TE elements were 
more highly expressed in Δago1 cells (Figure 4, red dots), no other gene appeared to be 
dysregulated in the absence of RNAi (Figure 4, blue dots).  For reference, the highly expressed 
genes in both samples are alpha-tubulin. These data are preliminary, and more clones are 
currently being sequenced in order to allow statistical analysis of differential expression. The 
lack of an effect on global gene expression levels following knockout of AGO1 further confirms 
that RNAi is not involved in the regulation of these loci. 
3.3.5 – Minimal change in LRV1 levels on loss of AGO1 
In other organisms, mutation of RNAi pathway components results in increases in virus 
titer by up to 1,000-fold (18, 30–34). If the RNAi pathway plays a role in controlling LRV1 
levels, then loss of AGO1 should result in an increase in LRV1 levels. To determine whether this 
occurred, we analyzed capsid protein level by flow cytometry using a polyclonal antibody raised 
against the capsid protein found in L. guyanensis strain M4147 (5).  The WT line, Δago1, and 
+AGO1c parasites were indistinguishable from one another (Figure 5a), indicating that a loss of 
RNAi activity did not result in increased translation of viral protein.  
To determine whether LRV1 RNA levels were likewise unchanged, we performed qPCR 
using primers specific to LRV1. We found that the Δago1 parasites had ~35% higher LRV1 
RNA levels than did the WT line, and that this increase was eliminated in the complemented 
lines (Figure 5b). While the increase in LRV1 levels observed in the knockout was statistically 
significant, such a small effect is unlikely to indicate a major mechanism of virus control.  
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3.3.6 – LRV1 capsid knockdown transgene does not reduce LRV1 levels in Δago1 parasites 
Previous work from our lab has shown that LRV1 can be eliminated from RNAi-
competent Leishmania by stable integration into the parasite genome of a stem-loop containing 
sequence from LRV1 (23). We proposed that this occurred through massive overproduction of 
siRNAs targeting LRV1. If this were the case, then LRV1 StL constructs should not reduce 
LRV1 levels in RNAi-deficient Δago1 parasites. Indeed, integration of the CapsidStL construct 
did not reduce LRV1 protein levels as assessed by flow cytometry, or RNA levels as assessed by 
qPCR (Figure 6). Instead, Δago1 CapsidStL lines had ~33% higher LRV1 RNA than the WT 
(RNAi-competent) line, similar to levels seen for the Δago1 alone (Figure 6b).  
3.3.7 – Virulence of Δago1 parasites is elevated compared to WT 
In the LRV1-negative L. braziliensis strain M2903, Δago1 parasites have decreased 
virulence and metastasis in mouse footpad infections (Hickerson & Beverley, unpublished data). 
We predicted that loss of AGO1 in L. guyanensis would, in the absence of LRV1, result in a 
similar virulence defect, but that the elevated levels of LRV1 in the Δago1 line would reduce this 
loss of virulence or even make this line more virulent that the WT line. To untangle the 
respective contributions of RNAi and LRV1 to virulence, we generated LRV1-negative clones of 
the WT, Δago1, and +AGO1c lines using the small molecule 2’C-methyladenosine (2CMA). 
Previous work in the lab has shown that short-term treatment with a low dose of 2CMA leads to 
a heterogeneous population of cells, some of which have lost LRV1 (35). This population can be 
sub-cloned to generate isogenic lines that bear and lack LRV1. We injected 2CMA-treated 
parasites of each genotype, both LRV1+ and LRV1-negative clones, into the hind footpad of 
C57B/6 mice and monitored infection by measuring lesion size (a measure of pathology) and 
luciferase activity (a measure of parasitemia).  
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As expected, LRV1-negative clones of each line were less virulent than were the LRV1+ 
clones (Figure 7). Somewhat to our surprise, there was no significant difference between the 
Δago1 line and either the WT or complemented line in the absence of LRV1. In contrast, in the 
presence of LRV1, the Δago1 line was more virulent than either the WT or complemented line at 
the peak of infection, with 25% higher footpad swelling and ~2-fold higher parasitemia in the 
Δago1 parasites than the WT.  
Previous work has shown that infection of IFN-γ –deficient mice with L. guyanensis 
results in a chronic infection and a tendency for parasites to metastasize to the tail and/or 
uninjected foot (36). To determine whether the loss of AGO1 (and increase in LRV1) affected 
metastasis, we injected the same 2CMA-treated lines used above into IFN-γ-/- mice. A number of 
mice developed severe infections and had to be sacrificed before metastases could develop 
(Figure 8A). Of the remaining mice, infection with parasites containing LRV1 was more likely to 
lead to tail metastasis than infection with LRV1-negative parasites (Figure 8B). In the LRV1-
negative lines, loss of AGO1 did not appear to affect the development of metastases, similar to 
the virulence data in WT mice. In contrast, infections with Δago1 parasites were more likely to 
metastasize than WT in the presence of LRV1. This data is preliminary, and these experiments 
will have to be repeated with a lower inoculum to reduce mouse mortality and obtain high-
confidence data. 
3.4 – Discussion  
In our experiments, knockout of AGO1 from L. guyanensis parasites resulted in ablation 
of the RNAi pathway, as occurred in L. braziliensis. In the knockout parasites, introduction of a 
stem-loop targeting the luciferase ORF had no effect on luciferase activity, while in the WT line 
the same construct results in a greater than 95% reduction in luciferase activity (Figure 2A). 
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Likewise, levels of the TATE element transcript tripled, indicating that control of endogenous 
targets was disrupted (Figure 2B & C).  
Interestingly, SLACS levels did not appear to change with loss of AGO1in these 
experiments, whereas they were clearly affected by loss of AGO1 in L. braziliensis (24). It is 
unclear why this should occur. It is not likely due to the level of expression, as there was not a 
large discrepancy in the proportion of RNAseq reads mapping to SLACS compared with TATE 
(there were 2-fold more TATE-mapping reads) (Figure 2B), and reads mapped to each TE at 
levels higher than any of the housekeeping genes that we examined. Sequencing of sRNAs in L. 
guyanensis revealed that a large proportion of sRNAs originate from SLACS (23), so 
presumably they should be capable of repressing SLACS transcripts. Instead, it may be an 
artifact of the methods used, as neither RNAseq nor qPCR can differentiate between large 
degradation products and full transcripts. We have previously shown that qPCR over-estimates 
the level of an RNA undergoing knockdown (22) compared with the level of expression 
determined by Northern blot. It is possible that our analysis overestimated the level of full 
transcript in WT and +AGO1c lines; further work would be required to confirm this. 
 Because of the substantial effect of RNAi on virus levels in other systems, we 
hypothesized that loss of AGO1 would result in a large increase in LRV1 levels, to the point that 
it could have been lethal. Not only were Δago1 parasites viable, the increase in LRV1 RNA was 
much smaller than expected, only 35% over the level in the WT line (Figure 3). Further, the 
parasites do not appear to accumulate increasing levels of LRV1 RNA during continued culture, 
indicating that the 35% increase represents a new “set point” level of LRV1. While this increase 
(and subsequent decrease upon complementation) was statistically significant, this small of an 
effect does not support a substantial role for Ago1-dependent RNAi in the control of LRV1. It 
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does not, however, rule out a role for AGO1 in control of LRV1, either. We hypothesized that 
loss of AGO1 could result in uncontrolled virus replication, resulting in loss of parasite viability. 
If this occurred, only parasites that had developed a compensatory mechanism for controlling 
LRV1 levels would survive to be evaluated; perhaps the clones analyzed in this work have such a 
compensatory mechanism. Alternatively, small changes can have large effects over long 
timescales. It is possible that this small increase in LRV1 is too mild a stress to measure in a 
laboratory setting, but is substantial enough to support the maintenance of LRV1 over millions of 
year of evolution.  
In previous work, we showed that the introduction of the CapsidStL construct into the 
WT line resulted in a loss of LRV1 (23). As transgene-driven RNAi was ablated in the Δago1 
line we expected that the StL construct would be non-functional, and indeed introduction of the 
CapsidStL construct into the Δago1 line did not affect LRV1 levels (Figure 4). These results 
confirm the AGO1-dependency of the CapsidStL and suggest that the interaction between LRV1 
and the RNAi pathway functions differently in the presence of the StL construct than in its 
absence. Our previous work showed that the CapsidStL construct results in massive over-
production of LRV1-mapping sRNAs (23); perhaps there is a maximum level of RNAi pressure 
that LRV1 is able to withstand, and the levels of anti-LRV1 siRNAs produced under normal 
conditions do not meet this threshold.  
While Δago1 L. braziliensis parasites had decreased virulence in the mouse model of 
infection, this did not occur in LRV1-negative L. guyanensis; instead, the Δago1 line was not 
significantly different from the WT line (Figure 5A & B). There are two possibilities why this 
may occur. First, it appears that RNAi is somewhat less efficient in L. guyanensis than in L. 
braziliensis (22). It is possible that this less-efficient RNAi pathway has less of an effect on 
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virulence than the more active L. braziliensis pathway. Second, this may suggest that RNAi 
regulates a virulence-associated endogenous target in L. braziliensis but not in L. guyanensis.  
In contrast, loss of AGO1 in the presence of LRV1 resulted in an increase in virulence 
(Figure 5C & D). This is likely due to the increased levels of virus in LRV1+ Δago1 parasites 
compared to WT. Previous reports found that the presence of LRV1 significantly increased the 
virulence of L. guyanensis parasites in mouse models of infection (9). Additionally, previous 
work in strains of L. aethiopica containing LRV2 showed that the inflammatory response in 
macrophages was correlated with viral load (6). The previous studies relied on different strains 
with varying LRV1 burdens, and some of the observed differences in virulence could be due to 
parasite genetic factors. In our experiments, we examined two isogenic lines with different levels 
of LRV1; to our knowledge, this is the first experiment of its type. As relatively small increases 
in LRV1 resulted in observable increases in virulence, these results suggest that it is possible to 
improve patient outcomes by reducing the level of LRV1 even partially in patient infections. 
Many RNA viruses infecting plants and insects encode Viral Suppressors of RNAi 
(VSRs) to evade their hosts’ antiviral RNAi pathways (reviewed in Szittya and Burgyan 2013; 
Bronkhorst and Van Rij 2014). LRV1 does not appear to have the coding capacity for such a 
mechanism, and certainly there is no trans-acting VSR, as L. guyanensis parasites with LRV1 
are equally capable of downregulating luciferase by RNAi as an LRV1-negative isogenic line 
(22). Additionally, the ability of the LRV1 StL to ablate LRV1 suggested that there was no cis-
acting VSR; however, the StL generated massive amounts of LRV1-targeting siRNAs, which 
could overwhelm any VSR present (23). It is possible that LRV1 encodes a cis-acting VSR 
capable of evading the RNAi pathway at natural levels of pressure. If this were the case, loss of 
AGO1 would have little effect on LRV1 level. 
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Alternatively, it is possible that anti-LRV1 siRNAs are bound to another Argonaute 
protein than AGO1. Trypanosomatids have a second Argonaute, termed “Piwi” (so named 
because the PAZ domain has a highly divergent sequence and is apparent only by structural 
homology (38), leaving only an identifiable Piwi domain), whose function is unknown. Perhaps 
anti-LRV1 sRNAs preferentially bind Piwi rather than AGO1, and RNAi control of LRV1 
occurs through Piwi, with only incidental regulation via AGO1. Future experiments will be 
needed to determine whether this is the case; however, efforts to knock out Piwi in Viannia 
subgenus parasites have thus far been unsuccessful, and RNAi knockdown of Piwi did not result 
in a decrease in Piwi RNA levels (Appendix C). 
It is also possible that RNAi control of LRV1 occurs at the level of Dicer. Perhaps the 
LRV1-derived sRNAs, while capable of eliciting downregulation of LRV1 at high 
concentrations, don’t efficiently direct cleavage of the LRV1 transcript at physiological levels; 
rather, cleavage of the LRV1 dsRNA genome by Dicer is sufficient to inhibit LRV1 replication 
and maintain sustainable virus levels. There are some reports in the literature in which loss of 
Dicer impacted virus levels more strongly than loss of Argonaute (18, 39, 40). Finally, it is 
possible that neither cleavage of the LRV1 dsRNA genome by Dicer, nor cleavage of the LRV1 
transcript by AGO1 plays a substantial role in control of LRV1 levels. If this were the case, some 
other unknown mechanism would be required to maintain LRV1 at sustainable levels. 
3.5 – Materials and Methods 
Parasite strains and cell culture 
L. guyanensis strain M4147 (MHOM/BR/78/M4147) was obtained from Jean Patterson 
(Southwest Foundation for Biomedical Research, San Antonio, Texas) and transfected with 
SwaI-linearized B6367 pIR2SAT-LUC(B). Clonal lines were derived, and clone 3 was used in 
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further experiments. Parasites were grown in fresh Schneider’s Insect Medium supplemented 
with 10% heat-inactivated fetal bovine serum, 100 μM adenine, 5 x 10-5% hemin, 2 μg/mL 
biopterin, 2mM L-glutamine, 500 units/ml penicillin and 50 ug/mL streptomycin. 
Selective agents used were nourseothricin sulfate (Gold Biotechnology), blasticidin S 
HCl (Fisher Scientific), puromycin dihydrochloride (Sigma-Aldrich), and hygromycing B 
(Hygro99, Gold Biotechnology). 
Constructs and transfections 
1x108 cells were resuspended in 0.5 mL cytomix buffer (120 mM KCl, 150 M CaCl2, 10 
mM K2HPO4, 25 mM Hepes, 2 mM EDTA and 5 mM MgCl2,  pH 7.6 using KOH), mixed with 
10 μg linearized DNA, and electroporated twice in a 4mm gap cuvette at 1400 V and 25 μF, 
waiting 10s between zaps. Cells were placed in 10 mL Schneider’s Medium without selection 
and allowed to recover overnight. 
To generate Δago1 parasites, the blasticidin and puromycin resistance genes were fused 
between 823bp of sequence at the 5’ flank and 281bp of sequence at the 3’ flank of the AGO1 
gene. These constructs were used to successively replace the two alleles of AGO1. Transfected 
cells were plated on semisolid media containing 100 μg/mL nourseothricin and either 10 μg/mL 
blasticidin or 20 μg/mL puromycin. Colonies were picked into 1 mL Schneider’s Medium 
without selection, expanded to 5 mL Schneider’s Medium with 50 μg/mL nourseothricin and 5 
μg/mL of either blasticidin or puromycin, and passaged thusly. 
To generate the complemented +AGO1c line, we tagged the N-terminus of the AGO1 
gene with the Ty1 epitope (EVHTNQDPLD) and cloned this ORF into a modified pIR1HYG 
vector that replaces the BglII cloning site with a PacI site [B7397 pIR1HYG(B-PacI)]. We 
linearized this DNA with SwaI and transfected it into Δago1 parasites. Clones were selected on 
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semisolid media containing 50 μg/mL nourseothricin and 150 μg/mL hygromycin B and 
passaged in liquid Schneider’s Medium containing 25 μg/mL nourseothricin, 2.5 μg/mL 
blasticidin, 2.5 μg/mL puromycin, and 50 μg/mL hygromycin B. 
B7066 pIR2HYG-LRV1_LgyM4147_CapsidStL(A) and B6486 pIR2HYG-LUCStL(A) 
were linearized with SwaI and transfected into Δago1 parasites. Control LUCStL lines were 
generated by transfection of B6486 into L. guyanensis M4147 LUC c3. Clonal lines were 
selected by limiting dilution in 96-well plates. Transfected cells were allowed to recover 
overnight and diluted to 105 cells/mL in Schneider’s Medium containing 50 μg/mL 
nourseothricin and 75 μg/mL hygromycin B. 200 μL of cells were seeded into 96-well plates. 
Wells that survived selection were expanded and passaged in Schneider’s Medium containing 25 
μg/mL nourseothricin and 50 μg/mL hygromycin B, with the addition of 2.5 μg/mL blasticidin 
and 2.5 μg/mL puromycin for the Δago1 transfections. Control CapsidStL lines were described 
previously (23). 
Treatment with 2’C-methyladenosine (2CMA) 
Parasites were seeded at 1x105 cells/mL in Schneider’s medium lacking supplemental 
adenine and containing 10 μM 2CMA. After 5 cell doublings, cultures were pelleted at 3,000 
rpm and resuspended in fresh Schneider’s medium containing adenine without 2CMA. After 48 
hours, cells were plated on semisolid media. Colonies were picked into 1 mL Schneider’s 
medium, expanded to 5 mL with appropriate selective antibiotics, and evaluated for LRV1 levels 
using flow cytometry. 
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Western blot 
Mouse BB2 antibody was obtained from Sigma-Aldritch. Rabbit anti-H2A (41) and anti-
AGO1 antibodies were produced by Proteintech. Secondary antibodies used were IRDye800CW 
goat anti-mouse and IRDye680RD goat anti-rabbit (LI-COR Biosciences). 
5 x 107 cels from mid-log culture were resuspended in 100 μL 1x Laemmli buffer (62.5 
μM Tris, pH6.8; 2% SDS; 10% glycerol; 2.5% 2-mercaptoethanol; 0.001% bromophenol blue) 
and heated at 95°C for 5 min. Cell lysates were stored at -20°C. Lysates were run on 
polyacrylamide (4% stacking, 10% resolving) gels at 200V and proteins were transferred to 
nitrocellulose membranes at 60V for 2 hours at 4°C. Membranes were blocked overnight at 4°C 
in Odyssey blocking buffer (LI-COR Biosciences). Primary antibodies were incubated at room 
temperature for 2 hours at the following dilutions: α-BB2, 1:00; α-H2A, 1:10,000; α-Ago1, 
1:1,000. All primary antibody dilutions were made in Odyssey blocking buffer. Membranes were 
washed 4 times with PBS-T (0.1% Tween-20 in PBS) for 10 min per wash. Secondary antibodies 
were diluted 1:10,000 in Odyssey blocking buffer containing 0.2% Tween-20 and membranes 
were incubated for 1 hour at room temperature in the dark. All subsequent steps occurred in the 
dark. Membranes were washed again 4 times with PBS-T for 10 minutes/wash and twice with 
PBS (no Tween-20). Membranes were scanned using the LI-COR Odyssey Infrared Imaging 
System.  
Luciferase activity assay 
106 log phase cells in 200 μL of Schneider’s Medium were added to a 96-well plate 
(Black plate, Corning Incorporated, NY, U.S.A.). D-luciferin (Biosynth AG) was added to a final 
concentration of 150 μg/mL and plates were incubated for 1 min. Plates were imaged using a In 
Vivo Imaging System (IVIS) photoimager (Perkin Elmer), and luciferase activity quantified as 
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photons/s. Each sample was run in duplicate. Three clones each of the WT line and two knockout 
clones transfected with empty vector and the LUCStL construct were evaluated. 
Flow cytometry 
Flow cytometry using the anti-capsid antibody (5) was performed as described previously 
(23). 
RNA preparation 
2.5-3 x 108 log phase promastigotes were spun down and resuspended in 1 mL Trizol 
reagent (Ambion, Thermo Fisher Scientific), and 250 μL of dissolved cells were used for each 
preparation of total RNA. RNA was isolated using the RNA miniprep kit (Zymo Research), 
DNaseI-treated in a 200 μL reaction using 20 Units of enzyme and the supplied buffer (Ambion, 
Thermo Fisher Scientific) for 1 hour at 37°C. Enzyme was removed using RNA Clean & 
Concentrator - 25 kit (Zymo Research) and eluted in 50 μL nuclease-free water. RNA 
concentrations were obtained using the Qubit RNA Broad-Range assay (Thermo Fisher 
Scientific) and RNAs were stored at -80°C. 
RNA sequencing and bioinformatics analysis 
RiboZero RNA libraries were generated from total RNA as described (42). Briefly, 
sample integrity was assessed by Agilent Bioanalyzer 2100 (Santa Clara, CA). rRNA was 
depleted from 1 mg input RNA with the Ribo-Zero™ rRNA Removal Kit (“RiboZero”) from 
EpiCentre (an Illumina company, Madison, WI). RiboZero-depleted RNA was chemically 
fragmented to generate fragments ranging from 200-600 nt in length, then made into cDNA with 
Superscript III (Life Technologies, Thermo Fisher) and random hexamers followed by a second 
strand reaction. cDNA was then end-repaired, A-tailed, and standard Illumina adapters were 
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ligated on. Libraries were amplified with primers to incorporate a unique index to each sample. 
Equal masses of each library were pooled and sequenced on an Illumina HiSeq2500 platform, 
with 2 × 100 base pair paired end reads (Illumina Inc., San Diego, CA). 
Data were analyzed using CLC Genomics v9.5.3. Briefly, 5’ and 3’ adaptors were 
removed and trimmed reads were mapped to annotated genes and transposable elements from the 
L. guyanensis M4147 genome, as well as to LRV1 genes (KX808487) using default RNA-Seq 
parameters. Reads mapping to multiple locations were aligned randomly. 
cDNA synthesis and qPCR 
cDNA was synthesized by reverse transcription using the Superscript III First Strand 
Synthesis kit (Thermo Fisher Scientific) according to manufacturer instructions in a 20 μL 
reaction containing 0.25 μg purified total RNA. Control reactions contained an equal amount of 
RNA but lacked reverse transcriptase enzyme. 
Primers used for qPCR can be found in Table 1. Annotated SLACS elements were 
aligned to identify consensus regions in common among multiple elements, and primers were 
designed to amplify a 97 bp region of this consensus sequence. These primers bind to 7/15 
annotated elements, which are responsible for 61,740/88,075 (70.0%) of total SLACS-mapping 
sequencing reads. Similarly, TATE elements were aligned to identify common sequences, and 
primers were designed to amplify 106 bp of this consensus sequence. These primers bind to 
15/53 annotated elements, which are responsible for 210,037/298,077 (70.5%) of TATE-
mapping sequencing reads. LRV1-specific primers were designed to amplify an approximately 
100 bp region of the LRV1 genome. Control primers were designed to amplify approximately 
150 bp of the KMP-11 5’ UTR. 
104 
 
qPCR reactions were performed in MicroAmp Optical 96-well plates or MicroAmp Fast 
Optical 96-well plates (Thermo Fisher Scientific) using 20 μL reactions. Each reaction contained 
5 μL of ten-fold diluted cDNA, 10 μL of 2x Power SYBER Green Master Mix (Applied 
Biosystems, Thermo Fisher Scientific), and primers to a final concentration of 0.2 μM each. 
Reactions were run on the ABI PRISM 7000 Sequence Detection System or ABI ViiA 7 Real-
Time PCR System (Applied Biosystems, Thermo Fisher Scientific). PCR amplifications were as 
follows: 50 °C for 2 min and 95 °C for 10 min followed by 40 cycles of 95 °C for 15 sec and 60 
°C for 1 min. PCR products were confirmed to be specific by melt curve analysis. +RT reactions 
were performed in triplicate and –RT control reaction in duplicate. 
Serial 4-fold dilutions of cDNA were used to generate primer efficiency curves for each 
primer set on each plate, and relative SLACS, TATE, and LRV1 level was determined using the 
Pfaffl method (43). For the SLACS and TATE experiments, three biological replicates of the WT 
line, two biological replicates of each of two Δago1 clones, and four +AGO1c clones were 
averaged and statistical significance determined by ANOVA followed by the Tukey post hoc 
test. For the LRV1 experiment, four biological replicates of the WT line (L. guyanensis M4147 
LUC c3), two biological replicates of each of two ago1- clones, and 12 clones of the Ty1-tagged 
complemented line were averaged and statistical significance determined by ANOVA followed 
by the Tukey post hoc test. 
Statement on Institutional and Licensing Committee Approval of Animal Experiments 
Animal handling and experiments were carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals (44) of the US 
National Institutes of Health. Animal studies were approved by the Animal Studies Committee at 
Washington University (protocol 20090086) in accordance with the Office of Laboratory Animal 
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Welfare’s guidelines and the Association for Assessment and Accreditation of Laboratory 
Animal Care International. 
Mouse infection 
Female C57/B6 mice were obtained from Jackson Laboratories. IFN-γ-/- mice were 
obtained from Dr. Herbert Virgin (Washington University School of Medicine, St. Louis, MO) 
Parasites were grown to day 2 stationary phase and collected at 1x106 cells/50 μL DMEM. Mice 
were injected subcutaneously in the left hind footpad with 1x106 parasites using a 30 gauge 
needle. Luciferase activity was monitored weekly by imaging using the IVIS (Perkin Elmer). 
Briefly, mice were injected intra-peritoneally with 150 mg/kg D-luciferin, potassium salt (Gold 
Biotechnology) 10 minutes before imaging. Five minutes before imaging they were 
anaesthetized with isofluorane, and anesthesia was continued throughout the procedure. Emitted 
photons were quantified using Living Image v2.60.1 software (Perkin Elmer). Lesion size was 
measured weekly using calipers. 
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3.7 – Table Legends 
Table 3-1: Primers used in qPCR analysis of SLACS, TATE, and LRV1 RNA levels.  
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3.8 – Figure Legends 
Figure 3-1: Confirmation of AGO1 replacement by PCR.  
A) Schematic of replacement of AGO1 by drug resistance cassettes.  
B) Schematic of PCR primer binding sites for the confirmation of integration. For each 
reaction, one primer binds within the drug resistance gene; the other binds to a region of 
the flanking region outside the targeting construct. Expected PCR product size is 
indicated.  
C) Integration PCR products confirming replacement. Left, replacement with BSDR to 
generate the heterogygote; right, replacement with PACR to generate the knockout. NTC, 
no-template control. 
Figure 3-2: Replacement of AGO1 alleles results in Δago1 parasites.  
A) PCR failed to amplify the AGO1 gene in L. guyanensis knockout clones 15, O, and R, 
as well as L. braziliensis strain M2093 Δago1 (Lbr Δago1), but not in the L. guyanensis 
AGO1 heterozygote. NTC, no template control.  
B) AGO1 protein was undetectable by Western blot in Δago1 clones and present at WT 
levels in +AGO1c complemented lines. Loading control, α-Histone H2A antibody. 
Figure 3-3: Δago1 parasites are functionally RNAi-deficient. 
 *  p<0.05; ****  p<0.0001.  
A) Δago1 parasites transfected with a transgenic RNAi construct targeting luciferase 
(LUCStL) have no reduction in luciferase activity compared to empty vector control.  
B) Fraction of RNAseq reads mapping to SLACS and TATE transposable elements, as 
well as to Argonaute and two housekeeping genes, glucose-6-phosphate dehydrogenase 
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(G6PD) and the large subunit of RNA polymerase II (RNAPII-LS). Reads mapped at 
similar frequencies  to SLACS and the two housekeeping genes between the WT, Δago1, 
and +AGO1c lines. TATE-mapping reads were significantly higher in the Δago1 line.  
C) Relative level of SLACS and TATE transposable element RNA by qPCR. SLACS 
levels were similar between the lines, while TATE levels were increased in Δago1. 
Figure 3-4: Comparison of global gene expression between WT and Δago1 parasites.  
Average read counts of two biological replicates are plotted for each genotype. Red, TE 
genes; blue, all other genes. rRNA genes and LUC were removed from the analysis. The 
location of the AGO1 data point is indicated. 
Figure 3-5: Knockout of AGO1 results in small increases in LRV1.  
A) Flow cytometry of WT line (red), Δago1 (green), +AGO1c (purple), and LRV1-
negative (black) parasites using an anti-capsid antibody. Traces are representative of 3-4 
clones/biological replicates.  
B) LRV1 RNA levels determined by qPCR. Averages and standard deviations are of 4-12 
biological replicates/clones. *  p<0.05 
Figure 3-6: The CapsidStL transgenic RNAi construct is non-functional in Δago1 parasites.  
A) Flow cytometry of WT line (red), Δago1 (green), Δago1 + CapsidStL (purple), 
LRV1-negative (black), and WT + CapsidStL (blue) parasites using the anti-capsid 
antibody. Traces are representative of  2-6 clones/biological replicates.  
B) LRV1 RNA levels determined by qPCR. Averages and standard deviations are of 2-6 
biological replicates (WT) or independent clones (Δago1 CapsidStL).  ****  p<0.0001. 
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Figure 3-7: Virulence of Δago1 parasites in the presence and absence of LRV1. 
Infections in WT mice with Δago1 parasites have similar virulence in the absence of 
LRV1 (top panel), while Δago1 parasites are more virulent in the presence of LRV1 
(bottom panel). Parasitology was evaluated by luciferase activity (panels A & C) and 
pathology by lesion size (panels B & D). Averages and standard deviations are of 3 
experiments with two clones per group, 4 mice per clone. #, significance of Δago1 vs 
WT; +, significance of WT vs +AGO1c; *, significance of Δago1 vs +AGO1c. *  p<0.05; 
**  p<0.01; ****  p<0.0001. 
Figure 3-8: LRV1+ parasites are more likely to metastasize than LRV1-negative parasites in 
IFN-γ-/- mice.  
A) Mouse survival curve of lines evaluated.  
B) Number of tail metastases per mouse. 
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B7907 5’-GGCACCGACTCCTTCATG 
LRV1 B6415 5’-CACGCTAGATGAGTACATCTGG 
B6416 5’-GTAGTTGCGGAATCTGACG 
KMP-11 B5023 5’-AACGCTATATAAGTATCAGTTTCTGTACTTTA 
B7412 5’-GGTGACGATGCGGGTACC 
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Chapter 4:  Popping DNA out of the Leishmania genome – a control for mutants with 
dominant phenotypes 
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Preface 
The experiments in this chapter were designed, performed, and analyzed by EAB under the 
supervision of SMB. The first draft of the chapter was written by EAB, and the final version 
presented here incorporates comments from SMB.  
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4.1 – Abstract  
Here we present a method for short-term expression of a gene or RNAi transgene in Leishmania 
(Viannia) parasites. We show that parasites transfected with these constructs display a mutant 
phenotype, and revert to a wild-type phenotype following removal of the construct. This method 
provides a tool to determine the essentiality of genes, which could not previously be sufficiently 
proven in L. (Viannia) species.  
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4.2 – Introduction  
The process of culturing cell lines in the laboratory leads to mutations and gene 
expression alterations that affect cell growth and biology (1–4). If these changes occur during the 
course of planned genetic manipulations, they can confound interpretation of the results of the 
experiment. To combat this, one must take steps to separate effects of the planned manipulations 
from culture artifacts. For example, when genes are knocked out, it is standard procedure to 
complement the mutant by expression of the deleted gene. If the complemented line reverts to a 
WT phenotype, one can be reasonably certain that any phenotype observed in the mutant is due 
to the loss of the gene under investigation. 
Similar controls are less common during the expression of dominant genes, including the 
expression of dominant negative mutants or heterologous genes. Typically, multiple independent 
mutants are evaluated to rule out random mutations. This, however, does not control for 
compensatory mutations.   
Many Leishmania species, such as L. major, L. mexicana, and L. donovani, support the 
replication of circular extrachromosomal elements called episomes (5–8). In these species, short-
term expression of genes can be achieved by transfection of an episome that confers resistance to 
a selective agent, and that can then be lost after removal of selective drug pressure. By 
expressing dominant genes from an episome, one can confirm that an observed phenotype is 
gene-specific by selecting for cells that have lost the episome and confirming that they have a 
WT phenotype. 
These episomes, however, do not work well in Leishmania (Viannia) species (9), 
possibly because transcription from these episomes occurs from both strands (10). This likely 
results in long dsRNA that enters the RNAi pathway, which is present in Viannia species, but not 
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Leishmania (Leishmania) species (9, 11). As a result, any genes expressed from the episome, 
including those conferring resistance to a selection agent, are likely silenced. Because of this, 
genes must be stably integrated into the parasite genome to attain expression, which is 
effectively a permanent modification. 
Here we describe an analogous method of gene expression for use in Leishmania. 
“Popout” constructs integrate into the parasite genome and confer GFP expression, allowing 
cells to be rapidly scored for presence or absence of the construct. We show that popout 
constructs carrying an RNAi transgene targeting the paraflagellar rod 2 (PFR2) gene trigger 
downregulation of PFR2, and that loss of the construct returns cells to a wild-type phenotype. 
4.3 – Results  
4.3.1 – Construction of a removable expression construct 
We had three criteria for the design of our expression construct: 1) stable integration into 
the parasite genome; 2) a propensity for spontaneous loss; and 3) a rapid and facile method to 
identify parasites that had lost the construct. To accomplish this, we cloned the GC-rich GFP+ 
ORF (12) into the “B” cloning site of pIR3 and pIR3-GW(A) plasmids (Figure 1A). pIR3 
plasmids are derivatives of pIR1 (11), and replace the L. pifanoi CYS2 intergenic region of IR1 
with the L. braziliensis alpha-tubulin intergenic region. These plasmids integrate into the 18S 
small subunit ribosomal RNA array by homologous recombination, where they are transcribed at 
high levels (13). The pIR3-GW(A) plasmid uses Gateway technology (Invitrogen, Thermo 
Fisher Scientific) to facilitate cloning of an inverted repeat (stem-loop, StL). These StL 
constructs are used to trigger transgene-driven RNAi in Leishmania (Viannia) species (9, 14). 
In principle, we expected these constructs to behave in a manner analogous to the pXG 
episome (15, 16) (Figure 1B). Briefly, integration of a pIR3-GFP+(B) construct into the 
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Leishmania genome would cause expression of three genes: one conferring resistance to 
selection antibiotic; GFP; and the desired gene or StL. Transfectants could be selected either by 
culturing with the selective antibiotic or by single-cell sorting for GFP-positive cells. Removal of 
drug selection would allow the integrated DNA to be lost by gene conversion – “popped out” – 
at which time cells would no longer express GFP, the antibiotic resistance gene, or the transgene 
or StL. Single-cell sorting for GFP-dim cells would allow recovery of clonal populations that no 
longer contain the construct. Due to the ability of these constructs to be readily lost, we have 
termed them “pop-out constructs.” 
4.3.2 – Knockdown of paraflagellar rod 2 (PFR2) using a popout construct efficiently 
downregulates PFR2 expression 
To test the functionality of pop-out constructs, we targeted the paraflagellar rod 2 
(PFR2) gene by RNAi in WT L. braziliensis strain M2903 using a pop-out StL construct.  We 
previously showed that knockdown of this gene results in loss of the paraflagellar rod structure 
and defective motility (9), similar to deletion mutants in L. mexicana (17, 18). We integrated the 
PFR2StL(A)-GFP+(B) construct or a GFP-only control into the L. braziliensis genome and 
obtained clonal lines by drug selection on semisolid media. Transfectants expressed GFP at high 
levels, and cell pellets were visibly green. PFR2StL(A)-GFP+(B) clones had a ~80% reduction 
in PFR2 RNA compared to cells expressing GFP alone (Figure 2). 
4.3.3 – Removal of PFR2 StL returns cells to WT phenotype in L. braziliensis 
We withdrew drug selection from the PFR2StL(A)-GFP+(B) and the GFP-only control 
lines to enable cells to lose the integrated DNA. A substantial GFP-negative population arose 
within two passages without selection, or roughly 12 cell doublings (Figure 3). We single-cell 
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sorted for GFP-positive and GFP-negative cells to obtain clonal lines with the constructs 
integrated and popped out, respectively. Hereafter, clones with an integrated construct are 
labeled “SSU:Construct” (ex, SSU:GFP+(B)); clones with a construct popped out are labeled 
“PO:Construct (ex, PO:GFP+(B)). 
 Cell survival following sorting was markedly higher for GFP-negative clones than for 
GFP-positive clones (78.8 ± 7.6% vs. 37.1 ± 8.9%, p<0.0001). After the cultures grew out we 
tested clones for GFP expression; 37 of 38 clones had the expected level of GFP expression. A 
single GFP-low clone expressed high levels of GFP; this clone was likely a result of imperfect 
sorting. 
We next performed PCR on genomic DNA from the GFP-positive SSU:PFR2StL(A)-
GFP+(B) and GFP-negative PO:PFR2StL(A)-GFP+(B) clones to confirm the presence/absence 
of the StL construct. We were able to amplify PCR products confirming both 5’ and 3’ 
integration of the PFR2StL(A)-GFP+(B) construct for six of eight SSU:PFR2StL(A)-GFP+(B) 
clones (Figure 4A). Unexpectedly, we amplified the 5’ and 3’ integration products from six of 
nine popped-out PO:PFR2StL(A)-GFP+(B) clones, as well (Figure 3B). This suggested that, 
even though the clones did not express GFP, they still retained portions of the StL construct. The 
three PO:PFR2StL(A)-GFP+(B) clones that were confirmed to have lost the construct had PFR2 
mRNA levels similar to that of SSU:GFP+(B) and PO:GFP+(B) clones (Figure 4B). 
Finally, we functionally evaluated the SSU:PFR2StL(A)-GFP+(B) and PO:PFR2StL(A)-
GFP+(B) clones for loss of PFR2 protein. We expected that, since PFR2 RNA levels rebounded 
following pop-out, protein levels would as well. In this situation, PO;PFR2StL(A)-GFP+(B) 
lines would have a WT phenotype. EM imaging of SSU:PFR2StL(A)-GFP+(B) cells revealed a 
lack of paraflagellar rod structure, which was clearly visible in both SSU:GFP+(B) and 
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PO:PFR2StL(A)-GFP+(B) cells (Figure 5, top). Finally, substantially fewer cells swam 
normally in the SSU:PFR2StL(A)-GFP+(B) line than either the SSU:GFP+(B) or 
PO:PFR2StL(A)-GFP+(B) line; the SSU:GFP+(B) line and PO:PFR2StL(A)-GFP+(B) line had 
comparable proportions of cells swimming normally (Figure 5, bottom). These results are in 
agreement with our previous knockdown of PFR2 (9). Further, they support the use of popout 
constructs to return cells to a WT phenotype. 
4.4 – Discussion  
In our tests of the popout system using the PFR2StL(A)-GFP+(B) construct, we 
successfully showed that 1) StL constructs using this system are functional in the downregulation 
of their target; 2) popout constructs can be lost from the Leishmania genome; and 3) following 
popout, expression from the construct ceases, and cells become phenotypically wild-type. 
There are a few considerations to keep in mind when performing these experiments. First, 
cell survival was lower following single-cell sorting for integrated (GFP-expressing) cells than 
for popped-out (GFP-negative) cells. This may have occurred because GFP-expressing cells 
were sorted into culture media containing selective antibiotic to preserve integration of the 
construct; GFP-negative cells were sorted into culture media lacking selection. Survival of GFP-
expressing cells could likely be increased by sorting into culture media lacking antibiotic and 
resuming selection once cell density has increased. 
Second, a large fraction of the GFP-negative cells analyzed retained portions of the StL 
construct. This demonstrates the importance of thoroughly validating any clones obtained; 
fortunately, the validation is easily accomplished with a simple PCR reaction. The presence of 
portions of the construct but absence of GFP expression suggests that GFP expression may be 
deleterious. It is possible that high levels of GFP act as negative selection, and cells that eject the 
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GFP ORF have a selective advantage. Continued culture with selective antibiotic maintained 
high levels of GFP expression in the vast majority of cells, suggesting that loss of GFP and drug 
resistance occurs simultaneously. 
There are a number of publications of transgenic Leishmania parasite lines expressing 
GFP from the 18S rRNA locus (19–22). In most instances, the authors report stable expression of 
GFP, even after prolonged removal of drug selection. However, their data show small 
populations of GFP-negative cells within “GFP-expressing” populations (less than 1% to more 
than 10% of total cells). In our hands, cells cultured with selection had proportions of GFP-
negative cells in this range (Figure 3). In contrast, up to 40% of cells lost GFP expression after 
we removed selection. Of these, the majority (two thirds) of cells tested retained portions of the 
construct integrated into the parasite genome. It is possible that, when expressed from our 
constructs, GFP expression was less stable in the absence of drug selection. The other groups 
used different expression vectors in their experiments, with different intergenic regions driving 
trans-splicing and polyadenylation. As gene regulation in Leishmania primarily occurs post-
transcriptionally and relies heavily on untranslated regions (reviewed in (23–25)), this could 
affect the steady-state level of protein expression.  
Popout constructs have many potential uses. For experiments utilizing StL constructs, 
popout of the construct would confirm that any observed phenotype is due to the presence of the 
construct rather than due to culture artifacts or compensatory mutations. Additionally, popout 
constructs driving expression of genes could be of particular use. For example, they could drive 
the expression of Cas9 until gene editing is successfully completed, at which time the Cas9 
construct could be popped out, eliminating any off-target effects due to the presence of the 
nuclease.  
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Further, since Leishmania (Viannia) species appear unable to support the replication of 
episomes (9), popout constructs could enable functional tests of essentiality. In other Leishmania 
species, essentiality can be confirmed using an episome sort method, wherein a gene is expressed 
from an episome that also carries the GFP ORF during replacement of chromosomal alleles (15, 
16, 26). After a chromosomal null mutant is obtained, selection maintaining the episome is 
removed, and cells are sorted on the basis of GFP expression. If GFP-dim cells survive, and have 
lost resistance to the selective agent, then the episome is no longer present and the gene is not 
essential. If, however, few GFP-dim cells survive, and those that do are still resistant to the 
selective agent, then the episome is still present, and the gene is likely essential.  
Because of the inability to perform these experiments in Viannia subgenus species, genes 
must be presumed essential if knockout or knockdown fails to yield viable mutants. This 
presumption is not always accurate; there have been instances in which genes presumed essential 
by this criterion were successfully knocked out using the episome sort protocol (16, 27). Now, 
the gene to be knocked out can be cloned into the popout construct and transfected into parasites. 
The construct would integrate, and the gene would be expressed ectopically while the alleles 
from the native locus are replaced. After a chromosomal knockout is obtained, the ectopic copy 
would be popped out. This procedure would facilitate the generation of “difficult” mutants or 
rule out technical hurdles in the attempted generation of those mutants. 
While this system was designed with Leishmania (Viannia) species in mind, it should 
work in any Leishmania species, including those for which the episome sort works well. For 
experiments requiring high expression of a gene, or little inter-clone variation in expression (13), 
the integrating popout constructs are likely a better choice, as episomes copy number can vary 
from cell to cell (5, 6). 
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4.5 – Materials and Methods 
Parasite strains and cell culture 
L. braziliensis strain M2903 (MHOM/BR/75/M2903) was obtained from Diane 
McMahon-Pratt (Yale University). Parasites were grown in fresh Schneider’s Insect Medium 
supplemented with 10% heat-inactivated fetal bovine serum, 100 μM adenine, 5 x 10-5% hemin, 
2 μg/mL biopterin, 2mM L-glutamine, 500 units/ml penicillin and 50 ug/mL streptomycin. 
Constructs and transfections 
The GFP+ ORF was amplified by PCR using primers B6857 and B6858 (5’ – 
ATCGATAAGATCTCCACCATGGTGAGCAAGGGCGAG / 5’ –  
ATCGATAAGATCTTTACTTGTACAGCTCGTCCATGC), which flank the ORF with ClaI 
and BglII sites, A-tailed, and cloned into pGem-T (Promega). The ORF was released from 
B7379 pGEM-GFP+ with BglII and ligated into the BglII site of B7089 pIR3HYG to generate 
pIR3HYG-GFP+(B). The GFP+ ORF was released from B7379 pGEM-GFP+ with ClaI and 
ligated into the ClaI site of B7381 pIR3HYG-GW(A) to generate B7405 pIR3HYG-GW(A)-
GFP+(B). A 718 bp region of PFR2 was amplified with primers B3515 and B3517 (5’ – 
CGCTAGTCTAGATTACGCTACGCAGAAAGAGAAG / 5’ –  
CGCTAGTCTAGAGCCGTCCTCCACCTCCTCCGCG) and cloned into pCR8/GW/TOPO 
(Invitrogen, Thermo Fisher Scientific) according to the manufacturer instructions. The PFR2 
sequence was transferred to pIR3HYG-GW(A)-GFP+(B) using LR Clonase II (Invitrogen, 
Thermo Fisher Scientific) in an overnight reaction at room temperature (RT); the reaction was 
terminated by digestion with proteinase K for 1 hr at 37 ℃.  
Transfections were performed as described previously (9, 11). Following transfection, 
cells were plated on semisolid media containing 15 µg/mL hygromycin B (Gold 
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Biotechnologies). Colonies were picked and grown to stationary phase in 1 mL of media and 
passaged thereafter in 5 mL of media containing 10 µg/mL hygromycin B.  
RNA and cDNA preparation and qPCR 
2.5-3x108 cells were pelleted and dissolved in 1mL Trizol reagent (Ambion, Thermo 
Fisher Scientific). 250 µL of dissolved cells were used to isolate total RNA with the RNA 
miniprep kit (Zymo Research). RNAs were digested with 20 Units of DNaseI (Ambion, Thermo 
Fisher Scientific) in a 200 µL reaction using the supplied buffer and purified using the RNA 
Clean & Concentrator kit (Zymo Research) and eluted in 50 µL of nuclease-free water.  
cDNA was synthesized by random hexamer-primed reverse transcription using the 
Superscript III First-Strand Synthesis kit (Thermo Fisher Scientific) in 20 µL reactions 
containing 0.25 µg RNA. Control reactions contained an equal amount of RNA but omitted the 
reverse transcriptase enzyme. 
qPCR reactions were performed using 5 µL of ten-fold diluted cDNA in a 20 µL reaction 
containing 10 µL of 2x Power SYBR reaction mix (Applied Biosystems, Thermo Fisher 
Scientific) and primers (Table 2)to a concentration of 0.2 µM each in MicroAmp Optical 96-well 
plates (Thermo Fisher Scientific). Reactions were run on the ABI PRISM 7000 Sequence 
Detection System. PCR amplifications were as follows: 50 °C for 2 min and 95 °C for 10 min 
followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. PCR products were confirmed to 
be specific by melt curve analysis. +RT reactions were performed in triplicate and –RT control 
reactions in duplicate. 
On each plate, 5-fold dilution series were performed for each primer set to calculate 
primer efficiencies, and relative PFR2 level calculated using the Pfaffl method (28) using 
amplification of KMP-11 as an internal control. The data are averages and standard deviations of 
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3-6 independent clones, and significance was calculated by t-test (Figure 2B) or ANOVA 
followed by the Tukey post hoc test (Figure 2D). 
Removal of StL construct, flow cytometry, and cell sorting 
Cells containing a StL construct were split to 105 cells/mL in Schneider’s medium 
lacking selection and GFP expression monitored by flow cytometry. Parallel cultures under drug 
selection were used as a comparison. When a GFP-negative population appeared in the cultures 
lacking selection, clonal lines were obtained by single-cell sorting. 
Log-phase cells were resuspended in phosphate-buffered saline, passed through a 
CellTrics 50 µm filter (Partec) to remove clumps, and single cells were recovered on the basis of 
GFP expression using a Beckman Coulter MoFlo cell sorter. Individual cells were placed into 
wells of a 96-well plate containing 200 µL of Schneider’s Insect Medium containing no selective 
antibiotic (GFP-negative cells) or 10 µg/mL hygromycin B (GFP-positive cells) and incubated at 
27 ℃ for 10 days before parasite growth was scored. Wells were expanded to 5 mL with or 
without antibiotic, as appropriate, and passaged thusly. 
Genomic DNA preparation and PCR 
108 cells were pelleted and washed with phosphate buffered saline, resuspended in 0.5 
mL TELT lysis buffer (50mM Tris HCl, pH 8.0; 62.5 mM EDTA, pH 9.0; 2.5M LiCl; 4% v/v 
Triton X-100), incubated 5 min at RT, and extracted twice with an equal volume of 
phenol:chloroform (1:1). Genomic DNA was ethanol precipitated and resuspended in TE 
containing 20 µg/mL RNase A. 
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Genomic DNA was ten-fold diluted and 1 µL used in a 25 µL PCR reaction using 
KlenTaq-LA polymerase. Primers used were: 5’ integration, B2618 and B3515 (5’ – 
ACATCAGACGTAATCTGCCGC / 5’ –  
CGCTAGTCTAGATTACGCTACGCAGAAAGAGAAG); 3’ integration, B3517 and B2619 (5’ 
– CGCTAGTCTAGAGCCGTCCTCCACCTCCTCCGCG / 5’ –  
CGACTTTTGCTTCCTCTATTG). PCR products were run on 1% agarose gel and visualized 
with ethidium bromide staining. 
Transmission electron microscopy 
For ultrastructural analyses, samples were fixed in 2% paraformaldehyde/2.5% 
glutaraldehyde (Polysciences Inc., Warrington, PA) in 100 mM sodium cacodylate buffer, pH 
7.2 for 1 hr at room temperature.  Samples were washed in sodium cacodylate buffer and 
postfixed in 1% osmium tetroxide (Polysciences Inc.) for 1 hr.  Samples were then rinsed 
extensively in dH20 prior to en bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc., 
Redding, CA) for 1 hr.  Following several rinses in dH20, samples were dehydrated in a graded 
series of ethanol and embedded in Eponate 12 resin (Ted Pella Inc.).  Sections of 95 nm were cut 
with a Leica Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained 
with uranyl acetate and lead citrate, and viewed on a JEOL 1200 EX transmission electron 
microscope (JEOL USA Inc., Peabody, MA) equipped with an AMT 8 megapixel digital camera 
and AMT Image Capture Engine V602 software (Advanced Microscopy Techniques, Woburn, 
MA). 
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Swimming assay 
Log-phase cell culture was placed in a hemocytometer and 150 cells were visually scored 
on the basis of swimming ability. A focal plane between the bottom of the cell and coverslip was 
used to avoid counted cells adhering to either surface as immotile. Non-adjacent fields of view 
were examined to minimize re-counting of motile cells. Cells were scored as immotile if flagellar 
beating resulted in tumbling or in lack of forward motion. 
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4.7 – Table Legends 
Table 4-1: Primers used in qPCR analysis of PFR2 levels. 
4.8 – Figure Legends 
Figure 4-1: The popout construct system. 
A) Schematic of IR3-GFP+(B) and IR3-GW(A)-GFP+(B) constructs carrying resistance 
to hygromycin B (HYGR). Constructs carry a sequence from the 18S rRNA locus that 
enables integration into the parasite genome by homologous recombination and splice 
acceptor sites (SA) that permit proper trans-splicing and polyadenylation of transcribed 
RNA. The GFP+ ORF is inserted into the B cloning site, while the A site remains 
available for cloning of a gene of interest (GOI) or an RNAi transgene targeting the GOI.  
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B) Workflow for the use of popout constructs. 
Figure 4-2: qPCR analysis of PFR2 levels following integration of the PFR2StL(A)-GFP+(B) 
construct.  
The PFR2StL(A)-GFP+(B) construct efficiently suppresses PFR2 expression while 
integrated. **** p≤0.0001.  
Figure 4-3: Withdrawal of drug selection from cells containing an integrated GFP+(B) 
orPFR2StL(A)-GFP+(B) construct allows for the accumulation of a GFP-negative population.  
Cells were grown for two passages (~12 cell doublings) with or without hygromycin B 
selection and analyzed by flow cytometry. Shown is one representative clone out of three 
examined for each construct. 
Figure 4-4: Confirmation of the loss of PFR2StL(A)-GFP+(B) following popout. 
A) PCR amplification across the integration site after sorting for GFP expression. Six of 
nine GFP-negative clones amplified both integration PCR products, indicating that the 
PFR2StL(A)-GFP+(B) construct was still present despite the lack of GFP expression.  
B) qPCR analysis of PFR2 levels following popout of PFR2StL(A)-GFP+(B) and 
control GFP+(B) constructs. *** p<0.001; **** p≤0.0001; all other comparisons NS. 
Figure 5: SSU:PFR2StL(A)-GFP+(B) parasites lack a paraflagellar rod structure and are 
defective in swimming.  
Transverse (top) and longitudinal (middle) sections of flagella imaged by transmission 
electron microscopy of SSU:GFP+(B) control, SSU:PFR2StL(A)-GFP+(B), and 
PO:PFR2StL(A)-GFP+(B) cells. The paraflagellar rod structure is indicated (PFR). 
Bottom: fraction of promastigote cells that swim normally in culture. 
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Table 4-1 
 
Target Primer ID Sequence 
KMP-11 B5023 5’-AACGCTATATAAGTATCAGTTTCTGTACTTTA 
B7412 5’-GGTGACGATGCGGGTACC 
PFR2 B3638 5’- CAGACGGAGGACGAGAACAGGGG 
B3639 5’- TGGATTGCATCGTGCAGGCTGTG 
 
  
18S rRNA
A
GFP+ HYGR
B
SA SASA
18S rRNA
18S rRNA
A
GFP+ HYGR
B
SA SASA
18S rRNAGOIGOI
IR3HYG-GFP+(B)
IR3HYG-GW(A)-GFP+(B)
GOI
A
B
Transfect construct and select 
transfectants with drug or 
GFP expression
Perform required validations 
and/or manipulations
Remove drug selection and 
continue culturing
Single-cell sort on the basis 
of GFP expression
GFP+
Construct integrated
GFP-
Sensitive to drug?
Construct popped out Construct integrated
YES NO
Figure 4-1
142
SS
U:
GF
P
SS
U:
PF
R2
StL
-G
FP
0.0
0.5
1.0
1.5
R
el
at
iv
e 
PF
R
2 
R
N
A
****
Figure 4-2
143
GFP+(B) +drug
GFP+(B) -drug
PFR2StL(A)-GFP+(B) +drug
PFR2StL(A)-GFP+(B) -drug
101 102 103 104
#
of
ce
lls
GFP fluorescence
Figure 4-3
144
AB
SSU:PFR2StL-GFP PO:PFR2StL-GFP
5' integration
3' integration
PFR2PFR2 GFP HYGR SSUSSU
5' integration 3' integration
0.0
0.5
1.0
1.5
R
el
at
iv
e 
PF
R2
 R
N
A *******
SSU: SSU:PO: PO:
GFP+ PFR2StL-
GFP+
Integrated or popped out:
Construct:
Figure 4-4
145
PFR
PFR
PFR
PFR
SSU:GFP SSU:PFR2StL-
GFP
PO:PFR2StL-GFP
Fraction of cells 
swimming normally
141/150 9/150 147/150
Figure 4-5
146
147 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5: Conclusions and Future Directions 
 
 
 
 
 
 
 
 
 
 
 
148 
 
Preface 
The first draft of this chapter was written by EAB. The final version presented here incorporates 
comments from SMB. 
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5.1 – Project Goals 
The presence of Leishmania virus 1 (LRV1) profoundly affects the severity of disease 
caused by Leishmania (Viannia) parasites (1, 2) and correlates with chronic disease, treatment 
failure, and relapse (3–5). Little is known, however, about the mechanisms by which LRV1 copy 
number is controlled within the parasite. Disruption of these mechanisms could augment 
treatments for leishmaniasis that occurs in the presence of LRV1, with potential for improved 
patient outcomes. Until relatively recently, virus infection of protozoa had been a curiosity with 
little known relevance to the biology of the host organism. As such, little work has been done to 
investigate antiviral mechanisms in these organisms. One way in which the parasite may regulate 
the replication of LRV1 is through the RNAi pathway, which serves an antiviral function in 
many eukaryotic organisms. The bulk of this work investigates the interaction between LRV1 
and the RNAi pathway of L. guyanensis and L. braziliensis parasites. These experiments are 
described in Chapters 2 and 3, and in Appendices C and D. In the course of the completion of 
this work, I also developed tools for working with Leishmania in the laboratory (described in 
Chapter 4 and Appendix B) and identified complications in our understanding of Leishmania 
biology (described in Appendices A, E, and F). In this chapter, I will discuss the broader 
conclusions of this work, and propose future directions. 
5.2 – LRV1 is not immune to RNAi pressure, but Argonaute 1-dependent RNAi plays little 
role in control of LRV1 
In Chapter 2, we investigated whether LRV1 is processed by the RNAi pathway by 
sequencing small RNAs (sRNAs) from infected cell lines. We found that substantial proportions 
of the sRNA pool mapped to LRV1, similar to levels seen with an efficiently-silenced luciferase 
knockdown reporter. This reporter elicits a 30-fold reduction in luciferase (LUC) activity in L. 
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guyanensis and a 300-fold reduction in L. braziliensis (Chapter 3 and ref.  6), so this level of 
LRV1-derived sRNA could be evidence of substantial targeting of LRV1 by the RNAi pathway. 
When we knocked out AGO1 in L. guyanensis, however, we observed only small effects on 
LRV1 levels (Chapter 3). All RNAi in Leishmania is believed to occur through the activity of 
AGO1 (7, 8); therefore, if RNAi played a role in control of LRV1, we expected to see a much 
larger effect. 
This apparent contradiction could be explained if the LRV1-derived sRNAs are not true 
siRNAs, and do not associate with AGO1 to direct cleavage of the LRV1 transcript. I do not 
think this scenario is likely. While we did not definitively prove that the LRV1-derived sRNAs 
are true siRNAs, we showed that the sRNA pool that we sequenced resembles siRNAs in size 
and chemical composition. Specifically, both sRNA and siRNA lengths ranged from 20-26 nt 
with a mode of 23 nt. Both contained untemplated bases at the 3’ end. Finally, the sRNAs map to 
genomic loci in the same proportions as do AGO1-bound siRNAs. Therefore, there is no reason 
to suspect that the LRV1-derived sRNAs would not be bioactive and capable of reducing LRV1 
gene expression, thereby reducing LRV1 levels. Loss of AGO1 is known to destabilize the 
siRNAs that bind to it (7, 8), so we could use the Δago1line to confirm that the sRNAs derived 
from LRV1 are true siRNAs. Specifically, we plan to evaluate the level of LRV1-derived sRNAs 
by Northern blot in the WT and Δago1 lines of L. guyanensis. If the levels of LRV1-derived 
sRNAs fall in the Δago1 line, it would suggest that they are stabilized by AGO1 and are 
therefore siRNAs.  
I consider it more likely that a combination of transcript abundance and protection within 
the protein capsid is responsible for the relative insensitivity of LRV1 to AGO1-dependent 
RNAi. As described in the introduction (Chapter 1), LRV1 replicates by transcribing a plus-
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strand and extruding it into the cytoplasm, where it is translated and encapsidated. After 
encapsidation, the minus-strand is synthesized, regenerating the dsRNA genome. Because of 
this, some fraction of the LRV1 transcript is enclosed within the capsid and therefore is 
inaccessible to cytoplasmic complexes, such as AGO1-siRNA and ribosomes. Work in T. brucei 
showed that siRNAs co-sediment with actively translating ribosomes (9), so exclusion of 
ribosomes likely would further prevent the transcript from encountering AGO1. The dynamics of 
transcript encapsidation have not been investigated. It is unknown how long a transcript is 
exposed to the cytoplasm (and AGO1), or what fraction of transcripts become encapsidated. If 
unprotected LRV1 transcripts are relatively rare, then encounters between them and AGO1 
proteins loaded with anti-LRV1 siRNAs would be relatively infrequent. Further studies into the 
dynamics of encapsidation would be required to determine whether this is a plausible mechanism 
for the evasion of AGO1-dependent RNAi. 
We further showed in Chapter 2 that introduction of an RNAi transgene (stem-loop 
construct, StL) targeting LRV1 resulted in total loss of the virus from cells. Concomitantly, the 
proportion of sRNAs derived from LRV1 increased dramatically. This is consistent with the 
above hypothesis that the LRV1 transcript is protected from cleavage by AGO1 within the 
capsid. The increase in LRV1-targeting siRNAs would increase the likelihood that a newly-
synthesized transcript encounters a molecule of AGO1 loaded with an anti-LRV1 siRNA before 
it is encapsidated. As the degradation of free transcript increased, translation of LRV1 protein 
would decrease. As the level of protein translation decreased, fewer transcripts would be 
protected, and more would be cleaved by AGO1. Eventually, there would be insufficient 
transcript levels to maintain LRV1. By this hypothesis, loss of AGO1 should lead to substantial 
increases in LRV1 level. Without the cleavage of free transcript by AGO1, more protein should 
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be translated and more transcripts should be encapsidated, leading to even higher levels of 
transcription and translation. Alternative mechanisms for limiting translation of the LRV1 
transcript will be discussed later in this chapter. 
It remains possible that cleavage of the LRV1 dsRNA genome by Dicer, or of the 
transcript by Piwi, plays a substantial role in control of LRV1. I was unable to probe this 
conclusively in this work due to technical difficulties (Appendix C), but the advent of CRISPR 
technology will likely make the generation of these mutants much simpler. By generating single 
and double mutants of the two Dicer genes, we can determine whether Dicer cleavage of the 
LRV1 genome reduces virus replication. Further, while we previously were unable to generate 
Piwi-null mutants in L. braziliensis, the increased efficiency of CRISPR may facilitate this in the 
future. 
5.3 – An alternative mechanism for control of LRV1 
If further work reveals that control of LRV1 does not occur primarily via the RNAi 
pathway, LRV1 could be maintained at sustainable levels through a balance of replication and 
degradation. There are two main features of LRV1 would contribute to this balance: 
First, the LRV1 transcript is not capped or trans-spliced. This presents two hurdles to 
virus replication. First, the transcript cannot efficiently recruit ribosomes for translation of its 
gene products. The 5’ UTR of the LRV1 transcript contains an internal ribosome entry site 
(IRES) that is about 5% as efficient as a trans-spliced transcript at recruiting ribosomes (10), 
resulting in less translation and therefor slower replication. Second, the lack of a cap structure 
exposes the LRV1 transcript to degradation by RNases. There are six XRN family 5’-3’ 
exoribonuclease homologs in Leishmania, one of which is known to play a role in degrading 
mRNA(11, 12). It is reasonable to suspect that one or more of these may degrade LRV1 
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unencapsidated transcripts. 
Second, in addition to the possible degradation of LRV1 transcripts by exoribonucleases, 
cleavage of the LRV1 transcript by a mechanism other than AGO1 is known to occur. Prior work 
in LRV1 from the Patterson lab described a “short transcript” 320 nt in length that was produced 
by in vitro transcription from sucrose gradient-purified virions, and that was also present in 
living cells (13). This short transcript is generated via site-specific cleavage of the 5’ UTR of the 
LRV1 transcript by the viral capsid protein (14, 15). This would limit the accumulation of full-
length dsRNA genome, as any dsRNA generated using cleaved transcript as a template would be 
missing a portion of its sequence. Further, the LRV1 IRES loses substantial activity with the 
deletion of just 120 nt (10) from the 5’ end of the transcript. Therefore, this cleavage could serve 
as a double hit – reduction in full length genome, and reduction in protein translation. At the time 
of its discovery, this cleavage activity was hypothesized to act as a check on virus replication 
(14). 
I favor the hypothesis that LRV1 is controlled by a balance of replication and degradation 
not involving RNAi. This hypothesis is attractive because it would be effective independent of 
the species of Leishmania. RNAi is active only in the Viannia subgenus species; if RNAi played 
a substantial role in the control of LRV1, then a separate mechanism would likely be required for 
the control of LRV2 in L. major and other species of the Leishmania subgenus. In addition, this 
hypothesis addresses the lack of impact of AGO1 on control of LRV1. As the number of LRV1 
virions rises following loss of AGO1, so too would the cleavage of the transcript, limiting LRV1 
accumulation.  
This hypothesis also does not rule out a role for RNAi in control of LRV1, as the two 
mechanisms may be somewhat redundant in Viannia subgenus species. When both mechanisms 
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are present, loss of one may have minimal impact on virus levels. In this scenario, loss of AGO1 
has only a small impact on LRV1 levels while the virus is capable of self-regulation. If the 
transcript cleavage activity were ablated, loss of AGO1 may increase LRV1 levels to a much 
greater extent. The RNA sequence required for cleavage of the LRV1 transcript has been 
mapped. One could, in principle, mutate this sequence to investigate whether the cleavage 
activity restricts virus replication and whether this activity and RNAi are redundant. However, in 
the absence of a reverse genetics system in LRV1, these hypotheses remain difficult to test. 
5.4 – LRV1 may be unstable in some Leishmania strains 
In Appendix C, I showed that LRV1 was unstable in the WT line of L. guyanensis 
M4147. When I examined this line for capsid protein levels by flow cytometry, I observed a 
heterogeneous distribution with a sizeable fraction of cells stained similarly to an LRV1-negative 
control. When this line was cloned (whether following transfection or not), many clones (15/42, 
35.7%) of clones were uniformly LRV1-negative; these presumably arose from LRV1-negative 
cells within the original population. Of the clones that contained LRV1, a 17/42 (40.5%) 
displayed heterogeneity in LRV1 level similar to the parent/uncloned population. Even one of 
the clones that initially appeared homogeneously LRV1+ became heterogeneous over time in 
culture. This may have occurred in other LRV1+ clones were they cultured long enough, but I 
did not systematically test this. In contrast, the lab has worked extensively with a LUC-
expressing clone of this strain which has a uniform, high level of LRV1 capsid staining.  
The instability of LRV1 in the WT line was not apparent until now because previous 
work with WT examined LRV1 on a population level. For example, dsRNA bands were 
visualized from total RNA, LRV1 sequence was amplified by PCR, capsid protein was 
visualized by Western blot, or virions were purified from cell culture (16–19). Because many of 
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the cells in the population contain LRV1, these experiments identified the strain as LRV1+ but 
could not detect LRV1-negative cells in the population. The flow cytometry assay was developed 
by Matt Kuhlmann in our lab (20), but we were exclusively using the LUC-expressing clone and 
had never analyzed the WT. 
This observation does explain a lingering discrepancy in the field, however. The 
Patterson lab identified an LRV1-negative isogenic clone of L. guyanensis M4147 that arose in 
culture (21). This clone was isolated following transfection with a plasmid conferring resistance 
to hygromycin B, and they hypothesized that drug selection mediated the loss of LRV1. We were 
unable to replicate this; however, we were using other parasite strains or the LUC-expressing 
clone. It is possible that their LRV1-negative clone originated as an LRV1-negative cell in the 
WT population prior to plating, as occurred in my DCL knockout experiments.  
This heterogeneity in LRV1 level has not been observed in any other line we’ve 
evaluated by flow cytometry, which includes at least three strains of L. braziliensis. It is unclear 
what makes LRV1 stable in these lines, but unstable in L. guyanensis M4147. It is unlikely to be 
caused by the difference in species, as LRV1 is stable in the LUC-expressing clone of L. 
guyanensis M4147. In addition, it is unclear why the LRV1 is stable in the LUC-expressing 
clone, while it was unstable in the clones and transfectants of WT that I obtained. One possible 
explanation for this is a difference in the way clones were obtained. The LUC-expressing clone 
was isolated by plating on agar plates. At the time I was performing these experiments, agar did 
not support growth of Viannia subgenus species, and I obtained clones by limiting dilution. This 
strain is not “clumpy,” but I cannot rule out that my clones were not, in fact, mixed populations. 
If that were the case, the clones that appeared LRV1+ contained small numbers of LRV1-
negative parasites, which then increased in proportion during culture. We would likewise expect 
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apparently LRV1-negative clones to develop LRV1+ populations during culture; I did not 
cultivate LRV1-negative clones long enough to observe this.  
5.5 – StL constructs may not be biologically neutral 
In the course of this work, I and others in the lab began to notice alterations in 
Leishmania biology in the presence of StL constructs. These included the presence of stable 
dsRNA derived from the transcribed inverted repeat, defects in the knockdown of additional StL 
construct targets, and possibly augmented virulence. In Appendix E, I documented experiments 
designed specifically to investigate these observations. I also identified an increase in the level of 
TATE transposable elements (TEs) in cells containing a StL construct. This data do not provide 
irrefutable evidence that StL constructs are problematic; rather, they suggest that caution is 
warranted during their use. Further, as RNAi appears to be more efficient and to play a role in 
virulence in L. braziliensis, the presence of a StL construct in this species could be more 
problematic than in L. guyanensis. 
It is interesting to note that the effects of the presence of StL constructs are similar to 
those observed after the knockout of AGO1. In both cases, levels of TATE RNA rose and 
knockdown of a luciferase reporter fell, though the magnitudes of these effects were greater in 
the Δago1 lines. This leads me to believe that a StL construct functions as a dominant negative 
on the RNAi pathway – its presence depletes the ability of the RNAi pathway to knock down 
other targets. 
Additionally, in both the Δago1 and StL lines, LRV1 levels increased. In Chapter 2 I 
documented that the introduction of a StL targeting the LRV1 Capsid or RDRP, but not a control 
GFPStL, resulted in loss of LRV1. In fact, LRV1 levels in the GFPStL lines were 20-100% 
higher than WT, depending on the strain examined. At the time, we assumed this was the noise 
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of the assay; however, the small impact of the loss of AGO1, coupled with the observation that 
the GFPStL affected knockdown of LUC, caused me to rethink this assumption. In L. guyanensis 
M4147, LRV1 levels rose 35% upon loss of AGO1 and approximately 50% in the presence of 
the GFPStL. The data from the two experiments were analyzed differently, and the StL 
experiment examined fewer biological replicates. Because of this, the magnitudes of the two 
experiments cannot be directly compared, but the data suggest that the effect is similar. 
Together, this supports the hypothesis that AGO1-dependent RNAi has some function, 
albeit small, in reducing LRV1 levels in Leishmania (Viannia) species. The presence of the 
GFPStL impairs the regulation of other RNAi targets, and in its presence, LRV1 levels 
increased. If RNAi were not involved in control of LRV1, then the presence of the GFPStL 
would not have affected LRV1 levels. 
5.6 – New tools for the study of Leishmania 
During the course of my experiments, I required tools for working with Leishmania that 
did not yet exist. It was through these needs that the work described in Chapter 4 and Appendix 
B arose. 
During the RNaseIII experiments detailed in Appendix B, my transfections yielded many 
colonies, but initial screens did not identify any successful transfectants. Because of this, I 
needed a less cumbersome method to enable me to evaluate relatively large numbers of clones. 
The existing protocol required 1-2 weeks in culture and 11 mL of medium for each clone 
screened; by reducing these requirements I could save substantial time and materials. The 
“quick, crude gDNA prep” protocol that I developed reduces the media requirement by 10 mL 
and the time requirement by up to a week in culture. This allowed me to save approximately 300 
mL of media on this experiment, and perhaps more importantly, allowed me to quickly conclude 
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that the experiment was unlikely to succeed. If this protocol becomes widely used in the lab for 
integrations that are predicted to be rare, the cumulative time and materials savings could be 
substantial.  
I developed the crude gDNA prep protocol to a stage where it was functional in my 
hands, but there are aspects of the protocol that could be optimized. For example, the crude 
gDNA isolated in my protocol is not reliably stable beyond one day; increasing the stability of 
the gDNA in storage would increase its utility. One way to do this would be to incorporate a 
phenol:chloroform extraction, but the volumes are likely to small for this to be feasible. 
Increasing the volume would require either using more culture volume (more material and more 
time) or diluting the gDNA, which would necessitate adding an ethanol precipitation step. 
Instead, my protocol should be viewed as preliminary screening to identify promising clones. 
These can then be grown to a larger culture volume to prepare “clean,” stable gDNA. 
The popout constructs detailed in Chapter 4 and used in Appendix E arose out of our 
concern that the presence of a StL construct may not be neutral beyond its capacity to 
downregulate a target. We intended for LRV1StL parasites to be used to further probe the role of 
LRV1 in parasite biology and virulence because of a lack of isogenic lines. In order for this to be 
possible, however, parasite biology could not be altered by the LRV1StL construct. I developed 
the popout system both to 1) test the effect of the presence of the StL; and 2) remove the 
LRV1StL from parasites to create truly isogenic lines. This system works in principle: the StL 
construct is functional, and one can easily obtain cells that have lost it. However, there are signs 
that care must be taken with these lines.  
First, a very large percentage (up to 40%) of L. braziliensis PFR2StL(A)-GFP+(B) cells 
lost GFP expression when selection was withdrawn, but a sizeable fraction (6/9) of these retained 
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fragments of the StL construct integrated into the parasite genome. I suspect that the very high 
level of GFP expression selects for the loss of GFP by any means possible. I did not observe this 
phenomenon with the L. guyanensis CapsidStL(A)-GFP+(B) lines. In order for GFP-expressing 
L. braziliensis cells to be on the scale of the x-axis, I have to reduce the sensitivity of the flow 
cytometer approximately five-fold from settings I use to analyze L. guyanensis cells (data not 
shown). At the same time, less than 5% of L. guyanensis cells were GFP-negative following two 
passages without selection, and none of these contained the stable dsRNA that is characteristic of 
an integrated StL construct. This suggests that GFP is expressed less strongly in L. guyanensis 
than L. braziliensis, which may have helped the full construct remain integrated. 
Second, a fraction of the L. guyanensis CapsidStL(A)-GFP+(B) clones had elevated 
doubling times in culture and were avirulent in mice. While Leishmania cultured for long periods 
of time often lose virulence, we have not typically observed this in Viannia subgenus species, 
such as L. guyanensis. Many groups have found that high levels of GFP expression do not affect 
parasite virulence (22–24). Rather, it is possible that perturbations induced by single-cell sorting 
contributed to the loss of virulence. It may be wise to systematically test whether clones obtained 
by cell sorting are more likely to lose virulence compared to clones obtained by limiting 
dilutions or plating. Regardless, special attention should be paid to characteristics such as 
doubling time to minimize the possibility of infecting mice with “dud” clones. 
5.7 – Conclusions  
Through this work, I investigated the role of the RNAi pathway in control of LRV1 in 
Leishmania (Viannia) parasites. I found that parasites containing LRV1 produce abundant virus-
derived sRNAs, and that LRV1 can be eliminated by RNAi targeting. In contrast, endogenous 
RNAi has little effect on virus levels. Additional studies investigating the roles of other RNAi 
160 
 
pathway components were inconclusive. These experiments have deepened our understanding of 
parasite-virus interactions, and provided a starting point for further work on this topic. Further, I 
developed new tools for the study of Leishmania (Viannia) parasites, including a protocol for the 
isolation of genomic DNA from small numbers of parasites and a construct that facilitates 
removal of transfected DNA integrated into the parasite genome. Finally, I determined that 
increased caution may be warranted during RNAi experiments, as the StL construct may disrupt 
global RNAi within the cell. This knowledge will aid the study of Leishmania (Viannia) 
parasites going forward, and facilitate a wide range of investigations. 
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Appendix A: Chromosome 11/AGO1 locus architecture 
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Preface 
The experiments in this appendix were designed, performed, and analyzed by EAB under the 
guidance of SMB. The first draft was written by EAB and the final version presented here 
incorporates comments from SMB.  
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A1 – Introduction 
Previous work in the lab generated a Δago1 parasite line in L. braziliensis strain M2903. 
This line was functionally RNAi-deficient, both as assessed by RNAi reporters (Notton, Lye, and 
Beverley, unpublished data) and in terms of endogenous knockdown of transposable elements 
(1); ectopic expression of the AGO1 gene restored RNAi function. Together, these data 
suggested that the AGO1 gene was replaced as anticipated. However, during generation of this 
parasite line, the lab was unable to confirm proper integration of the knockout constructs at the 
3’ end into the AGO1 locus. This suggested that the assembly of this genomic region was 
incorrect. 
Further, when I was cloning constructs to knock out AGO1 in L. guyanensis, I discovered 
that there was an approximately 800 nt sequence just 3’ of the AGO1 ORF that was repeated in 
two other loci on chromosome 11. It is likely that the length of the repeat caused an error in 
assembly of these regions. Because I would need to confirm the integration of my knockout 
constructs into the AGO1 locus, I set about determining which sequence was immediately 3’ of 
the AGO1 gene and confirming the integration of the Δago1 line of L. braziliensis. 
A2 – Results  
A2.1 – The L. braziliensis and L. guyanensis genome assemblies are improperly assembled 
To determine whether genes on chromosome 11 in L. braziliensis M2903 and L. 
guyanensis M4147 were arranged as annotated in the L. braziliensis M2904 assembly, I used 
PCR to amplify across each individual repeat. I designed primers to bind to unique sites 5’ and 3’ 
of each repeat, and set up reactions containing each possible primer pair. The general scheme of 
primer binding is shown in Figure 1. For both species, PCR products of the expected size were 
obtained for the following primer combinations: a/d; c/b; and e/f (Figure 2). Other primer 
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combinations did not give PCR products of the expected size (data not shown). This suggests 
that the loci surrounding these intergenic regions are laid out as in Figure 3. 
The AGO1 replacement cassettes are properly integrated in the Δago1 line of L. braziliensis 
I next used PCR amplification to confirm the integration of the constructs used to knock 
out AGO1 in L. braziliensis strain M2903. I paired forward primers that hybridize to the drug 
resistance genes used in the AGO1 replacements with the proper reverse primer (primer d) that 
hybridizes to unique sequence 3’ of the repeat (Figure 4A). These PCR reactions gave products 
of the expected size (Figure 4B), indicating that the knockout constructs were properly integrated 
into the correct genomic locus in this parasite line. 
A2.2 – PacBio sequencing of L. guyanensis confirms chromosome 11 gene arrangement 
Since this work was completed, the L. guyanensis genome was sequenced on the PacBio 
platform. PacBio sequencing generates very long reads, which facilitates the assembly of 
repetitive elements. While the PacBio assembly does not precisely match my predicted 
arrangement of genes (compare Figure 3 with Figure 5, bottom), it is consistent with the results 
of my primer amplification experiments. Each of the regions of mis-assembly aligns to regions 
of the L. braziliensis assembly that contained sequencing gaps or the large repeat. These 
situations are known to contribute to difficulties in generating assemblies (2, 3). I identified other 
mis-assemblies due to sequencing gaps and gene families along the chromosome, as well. More 
surprisingly, chromosome 11 in the PacBio assembly contains a 90.7 kb sequence at the 5’ end 
that is annotated in the L. braziliensis assembly as chromosome 19. This sequence contains 31 
genes, none of which are annotated as part of L. guyanensis chromosome 19 in the PacBio 
assembly. This may be a sequencing artifact, or it may represent a true difference between the 
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two species, such as a chromosomal translocation. Further experiments will be required to 
differentiate between the two possibilities. 
A3 – Discussion  
Results from PCR amplification suggest that the presence of the 800nt repeat in 
chromosome 11 caused errors in the L. braziliensis strain M2904 genome assembly. Broadly, 
this particular mis-assembly is unlikely to dramatically impair study of these organisms, as it 
affects only a handful of loci. In the instance of the study of AGO1, however, it proved to be a 
stumbling block.  Fortunately, the existing Δago1 line of L. braziliensis had the anticipated and 
proper replacement of AGO1 with drug resistance genes. Further, I was able to use this new data 
in the successful generation of the Δago1 line in L. guyanensis (see Chapter 3). 
Whole genome sequencing of L. guyanensis M4147 using the PacBio platform revealed 
that there were additional errors in the L. braziliensis M2904 assembly. These errors were due to 
sequencing gaps, and to the presence of gene families. Chromosome 11 is not likely to be the 
only instance of these types of sequencing errors in the L braziliensis M2904 genome, so  it’s 
reasonable to assume that similar errors occur throughout the genome. Because the majority of 
genes on chromosome 11 were arranged as expected, however, the L. braziliensis M2904 
assembly is likely sufficient in most cases for planning genetic manipulations of Leishmania 
(Viannia) parasites. In cases where the L. braziliensis assembly is not sufficient, or cases where 
extra certainty is desired, a PacBio assembly such as the L. guyanensis M4147 assembly will 
provide a more accurate view of the parasite genome. 
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A4 – Materials and Methods 
Chromosome 11 sequences 
The L. braziliensis strain M2904 genome assembly (Genbank accession ID: 
GCA_000002845.2) was used to identify the repeat regions on chromosome 11 by BLAST 
search and to design primers to these regions. The entire intergenic regions containing the 
repeats were extracted and labeled Intergenic Regions 1 (IR1), 2 (IR2), and 3 (IR3). The 
chromosomal locations of these regions are listed in Table 1.  
Primers 
Oligonucleotide primers were designed to hybridize to unique regions 5’ and 3’ of each 
repeat region. Primer sequences can be found in Table 2, along with the locations they bind 
according to the annotated genome. Also included in the table are primers that bind to the drug 
resistance ORFs used in the knockout of AGO1 from L. braziliensis. 
PCR analysis of gDNA 
Genomic DNA (gDNA) was isolated from the WT and Δago1 lines of L. braziliensis 
strain M2903 and from L. guyanensis strain M4147. Briefly, 10
8
 parasites were lysed in TELT 
buffer (50mM Tris HCl, pH 8.0/62.5 mM EDTA, pH 9.0/2.5M LiCl/4% Triton X-100) and 
protein was removed by extraction twice with phenol:chloroform:isoamyl alcohol (25:24:1). 
Nucleic acids were concentrated by ethanol precipitation and RNA removed by digestion with 20 
μg/mL RNaseA.  
Purified gDNA was used as the PCR template at a final dilution of 1:500 in PCR 
reactions containing:1x KTLA buffer; 200 μM dNTPs; 400 μM each primer; 1M betaine; and 
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Klen-Taq LA polymerase to a final dilution of 1:500 in a 50 μL reaction. PCR products were 
analyzed by agarose gel electrophoresis. 
A5 – Table Legends 
Table A1: Chromosome 11 intergenic regions containing the approximately 800 nt repeat.  
The open reading frames (ORFs) annotated to be either side of each intergenic regions 
are specified, as well as the nucleotide positions of the intergenic regions. 
Table A2: Primers used to decipher the genomic architecture of chromosome 11.  
Primer orientation, sequence, and binding location on chromosome 11 are specified. 
A6 – Figure Legends 
Figure A1: Regions of chromosome 11 surrounding 800nt repeats. 
Repeats are depicted as black boxes labeled “R”, as annotated in the L. braziliensis 
M2904 assembly. Primer binding sites are indicated (a-f).  
Figure A2: PCR products obtained for L. guyanensis M4147 and L. braziliensis M2903 WT 
parasites. 
PCR products using genomic DNA from L. guyanensis (left) and L. braziliensis (right), 
indicating successful amplification across the repeated region.  
Figure A3: Inferred genomic arrangement surrounding repeated regions on chromosome 11. 
Repeats are depicted as black boxes. Primers that successfully amplified a PCR product 
of the expected size are indicated (a-f). 
Figure A4: Confirmation of proper integration of AGO1 knockout cassettes in L. braziliensis 
M2903. 
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A) Primer combinations for the confirmation of AGO1 replacements. Forward primers 
bind within the drug resistance cassette, and were paired with reverse primer d.  
B) PCR products of the expected size were amplified from the Δago1 line of L. 
braziliensis M2903, confirming the proper integration of the replacement constructs used 
to generate the line. 
Figure A5: Arrangement of genes on chromosome 11 surrounding repeat regions according to 
the L. guyanensis PacBio genome assembly. 
Errors in the L. braziliensis M2904 assembly of chromosome 11 (top) occur around 
regions containing sequencing gaps (gray boxes) and the repeat (black boxes). Bottom, 
chromosome 11 as ordered in the L. guyanensis PacBio assembly. In the PacBio 
assembly, gray boxes do not denote sequencing gaps, but rather regions where 
sequencing gaps occurred in the L. braziliensis assembly (for reference). Vertical lines 
between the two assemblies indicate how regions within the chromosome differ. Primer 
pairs that amplified the expected product are shown as arrows connected by solid lines. 
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Table A1  
 ORF annotated 5’ of IR Intergenic region 
beginning nucleotide 
Intergenic region 
ending 
nucleotide 
ORF annotated 3’ 
of IR 
IR1 LbrM11_V2_0360 
(Ago1) 
162020 164762 LbrM11_V2_0370 
IR2 LbrM11_V2_0460 219117 226131 LbrM11_V2_0470 
IR3 LbrM11_V2_0670 310863 317855 LbrM11_V2_0680 
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Table A2 
Primer 
ID 
Orientation Sequence Genomic 
location 
Region of 
binding 
B4911 Reverse 5’-
CACATTGTTCTCGCTTCCTGC 
163160-163140 IR1 
B4912 Forward 5’-
GCATGCGCTCTGCACTATTTG 
162247-162267 IR1 
B4922 Reverse 5’-
TCGGAAGAGGGGGGTACGGC 
315393-315374 IR3 
B4923 Reverse 5’-
GCCACAGCAATGACCCTTCT 
224162-224143 IR2 
B5080 Forward 5’- 
CGGTCCAAGTTTTGGTGAGG 
221499-221518 IR2 
B5081 Forward 5’- 
TGTGGCCCAGTTGTGAGTTG 
312694-312713 IR3 
B5102 Forward 5’-
ACTCGCCGATAGTGGAAACC 
NA HYG
R
 
B5104 Forward 5’-
CATTTTACTGGGGGACCTTGT 
NA BSD
R
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Figure 1 
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Figure 2 
 
L. guyanensis M4147 
 
L. braziliensis M2903 
 
Expected bands: 
4912/4923: 1621 bp                      5080/4911:1941 bp                      5081/4922: 2700 bp 
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Figure 3 
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Figure 4 
A
 
 
B 
 
Expected bands: 
HYG
R
: 1904 bp 
BSD
R
: 2101 bp 
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Figure 5 
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Appendix B – Development of a quick, crude Leishmania gDNA prep protocol 
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Preface 
The protocol presented here was developed by EAB under the supervision of SMB. The first 
draft of this appendix was written by EAB and the final version presented here incorporates 
comments from SMB.  
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B1 – Introduction  
The standard protocol for molecular validation of transfectants involves purification of 
genomic DNA (gDNA) from parasites followed by PCR amplification across the integration site. 
Previously, to obtain sufficient cells for gDNA purification, colonies were picked from semisolid 
agar plates, cells grown in 1 mL medium without selection to high parasite density (3-7 days), 
expanded to 10 mL with selective antibiotic and grown to high parasite density (2-5 days), and 
finally pelleted and the gDNA purified. In total, it requires 1-2 weeks of growth in culture, and 
11 mL of medium for each clone to be evaluated. When large numbers of colonies must be 
screened, this constitutes a large commitment of resources and time. 
To reduce the consumption of medium and the time required to screen clones, I 
developed a protocol to quickly isolate gDNA of sufficient quality to use as a PCR template from 
small numbers of Leishmania cells, as little as 200 μL of dense culture (2 x 106 – 2 x 107 cells, 
depending on species), with a minimal hands-on time commitment. This allows us to screen 
large numbers of clones at the 1 mL stage, and only expand promising clones to 10 mL for 
further analysis. It has a high rate of success – in my largest experiment using this method, I 
prepared gDNA from 24 clones, and a positive control PCR product was amplified in all 24 
reactions (Figure 1). 
There is undoubtedly room in the protocol for optimization, but it is sufficient for the 
purpose it was developed for. 
B2 – Protocol  
1) Grow cells to high density (late-log phase) 
2) Pellet desired number of cells and wash with 0.5 volumes PBS. 
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3) Resuspend cells in 0.2 volumes lysis buffer (1% Triton X-100 in PBS containing 50 
μg/mL proteinase K). 
4) Incubate at 37 degrees C for 1 hour. 
5) Heat-inactivate the proteinase K at 95 ℃ for 10 min. 
6) Pellet any cell debris in table-top microcentrifuge at full speed for 5 min. 
Use 2 μL of the supernatant as template in a 50 μL PCR reaction. 
Crude gDNA samples can be stored at -20 ℃ for use later that day, but do not give reliable 
amplification after overnight storage.  
B3 – Figure Legend 
Figure B1: Positive control PCR product was amplified from crude genomic DNA preparations 
from 24 of 24 transfectants. 
The WT line contained IR2SAT-LUC(B) integrated into the 18S rRNA small subunit 
locus, and primers bound either side of the site of integration. M, dsDNA ladder (the 1kb 
band is indicated); (+), positive control gDNA prepared via a “clean” protocol using 
Triton X-100/LiCl lysis followed by phenol:chloroform extraction; (-) no-template 
negative control. 
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Figure B1 
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Appendix C – Disruption of Dicers and Piwi 
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Preface 
The experiments described in this appendix were designed, performed, and analyzed by EAB. 
SMB supervised the work and contributed to study design. The first draft was written by EAB, 
and the final version presented here incorporates comments from SMB. 
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C1 – Introduction  
In Chapter 3, I hypothesized that the parasite RNAi pathway played a role in containing 
replication of LRV1 to levels that the cell could sustain, permitting persistent infection. Loss of 
Argonaute 1 (AGO1) did not produce the expected dramatic increase in LRV1 levels, suggesting 
that if a substantial antiviral role for RNAi exists in Leishmania, it likely is AGO1 independent 
(Chapter 3). To determine whether any other components of the RNAi pathway play a role in 
control of LRV1, I attempted to deplete the levels of these other components by gene knockout 
and/or RNAi knockdown. These components are illustrated in Figure 1. 
There remains a second Argonaute family protein in Leishmania whose function is 
unknown (1). Previous work in the Beverley lab suggested that this protein (known as Piwi) is 
localized to the mitochondrion, and efforts to knock it out in L. braziliensis M2903 were 
unsuccessful (Tsang, Anderson, and Beverley, unpublished data). It is unclear what role, if any, 
RNAi might play in mitochondrial function. However, RNAi knockdown of PIWI impaired 
concurrent knockdown of luciferase (Lye and Beverley, unpublished data), an effect similar to 
what was seen with knockdown of AGO1 (2). While this may suggest  that Piwi plays a role in 
the RNAi pathway, other possibilities not involving RNAi have not been eliminated and may be 
more likely. Nonetheless, it is possible that Piwi has a more substantial role than AGO1 in 
defense against viruses. 
Alternatively, experiments in other organisms suggest that Dicer can, in some cases, play 
a role equal to or larger than Argonaute in defense against viruses (3–5). Leishmania (Viannia) 
parasites encode two Dicer proteins, and work in Trypanosoma brucei suggests that the functions 
of these proteins have specialized to some extent (6). Perhaps inactivation of the LRV1 genome 
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through cleavage by one or both Dicer is sufficient to limit LRV1 replication. In this situation, 
the resulting siRNAs may have minimal impact on LRV1 levels. 
In this appendix, I present studies investigating the role of Piwi and Dicer proteins in the 
control of LRV1 in L. guyanensis. I first attempted to generate Dicer1 (DCL1) and Dicer2 
(DCL2) null mutants; however, technical hurdles resulted in the abandonment of this approach. 
RNAi knockdown of DCL1, DCL2, and PIWI did not affect LRV1 levels; however, it is unlikely 
that knockdown resulted in sufficient loss of function for an effect to be visible. No conclusions 
could be drawn from this work on the role of Dicer proteins or Piwi in control of LRV1. 
C2 – Results  
C2.1 – LRV1 is unstable in WT L. guyanensis M4147 
We first attempted to knock out the DCL1 and DCL2 genes individually by homologous 
recombination, replacing each allele with a drug resistance gene. We performed the initial rounds 
of replacement for each of DCL1 and DCL2 in WT L. guyanensis M4147 and obtained four 
heterozygous mutant clones for DCL1 (two with a PAC
R
 replacement and two with a HYG
R
 
replacement) and one heterozygous mutant clone for DCL2 (BSD
R
 replacement). Each 
heterozygous mutant clone had the expected PCR products confirming proper integration of the 
knockout cassettes (Figure 1). When I performed flow cytometry using the anti-capsid antibody, 
however, the WT parent and mutant clones were either LRV1-negative or a mixed population of 
LRV1-positive and LRV1-negative cells (Figure 2A). In an attempt to obtain homogeneous 
LRV1+ populations, I re-cloned the WT parent and two heterogeneous DCL1 replacement clones 
(one PAC
R
 replacement and one HYG
R
 replacement) by limiting dilution. I evaluated LRV1 
levels in 8-12 clones per genotype by flow cytometry (Figure 2B). The majority of clones were 
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either LRV1-negative or mixed populations, but a few clones appeared to be approximately 
homogeneous LRV1-positive. 
C2.2 – DCL1 double replacement clones retain a copy of the DCL1 ORF 
I performed a second round of replacement in a DCL1 PAC
R
 replacement subclone that 
appeared to be LRV1-positive (clone 2.6, Figure 2B) and obtained six double replacement 
clones. Transfectants were evaluated by drug resistance and PCR tests for the presence of the 
DCL1 ORF and proper 3’ integration of the replacement cassette. Five of six clones were 
properly integrated at the 3’ end, but all six retained a copy of DCL1 (Figure 3). Chromosome 
23, where DCL1 is located, is predicted by sequencing read depth to be trisomic (Shaik and 
Beverley, unpublished data). The presence of a third copy of the DCL1 ORF suggests that the 
gene is present in at least three copies, requiring a third round of replacement in order to generate 
a null mutant.  
C2.3 – Apparently-homogeneous lines develop substantial LRV1-negative populations over time 
When I evaluated the double replacement clones for LRV1 level by flow cytometry, the 
parent heterozygote that had previously appeared LRV1-positive (Figure 2B) was now 
heterogeneous (Figure 4). This suggested that either a small LRV1-negative population had been 
present previously or that LRV1 is intrinsically unstable in this line. Two double replacement 
clones were LRV1-negative, one was heterogeneous, and three were approximately LRV1-
positive (Figure 4). Because the double replacement clones are not null mutants and the parent 
heterozygote developed a substantial LRV1-negative population, the LRV1-negative double 
replacement clones likely arose from LRV1-negative parent cells. 
C2.4 – Knockdown of PIWI and DCL1/2 was inefficient and did not affect LRV1 level 
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Because of the instability of LRV1 in the WT L. guyanensis, I switched to a clone that 
had been transfected with a construct that confers luciferase expression and resistance to 
nourseothricin (SAT
R
). Previous work in the lab has demonstrated this clone to harbor a single 
LRV1-positive population, and transfectants similarly do not show instability in LRV1 levels (7, 
8). Leishmania have a limited number of available selection markers, which would make 
generating a DCL1/2 double null mutant challenging in this genetic background. Because of this, 
I used RNAi-of-RNAi to reduce levels of DCL1, DCL2, and PIWI. The lab has previously used 
this approach to investigate the role of AGO1 in the RNAi pathway (2). 
Integration of DCL1-, DCL2-, and PIWI-targeting stem-loop (StL) constructs reduced 
mRNA levels of their targets by 0-55% (Figure 5). The PIWIStL construct failed to reduce PIWI 
mRNA levels at all, while the DCL2StL construct halved DCL2 mRNA levels, and knockdown 
of DCL1 was intermediate between the two. Analysis of LRV1 level in knockdown lines by flow 
cytometry showed no change in LRV1 levels upon integration of the StL constructs (Figure 6). 
C3 – Discussion  
Heterogeneity in LRV1 level in the WT L. guyanensis M4147 
L. guyanensis M4147 WT, unexpectedly, was a mixed population of LRV1-positive and 
LRV1-negative cells. It is unlikely that this represents contamination with another strain or 
species of LRV1-negative parasites, as transfectants and clones of this line exhibited a wide 
range of LRV1 levels: LRV1-negative, heterogeneous, and LRV1-positive clones were readily 
obtained (Figure 2A and data not shown). If the LRV1-negative populations of the original WT 
line were merely the result of contamination or a mixed isolate, we would expect to obtain clones 
and transfectants that were LRV1-positive and LRV1-negative. We would not expect to obtain 
clones resembling the original line, with both LRV1-positive and LRV1-negative populations. 
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Further, when we re-cloned and subsequently transfected a heterozygous Dcl1 mutant, some of 
the resulting clonal lines displayed heterogeneity similar to the WT line (Figure 2B and Figure 
4). For the observed heterogeneity to persist through three cloning steps makes contamination 
unlikely to be the cause by parsimony. In addition, a clone that initially appeared to be LRV1-
positive developed substantial LRV1-negative populations over time in culture (compare Figure 
2B, green trace with Figure 4, red trace). This suggests that the cell-to-cell heterogeneity in 
LRV1 level stems from an inherent instability in LRV1. 
Because of this apparent instability of LRV1, the WT line of L. guyanensis M4147 is not 
a good candidate for further work exploring effects on LRV1 levels, whether in regard to the role 
of RNAi or other applications, including screening for antiviral compounds. It is unknown why 
LUC c3, which is derived from the WT line, has stable levels of LRV1, but this line is a better 
candidate for further study. Alternatively, L. guyanensis M4147 obtained from other sources may 
have stable, uniform LRV1 presence. 
Investigations into the role of Dicers and Piwi were inconclusive 
Two rounds of replacement generated multiple clones with two copies of Dcl1 replaced 
by drug resistance genes; however all of these retained a copy of Dcl1. Aneuploidy can signal 
that a gene is essential in Leishmania (9–11); however, it is unlikely that Dcl1 is essential in L. 
guyanensis, as Dcl1 mutants were viable in the related organism Trypanosoma brucei (6). In 
addition, L. guyanensis parasites are viable after knockout of Argonaute1, which ablates the 
parasite RNAi pathway (Chapter 3). Instead, it is more likely that chromosome 23 is trisomic, as 
predicted. Therefore, three rounds of replacement will be required to obtain a Dcl1KO line.  
Previous work in T. brucei found that the two Dicer proteins have some overlap in the 
substrates from which they produce siRNAs (6, 12). For example, loss of either Dcl1 or Dcl2 
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affects the accumulation of siRNAs derived from the CIR147 repeat element and from 
chromosomal inverted repeats (12). As Dcl1 protein is predicted to localize to the cytoplasm 
(13), we might expect this protein to play a predominant role in control of LRV1, which also 
localizes to the cytoplasm (14). We cannot rule out, however, that the presence of Dcl2 will 
compensate for loss of Dcl1. It may therefore be necessary to generate a double knockout in 
order to observe an effect on LRV1 levels, which would require five rounds of replacement and 
five different drug resistance cassettes. There are only six drug resistance cassettes commonly 
used in Leishmania, all of which would be required to generate a double knockout in the LUC c3 
background (which already contains a SAT
R
 cassette). In order to complement the mutant, the 
double knockout line would have to be cultured without selection for a time in the hope that gene 
conversion would replace one of the drug resistance genes with another, freeing it to be used to 
complement the knockout. This protracted approach is beyond the scope of this thesis. 
To circumvent this hurdle, I changed tactics to knocking down Dcl1, Dcl2, and Piwi by 
RNAi. This RNAi-of-RNAi approach is somewhat counter-intuitive, as the activity of the target 
is required for knockdown. Because of this, we expect less knockdown that would ordinarily be 
achieved with other, non-RNAi genes. It has been successfully used, however, in the 
establishment of AGO1 in the Leishmania RNAi pathway (2) and of Dcl1 in the Trypanosoma 
RNAi pathway (13). 
RNA levels fell by 55% at best (Dcl2) and, at worst, were unchanged (Piwi) following 
knockdown (Figure 5). This is likely to be an underestimate of knockdown at the RNA level, as 
the lab has previously documented the presence of large degradation intermediates by Northern 
blot (2). These degradation products would be amplified by PCR, even though they would not be 
competent for translation. A better estimate of knockdown could be achieved by Northern blot, 
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but more relevant would be Western blot analysis of knockdown at the protein level. Previous 
work in the lab showed that efficient knockdown at the RNA level did not guarantee equivalent 
reductions in protein level (2). Since Dcl1, Dcl2, and Piwi are predicted to play a role in the 
RNAi pathway, and are therefore required for knockdown of Dcl1, Dcl2, and Piwi, it is unlikely 
that protein levels would be dramatically reduced.  
Regardless of the precise level of knockdown attained, LRV1 levels were unchanged 
following knockdown of each gene (Figure 6). This could be due to some combination of 
insufficient knockdown, redundancy between Dicer proteins, and/or a lack of involvement of the 
proteins in control of LRV1. Concurrent knockdown of both Dcl genes could circumvent the 
issue of redundancy, but more effective may be a combination knockout-knockdown approach, 
wherein, for example, Dcl1 is knocked out and Dcl2 is simultaneously knocked down. In the 
absence of the redundant protein, knockdown may confer sufficient reductions in RNAi to reveal 
a role for Dcl proteins in control of RNAi. Since this approach would still confer only a partial 
phenotype, however, any lack of effect on LRV1 levels would not be meaningful. 
Alternately, CRISPR technology could be harnessed to delete all copies of a gene in a 
single transfection, using a single drug resistance marker. If this becomes routinely available in 
Leishmania, the double knockout could be generated rapidly and complemented to confirm any 
observed phenotypes. 
C4 – Materials and Methods 
Parasite strains and in vitro culture 
L. guyanensis M4147 (MHOM/BR/78/M4147) was obtained from Jean Patterson (Texas 
Biomedical Research Institute, San Antonio, Texas).   I transfected this line with the linear 18S 
rRNA-targeting SwaI fragment from B6367 pIR2SAT-LUC(B) (30), and clonal lines were 
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derived and validated. Either the WT parental line or the luciferase-expressing clone 3 was used, 
as indicated. Parasites were grown in fresh Schneider’s Insect Medium supplemented with 10% 
heat-inactivated fetal bovine serum, 100 μM adenine, 10 μg/mL hemin, 2 μg/mL biopterin, 2 
mM L-glutamine, 500 units/ml penicillin and 50 μg/mL streptomycin, and selective drugs as 
indicated below. 
Constructs 
To knock out DCL1 and DCL2, genes conferring resistance to blasticidin S HCl (BSD
R
), 
puromycin (PAC
R
), and nourseothricin (SAT
R
), hygromycin B (HYG
R
), as well as DNA regions 
flanking the DCL1 and DCL2 ORFs were amplified by PCR (from B6173 pIR1BSD, B6176 
pIR1PAC, B6351 pIR2SAT, B6441 pIR2HYG, and L. guyanensis M4147 WT genomic DNA, 
respectively) using Phusion polymerase and the primers found in Table 1. PCR products were 
gel-purified and used as templates in fusion PCR reactions. Reactions contained the 5’ flanking 
region forward primer, 3’ flanking region reverse primer, and 5µL each of 5’ flanking region, 
drug resistance ORF, and 3’ flanking region PCR products. Fusion PCR products were gel-
purified, ligated into pCR-Blunt using the Zero-Blunt PCR Cloning Kit (Thermo Fisher 
Scientific), and used to transform TOP10 chemically competent cells. Transformants were 
selected on 100 μg/mL kanamycin, colonies picked, and DNAs confirmed by restriction digest 
and sequencing. 
StL constructs to knock down DCL1, DCL2, and PIWI genes were similar to other RNAi 
constructs described in this document and elsewhere (7). “Stems” comprised of 600-900 bp 
regions of each ORF were amplified by PCR from L. guyanensis M4147 WT genomic DNA 
using the primers listed in Table 1 and KlenTaq-LA polymerase. Products were gel purified 
using the Qiaquick Gel Extraction kit (Qiagen), and ligated into pCR8/GW/TOPO (Thermo 
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Fisher) in a 10 min reaction at room temperature (RT). Stems were transferred into pIR3HYG-
GW(A) using LR Clonase II (Thermo Fisher) in overnight reactions at RT. Reactions were 
quenched by addition of proteinase K and incubation at 37°C for 1 hour. Constructs were 
confirmed by restriction digest. 
Transfections 
Stable transfections were performed as previously described (2, 7, 15). Clonal lines were 
obtained either by plating on semisolid media with 150 µg/mL hygromycin B (RNAi 
knockdowns) or by limiting dilution in liquid media with 5 μg/mL puromycin, 50 μg/mL 
nourseothricin, 5 μg/mL blasticidin S HCl, or 75 μg/mL hygromycin B, as appropriate 
(knockouts). Transfectants were grown to stationary phase in 1 mL media and passaged 
thereafter in 10 mL media with selective drugs, as appropriate for the construct. When the 
luciferase-expressing line was used, plates and liquid media also contained 50 μg/mL or 25 
μg/mL nourseothricin, respectively. 
Flow cytometry 
Flow cytometry using the anti-capsid antibody (16) was performed as described 
previously (7). 
RNA preparation and qPCR 
RNA was prepared as described previously (7). qPCR primers were designed to amplify 
~100 bp regions of the appropriate ORF that lie outside the regions targeted by the StL construct 
(Table 2). qPCR reactions were performed with cDNA templates in 20 µL total reaction volume 
using the Power SYBR Green Master Mix (Thermo Fisher), 5 µL of ten-fold diluted cDNA, and 
final primer concentrations of 0.2 µM. Reactions were run on the ABI PRISM 7000 Sequence 
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Detection System (Applied Biosystems, Thermo Fisher). PCR amplification conditions were as 
follows: 50 °C for 2 min and 95 °C for 10 min followed by 40 cycles of 95 °C for 15 sec and 60 
°C for 1 min. PCR products were confirmed to be specific by melt curve analysis. Amplification 
of KMP-11 was used to normalize parallel reactions. +RT reaction were performed in triplicate 
and –RT reactions in duplicate. A 10-fold dilution series was used to calculate primer efficiency 
and relative RNA calculated using the Pfaffl method (17). 
C5 – Table Legends 
Table C1: Primers used in the cloning of constructs to knock out Dicer 1 and 2 and to knock 
down Dicer 1, Dicer 2, and Piwi.  
Restriction sites to enable release of the knockout cassette from the plasmid are 
underlined. Linker regions enabling fusion PCR are in bold. 
Table C2: Primers used for qPCR of Dicer 1, Dicer 2, and Piwi. 
C6 – Figure Legends 
Figure C1: Schematic of RNAi pathway components Dicer1, Dicer2, Ago1, and Piwi in L. 
guyanensis. 
Figure C2: Confirmation of DCLl1 (A) and DCL2 (B) single replacement by PCR. Primers 
amplify across the site of integration. 
Figure C3: LRV1 levels by flow cytometry using an anti-capsid antibody.  
A) Substantial variability in LRV1 level is present in the WT and single replacement 
clones following transfection. Shown are representative clones. Black, LRV1-negative 
control; red, WT; blue, heterogeneous DCL1+/- clone; green, LRV1-negative DCL1+/- 
clone.  
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B) Re-cloning of a DCL1+/- clone generates sub-clones with substantial variability in 
level of LRV1. Representative clones are shown. Black, LRV1-negative control; purple; 
LRV1-negative subclone; green, LRV1-positive sub-clone; blue, heterogeneous sub-
clone. 
Figure C4: Confirmation PCR reactions following transfection of HYG
R
 replacement construct 
into PAC
R
 replacement of DCL1.  
Left, amplification across site of integration. Right, amplification of DCL1 ORF. NTC, 
no-template control reaction. HYG
R
 single replacement was used as a positive control (+). 
Figure C5: DCL1 double replacement clones display substantial variability in level of LRV1 as 
assessed by flow cytometry.   
Black, LRV1-negative control; red, single replacement parent; green, LRV1-positive 
clone; purple, LRV1-negative clone; blue, heterogeneous clone. 
Figure C6: qPCR analysis of DCL1 (A), DCL2 (B), and PIWI (C) mRNA levels after knockdown 
relative to untransfected cells. 
Averages and standard deviations are of two biological replicates of the parent line and 
six independent clones of each knockdown. 
Figure C7: Knockdown of DCL1, DCL2, and PIWI has no effect on LRV1 protein levels as 
assessed by flow cytometry.  
Representative clones are shown. Black, LRV1-negative control; red, untransfected 
parent line; green, Dcl1StL; blue, Dcl2StL; purple, PiwiStL.  
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Table C1 
Gene Region 
amplified 
Primer 
orientation 
Primer 
ID 
Sequence 
DCL1 5’ 
flanking 
Forward B6825 5’- CTCCAGCTGATTAAGGTGATGTG -3' 
Reverse B6826 5’- CGTCAGCCCGCACCGTTACCGCTACTGAGGGTGGCTGGC -3' 
3’ 
flanking 
Forward B6827 5’- GCACCTTACGTGGGATCTCGGGCTCACCCTACCCGCC -3' 
Reverse B6829 5’- GCAAGTTCGACGAGCTCGC -3' 
DCL2 5’ 
flanking 
Forward B6830 5’- CCATGCAGGTATCGATTCTCTG -3' 
Reverse B6832 5’- CGTCAGCCCGCACCGTTACCCACCTCCACCCCGTAGACC -3' 
3’ 
flanking 
Forward B6833 5’- GCACCTTACGTGGGATCTCGAGGGAAAAAAGGGCCAAGAG -3' 
Reverse B6835 5’- GAGGGCAGGAAGAGCAGG -3' 
BSD
R
 ORF Forward B2642 5’- GGTAACGGTGCGGGCTGACGCCACCATGGCCAAGCCTTTGTCTCA 
-3' 
Reverse B2556 5’- CGAGATCCCACGTAAGGTGCTTAGCCCTCCCACACATAACCAGAG 
-3' 
HYG
R
 ORF Forward B4076 5’- GGTAACGGTGCGGGCTGACGCCACCATGAAAAAGCCTGAACTC -
3' 
Reverse B2562 5’- CGAGATCCCACGTAAGGTGCCTATTCCTTTGCCCTCG -3' 
PAC
R
 ORF Forward B2557 5’- GGTAACGGTGCGGGCTGACGCCACCATGACCGAGTACAAGCCC -
3' 
Reverse B2558 5’- CGAGATCCCACGTAAGGTGCTCAGGCACCGGGCTTGCG -3' 
SAT
R
 ORF Forward B4077 5’- 
GGTAACGGTGCGGGCTGACGCCACCATGAAGATTTCGGTGATCCCTG 
-3' 
Reverse B4078 5’- CGAGATCCCACGTAAGGTGCTTAGGCGTCATCCTGTGCTCCC -3' 
DCL1 ORF 
(stem) 
Forward B3724 5’- CGTGGCGACTGAGCCGATCC -3’ 
Reverse B3727 5’- AACGGCAGCGAAGGACGTGG -3’ 
DCL2 ORF 
(stem) 
Forward B3984 5’- GAGACACGGATTCCTGTCGCTG -3’ 
Reverse B3973 5’- GCACATACATGTGCACAATCTC -3’ 
PIWI ORF 
(stem) 
Forward B5371 5’- TGCTGAACTCGATTCACACGCTCC -3’ 
Reverse B5376 5’- CAGCATATCGCCAATATCATGG -3’ 
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Table C2 
Target Orientation Primer ID Sequence 
DCL1 Forward B3344 5’- GGTCTACAAGCCGGAGGATT -3’ 
Reverse B7524 5’- GGTCGCTTCTCGGTACCGTAC -3’ 
DCL2 Forward B7419 5’- GCCAACAGATTGTCATAAGG -3’ 
Reverse B7420 5’- GGATGAGCACTTGCATGG -3’ 
PIWI Forward B7427 5’- GGTGCAAGGGAAGACTGGC -3’ 
Reverse B7428 5’- CCACAAAGACGGCCTGTACC -3’ 
KMP-
11 
Forward B5548 5’- GCCTGGATGAGGAGTTCAACA -3’ 
Reverse B5549 5’- GTGCTCCTTCATCTCGGG -3’ 
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Figure C1 
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Figure C5 
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Figure C6 
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Preface 
The experiments in this appendix were designed and performed by EAB under the guidance of 
SMB. The first draft was written by EAB and the final version presented here incorporates 
comments from SMB. 
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D1 – Introduction  
We previously showed that a substantial number of sRNAs are generated from LRV1 in 
Leishmania parasites (1). Loss of Argonaute1, however, did not elicit the expected increase in 
LRV1 level (this work, Chapter 3). This suggested that Argonaute1 is not involved substantially 
in control of LRV1. The presence of sRNAs derived from LRV1 implied that Dicer proteins 
cleaved the LRV1 dsRNA genome; perhaps this cleavage was sufficient to control LRV1 
replication without contribution from Argonaute. To test this, I attempted to over-express 
RNaseIII in LRV1+ L. guyanensis. 
 In most organisms, Dicer proteins contain two RNaseIII domains, a dsRNA binding 
domain (dsRBD), a helicase domain, a Piwi/Argonaute/Zwille (PAZ) domain, and a DUF283 
domain (2, 3). Work on the Dicer proteins of the relative parasite Trypanosoma brucei, however, 
has identified only the two RNaseIII domains (4, 5). In other systems, bacterial RNaseIII 
proteins have shown promise in degradation of RNA viruses. Langenberg et al. found that 
expression of E. coli RNaseIII in Nicotiana tabacum conferred increased resistance to a number 
of plant viruses, but also resulted in stunting (6). Lee et al. found that expression of E. coli 
RNaseIII in Bombyx mori resulted in an enhancement of RNAi activity, but also resulted in 
nonspecific RNA degradation (7). Together, these results suggest that bacterial RNaseIII proteins 
degrade viral dsRNA and/or generate sRNAs capable of entering the RNAi pathway, but also 
have the potential to be detrimental to cells.  
It is not known which Leishmania Dicer protein, if either, is responsible for control of 
LRV1, whether control of LRV1 requires the combined action of both proteins, or whether Dicer 
proteins can be overexpressed in Leishmania; therefore, I chose to express bacterial RNaseIII 
proteins from Escherichia coli and Staphylococcus aureus in L. guyanensis. In theory, this 
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should increase the cleavage of the LRV1 dsRNA genome, potentially resulting in loss of the 
virus. I was unable, however, to obtain viable RNaseIII-expressing parasites. 
D2 – Results  
D2.1 – Heterologous expression of bacterial RNaseIII proteins is likely toxic to Leishmania 
I transfected SwaI-linearized IR3HYG(empty), IR3HYG-Ecoli_RNaseIII(B), and 
IR3HYG-Saureus_RNaseIII(B) into a luciferase-expressing clone of L. guyanensis strain 
M4147. Transfection of the empty vector positive control yielded 4-10 times more colonies than 
transfection of the RNaseIII-bearing DNA (Table 1). This disparity in the number of colonies 
obtained can signal that the gene product being delivered is toxic. PCR reactions to confirm 
integration at the 3’ end of the construct yielded a product of the expected size (Figure 1A). I 
performed PCR reactions on genomic DNA to confirm integration at the 5’ end using a forward 
primer binding outside the targeting region and a reverse primer binding to the RNaseIII ORF; 
these reactions did not yield any product, even after optimization of reaction conditions (data not 
shown). To confirm that the RNaseIII ORF was present in the cells, I attempted to amplify the 
RNaseIII ORF from six clones of each RNaseIII construct. However, the expected PCR product 
did not amplify from any sample (data not shown). I repeated the transfection, and again, the 
positive control DNA yielded 10-fold higher numbers of colonies (Table 1). I did not attempt the 
integration PCR reactions, but again, none of the RNaseIII-transfected colonies examined 
contained the RNaseIII ORF by PCR (Figure 1B & C, data not shown), but control PCR 
reactions amplified a fragment of the luciferase construct in all DNAs. In total, I screened 18 
colonies transfected with the E. coli gene and 34 colonies transfected with the S. aureus gene. 
 
211 
 
D3 – Discussion  
This experiment attempted to increase RNaseIII activity in LRV1-positive L. guyanensis 
parasites through the heterologous expression of bacterial RNaseIII genes. I was unable, 
however, to recover viable cells with the RNaseIII ORF integrated, which suggests that it is toxic 
when expressed at the levels obtained by integration into the parasite 18S rRNA locus.  
The colonies that arose following transfection may have integrated the RNaseIII 
construct and ejected the RNaseIII ORF by rearrangement; in this situation, the cells would have 
carried the drug resistance gene. Indeed, PCR reactions to confirm 3’ integration use a forward 
primer binding to the HYGR gene, and generated a product of the expected size. This suggests 
that these clones may have contained the HYGR gene and therefore been transfectants, but 
ejected the RNaseIII ORF. My lack of success in amplifying a 5’ integration PCR product using 
a primers that binds to the RNaseIII ORF supports this conclusion. I could have further 
confirmed this by attempting to amplify the HYGR gene, but since none of the clones contained 
the RNaseIII ORF, I did not feel a need to. 
If this experiment were attempted again, more success might be had by integrating 
RNaseIII into a lower-expression locus, such as the alpha-tubulin locus. Additionally, this 
experiment would benefit from an inducible system, in which transcription could be initiated 
only when desired and the level of transcription better controlled. 
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D5 – Materials  and Methods 
Parasites and in vitro culture 
Leishmania guyanensis strain M4147 was obtained from Jean Patterson (Southwest 
Foundation for Biomedical Research, San Antonio, Texas). This line was transfected with the 
linear 18S rRNA-targeting SwaI fragment from B6367 pIR2SAT-LUC(B), and clonal lines were 
derived, validated, and used in these experiments. Parasites were grown in fresh Schneider’s 
Insect Medium supplemented with 10% heat-inactivated fetal bovine serum, 100 μM adenine, 10 
μg/mL hemin, 2 μg/mL biopterin, 2 mM L-glutamine, 500 units/ml penicillin and 50 μg/mL 
streptomycin, and selective drugs as indicated below. 
RNaseIII constructs 
Staphylococcus aureus genomic DNA was obtained from Dr. Gautam Dantas 
(Washington University School of Medicine) and Escherichia coli genomic DNA was isolated 
from strain K12. Briefly, bacterial cultures were pelleted, resuspended in lysis buffer (0.6% SDS 
and 0.12 mg/mL proteinase K in TE), and incubated at 37°C for 1 hour. DNA was extracted with 
phenol:chloroform (1:1), ethanol precipitated, and the pellet dissolved in TE. RNaseIII genes 
were amplified from bacterial genomic DNA using Phusion polymerase and the primers listed in 
Table 2 and ligated into the BglII site of pIR3HYG. RNaseIII ORFs were confirmed by 
sequencing. 
Transfection 
Stable transfections were performed as previously described(8, 9). After overnight 
recovery, clonal lines were obtained by spreading ⅙ of the transfected cells per plate on 
semisolid media with 50 μg/mL nourseothricin and 150 µg/mL hygromycin B. Colonies were 
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picked into 1 mL media without selection and passaged thereafter in 10 mL media with 50 
µg/mL hygromycin B. 
Leishmania genomic DNA isolation and PCR 
200 µL dense culture was pelleted, washed with phosphate buffered saline, and 
resuspended in 40 µL lysis buffer (1% Triton X-100 in PBS containing 50 μg/mL proteinase K). 
Samples were incubated at 37 ℃ for 1 hour and heat-inactivated at 95 ℃ for 10 min. 2 µL of 
genomic DNA was used in 50 µL PCR reactions. DNA was pooled (3 samples/pool) and PCR 
performed to amplify the RNaseIII ORF using the primers in Table 2. Genomic DNA from each 
sample was assayed for quality by amplification of a control PCR product. 
D6 – Table Legends 
Table D1: Colonies per µg of DNA obtained from transfection with positive control IR3YG and 
RNaseIII constructs.  
The number of plates used in each attempt in given in parentheses. For each attempt, 
transfected cells were allowed to recover overnight, and ⅙ of each transfection was 
spread per plate. 
Table D2: Primers used for cloning of RNaseIII genes from E. coli and S. aureus.  
BglII sites indicated in bold; 6x His tag indicated in italics; Kozak sequence indicated by 
underlining. 
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D7 – Figure Legends 
Figure D1: Confirmation of transfectants by PCR amplification of genomic DNA.  
A) PCR reactions to confirm 3’ integration of RNaseIII constructs. The forward primer 
binds to the HYGR ORF and the reverse primer binds 3’ of the targeting region. 12 of 12 
clones amplified a product of the expected size.  
B) In S. aureus RNaseIII-transfected cells, a control PCR reaction amplified a portion of 
the luciferase construct from all genomic DNAs tested.  
C) Genomic DNA from clones transfected with the S. aureus RNaseIII construct was 
pooled (3 clones/pool) and PCR performed to amplify the RNaseIII ORF. Plasmid DNA 
was used as a positive control (+). 
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Table D1 
 Colonies per µg transfected DNA 
 1st transfection 2nd transfection 
IR3HYG 85.8 16.9 
IR3HYG-Ecoli_RNaseIII 10 0.7 
IR3HYG-Saureus_RNaseIII 17.5 1.2 
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Table D2 
Target Primer ID Sequence 
E. coli B7014 5’-aaaaaAGATCTCCACCATGAACCCCATCGTAATTAATC 
B7015 TTTTTAGATCTTCAGTGGTGGTGGTGGTGGTGTTCCAGCTCCAG
TTTTT 
S. 
aureus 
B7016 aaaaaAGATCTCCACCATGCACCACCACCACCACCACTCTAAACAA
AAGAAAAGTGAGATAG 
B7017 TTTTTAGATCTCTATTTAATTTGTTTTAATTGCTTATAGGC 
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Figure D1 
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Preface 
The experiments presented in this appendix were designed, performed, and analyzed by EAB 
under the guidance of SMB. The first draft was written by EAB, and the final version presented 
here incorporates comments from SMB.  
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E1 – Introduction  
Evidence in the laboratory has accumulated over the last few years to suggest that stem-
loop (StL) constructs may not be biologically neutral. In this Appendix I will detail experiments 
that I have conducted to determine whether the presence of a StL construct integrated into the 
parasite genome alters Leishmania biology and virulence. While these results are not conclusive, 
they suggest that caution is warranted when StL constructs are used. 
E2 – Results  
E2.1 – The presence of a StL construct interferes with the effectiveness of a second StL 
Previous work in the lab found that the presence of LRV1 had no effect on the efficiency 
of the RNAi pathway (1), but this relied on a single LRV1-negative isogenic line. We decided to 
use our LRV1-targeting StL constructs to confirm this finding using multiple independent 
LRV1-negative clones. We transfected CapsidStL and RNA-dependent RNA polymerase (RDRP) 
StL constructs into a clone of L. braziliensis strain LEM2780 containing an integrated luciferase 
“self-reporter” (LUCSR) construct. This construct contains the luciferase (LUC) ORF and a 
luciferase-targeting StL and integrates into the 18S rRNA locus; L. braziliensis parasites 
transfected with this construct have LUC activity more than 100-fold below that of parasites 
transfected with the LUC ORF alone. The resulting lines were LRV1-negative as assessed by 
flow cytometry using the anti-capsid antibody (Figure 1).  
We then evaluated the lines for LUC activity relative to LUC-expressing, LRV1-negative LRV1 
StL lines (described in Chapter 2), as well as to untransfected LUC and LUCSR parasites. In 
untransfected cells, the LUC line had 143x higher luciferase activity than the LUCSR line; in the 
LRV1 StL parasites, the LUC line had 9x higher luciferase activity compared to the LUCSR line 
(Figure 2A). To control for non-specific effects of the stem-loop, we also transfected a GFP-
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targeting StL construct into the parental LUCSR line and compared LUC activity with LUC-
expressing cells carrying the same GFPStL (2). The untransfected LUC cells again had 141x 
higher luciferase activity than the untransfected LUCSR cells. The LUC GFPStL cells had 15x 
higher luciferase activity that LUCSR GFPStL cells (Figure 2B). This suggests that the reduction 
in knockdown of LUC was not specifically caused by knockdown of LRV1, but rather 
nonspecifically by the introduction of a second StL construct. 
E2.2 – Removal of StL targeting Leishmania RNA virus 1 (LRV1) in L. guyanensis does not 
rescue presence of LRV1 
I previously described a construct system that enabled integrated IR vectors to be easily 
removed from the parasite genome (see Chapter 4), termed “popout constructs.” These constructs 
use 18S rRNA sequence to integrate into the parasite genome by homologous recombination and 
carry two genes to enable selection: a drug resistance gene and green fluorescent protein (GFP). 
After culturing cells without positive selection, a proportion of the cells “pop out” the integrated 
construct and can be selected by their lack of GFP expression. 
In Chapter 2, we described LRV1StL-generated LRV1-negative lines as “isogenic.” 
Ideally, a true isogenic line would no longer contain the RNAi construct. Therefore, we created a 
popout version of the Capsid StL construct targeting LRV1 from L. guyanensis strain M4147. In 
addition to being truly isogenic, these lines would give us an opportunity to investigate the 
effects of the StL construct on Leishmania biology. 
I transfected linearized IR3HYG-CapsidStL(A)-GFP+(B) and IR3HYG-GFP+(B) into a 
luciferase-expressing clone of L. guyanensis strain M4147 (hereafter, WT). As an LRV1-
negative control, I also transfected IR3HYG-GFP+(B) into an LRV1-negative line that arose 
spontaneously in culture (M4147/HYG) (3). After transfection and subsequent popout, integrated 
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clones had GFP expression 300-fold above that of popped out clones (data not shown). In 
addition, popped out clones were sensitive to hygromycin B, while integrated clones were 
resistant. Parasites with the CapsidStL(A)-GFP+(B) construct integrated (hereafter, 
SSU:CapsidStL(A)-GFP+(B)) and parasites with the CapsidStL(A)-GFP+(B) construct popped 
out (hereafter, PO:CapsidStL(A)-GFP+(B)) were LRV1-negative by RT-PCR (Figure 3). WT 
cells transfected with the GFP+(B) construct contained LRV1, indicating that expression of GFP 
did not induce loss of LRV1 (Figure 3). As PO:CapsidStL-GFP clones are LRV1-negative and 
no longer contain the StL construct, they represent truly isogenic LRV1-negative lines. 
E2.3 – Integrated StL constructs mobilize transposable elements 
The results of the LUC activity assay in L. braziliensis LEM2780 above (Section E2.1) 
suggested that the presence of the StL construct non-specifically interferes with the efficiency of 
a second StL construct. As the RNAi pathway in Leishmania likely plays a role in the control of 
transposable elements (TEs) (2, 4), integration of StL constructs could also result in mobilization 
of TEs and a subsequent loss of genome stability. To assess whether this occurred in StL lines, 
we sequenced RNA from L. guyanensis SSU:CapsidStL(A)-GFP+(B), PO:CapsidStL(A)-
GFP+(B), and control SSU:GFP+(B) parasites (Figure 4A), and mapped the reads to the L. 
guyanensis and LRV1 genomes. The three lines had a similar proportion of reads mapping to the 
housekeeping genes glucose-6-phosphate dehydrogenase and RNA polymerase II large subunit. 
Likewise, reads mapped at a similar proportion to SLACS elements. In contrast, reads mapped to 
TATE elements at twice the frequency in SSU:CapsidStL(A)-GFP+(B) as in PO:CapsidStL(A)-
GFP+(B) or the SSU:GFP+(B) control. In SSU:GFP+(B), reads mapped to the entire length of 
the LRV1 genome, whereas in SSU:CapsidStL(A)-GFP+(B), reads mapped exclusively to the 
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region targeted by the StL construct (Figure 4B). Only 51 of 12,801,644 reads mapped to LRV1 
in PO:CapsidStL(A)-GFP+(B); these are likely noise. 
We also sequenced small RNAs (sRNAs) isolated from total RNA from these lines and 
mapped the 20-26 nt fraction to the L. guyanensis and LRV1 genomes. We have previously 
showed that the 20-26 nt fraction of sRNAs are a good proxy for siRNAs (2). Reads mapped to 
SLACS and TATE elements at similar proportions between PO:CapsidStL(A)-GFP+(B) and the 
SSU:GFP+(B) control (43.7 and 37.8% vs 39.8 and 33.9% of mapped reads for SLACS and 
TATE, respectively, in PO:CapsidStL(A)-GFP+(B) vs the SSU:GFP+(B) control) (Figure 4C). 
In contrast, sRNA reads from SSU:CapsidStL(A)-GFP+(B) mapped to SLACS and TATE 
elements at a frequency ~10% that of the PO:CapsidStL(A)-GFP+(B) or SSU:GFP+(B) 
controls. Simultaneously, frequencies of LRV1-mapping reads increased from 4.0% of mapped 
reads in the SSU:GFP+(B) control to 86.2% in the SSU:CapsidStL(A)-GFP+(B) line. These 
reads mapped exclusively to the region targeted by the StL construct (Figure 4D), similar to what 
was seen previously with LRV1 StL constructs (2). Likewise, the few LRV1-mapping reads in 
PO:CapsidStL(A)-GFP+(B) mapped to the stem region. 
The results of RNA and sRNA sequencing suggested that TATE elements were indeed 
mobilized in CapsidStL-containing lines. To confirm, we evaluated lines for SLACS and TATE 
transcript levels by qPCR (Figure 5). As was seen with sequencing, SLACS levels were similar 
across the lines, while TATE levels were approximately doubled in SSU:CapsidStL(A)-
GFP+(B) compared to PO:CapsidStL(A)-GFP+(B) or the SSU:GFP+(B) control. 
E2.4 – Integrated StL constructs produce stable dsRNA 
Other members of the laboratory have identified stable dsRNA in parasites transfected 
with StL constructs targeting viral RNAs. These dsRNA species were reverse transcribed, 
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cloned, and found to contain sequence from the inverted repeat of the StL construct (Akopyants, 
Lye, and Beverley, unpublished data). To examine this, I digested total RNA from parasites 
transfected with the CapsidStL(A)-GFP+(B) and control GFP+(B) constructs with S1 nuclease 
to determine if this stable dsRNA was present in integrated, but not popped out, StL lines. A 
clear LRV1 band was present in the LRV1+ SSU:GFP+(B) and PO:GFP+(B) controls and 
absent from SSU:CapsidStL(A)-GFP+(B), PO:CapsidStL(A)-GFP+(B), and LRV1-negative 
lines (Figure 6, white arrowhead). Both clones of SSU:CapsidStL(A)-GFP+(B) had visible 
dsRNA, which was not present in either of the PO:CapsidStL(A)-GFP+(B) clones (Figure 6, 
black arrow). 
E2.5 – The presence of a StL construct may affect parasite virulence 
It is thought that LRV1 increases parasite virulence by acting as a source of dsRNA, 
which is detected by TLR3 (5, 6). In support of this, the addition of LRV1 dsRNA to 
macrophages in vitro results in a release of cytokines similar to that observed when the 
macrophages are infected with L. guyanensis parasites containing LRV1 (5). It is possible that 
the stable dsRNA present in StL lines could serve as a source of dsRNA, similarly affecting 
parasite virulence. To test this, we injected the CapsidStL(A)-GFP+(B) popout lines and 
controls into the hind footpad of C57/B6 mice and monitored the infections for luciferase activity 
(a measure of parasite numbers) and lesion size (a measure of disease pathology). 
At least one clone each of SSU:GFP+(B), PO:GFP+(B), and SSU:CapsidStL(A)-
GFP+(B) failed to induce pathology or accumulate any substantial number of parasites (data not 
shown). These clones also had elevated doubling times in culture (data not shown). I concluded 
that they were exhibiting culture-induced loss of virulence, and omitted them from further 
analysis (7, 8). As expected, LRV1+ controls were significantly more virulent than LRV1-
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negative controls, regardless of the presence or absence of GFP expression (Figure 7). 
Unexpectedly, both SSU:CapsidStL(A)-GFP+(B) and PO:CapsidStL(A)-GFP+(B) parasites 
displayed virulence phenotypes intermediate between the LRV1+ and LRV1-negative controls 
(Figure 7). I had expected the PO:CapsidStL(A)-GFP+(B) parasites to behave similarly to 
LRV1-negative PO:GFP+(B) controls, as neither group contains LRV1 or expresses GFP. 
Possible reasons for this will be explored in the Discussion. 
E3 – Discussion  
In these experiments, introduction of a StL construct targeting either GFP or LRV1 into 
L. braziliensis LEM2780 interfered with the knockdown of luciferase. Additionally, integration 
of an LRV1StL popout construct into L. guyanensis resulted in increased levels of transposable 
element RNA and an accumulation of stable dsRNA. Both of these phenotypes returned to WT 
after the construct was popped out. Finally, the presence of the LRV1StL popout construct in L. 
guyanensis may affect parasite virulence, but the data were not conclusive. 
The use of popout CapsidStL-GFP+(B) constructs confirms that targeting of LRV1 by 
RNAi results in a complete loss of virus. In previous work (see Chapter 2), the StL construct was 
irreversibly integrated into the Leishmania genome. We were unable to amplify LRV1 sequence 
from cDNA or detect capsid protein by flow cytometry in these lines; however, we could not rule 
out that a very low level of LRV1 persisted in these cells, continually knocked down to 
undetectable levels. With the removal of the popout StL construct, LRV1 levels did not rebound, 
confirming that the virus is eradicated from these cells. 
One caveat to these results is that none of the StL constructs used here have a 
complementary target in the cell. Transfection of a StL targeting LRV1 results in loss of the 
virus, at which time there is no longer any viral transcript present for base paring with anti-LRV1 
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siRNAs. Similarly, the control GFPStL was transfected into a cell line that does not express 
GFP; therefore, siRNAs produced from that construct do not have a target. There are conflicting 
reports in the literature regarding the effect of the presence of target RNA on sRNA stability. On 
one hand, Chatterjee and Großhans found that the presence of a cognate target stabilized the let-7 
miRNA-AGO complex in C. elegans lysate and protected the miRNA from degradation (9). 
Conversely, De et al. found that the presence of a target RNA promoted the release of a miRNA 
from human AGO2 (10). If target binding does in fact promote siRNA turnover and degradation 
in Leishmania, then the absence of a target could result in an accumulation of AGO1 bound to 
StL-derived siRNAs at the expense of other siRNAs. More research will be required to confirm 
or refute this hypothesis. Further, more research will be required to extend the effects observed 
here to StL constructs targeting endogenous Leishmania genes. For these genes, continuing 
transcription of the target gene ensures the presence of the target of the StL-derived siRNAs. 
Little conclusive results can be drawn from the investigation of the effect of the StL 
construct on parasite virulence. I considered the PO:CapsidStL(A)-GFP+(B) parasites to be a 
negative control before the start of the experiment, and expected them to be indistinguishable 
from the LRV1-negative PO:GFP+(B) cells. However, they displayed a virulence phenotype 
intermediate between the LRV1+ and LRV1-negative controls. It is possible that some lingering 
effect of the StL construct persisted in the PO:CapsidStL(A)-GFP+(B) parasites, but I do not 
think this is likely. There were at least 80 cell doublings that separated SSU:CapsidStL(A)-
GFP+(B) and PO:CapsidStL(A)-GFP+(B) lines. I would anticipate this would be more than 
enough time for any StL-derived siRNAs or stable dsRNA to be lost by dilution. Indeed, no 
stable dsRNA was visible in PO:CapsidStL(A)-GFP+(B) lines following digestion with S1 
nuclease, and very few sRNA reads mapped to LRV1. 
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Rather, I think it is more likely that these results were due to a technical artifact. A 
number of the clones I injected failed to produce a lesion; it is possible that the LRV1-negative 
controls were similarly avirulent. Because I was expecting low virulence from these lines, I did 
not flag them as problematic. Without confidence in the negative control, I cannot draw any 
conclusions. In order to determine whether the StL construct results in increased virulence, new 
integrated and popped out clones should be obtained and evaluated. If these do not demonstrate 
culture loss of virulence, then we can have confidence in the results. 
The presence of a StL construct in Leishmania parasites appears to impair knockdown of 
other RNAi targets, lead to the accumulation of stable dsRNA, and may affect virulence of the 
parasite. Much of this data is preliminary, and more work will be necessary to attain a high 
confidence in these results. For example, I only sequenced RNA from one clone of each line – I 
will need to sequence additional clones in order to confirm these results. However, together the 
results suggest that caution is warranted when StL constructs are used.  
E4 – Materials and Methods 
Parasite strains and cell culture 
L. braziliensis LEM2780 (MHOM/BO/90/CS) was from Patrick Bastien (Université de 
Montpellier, Montpellier, France); L. braziliensis M2903 (MHOM/BR/75/M2903) was from 
Diane McMahon Pratt (Yale School of Public Health, New Haven, CT); and L. guyanensis 
M4147 (MHOM/BR/78/M4147) and its derivative L. guyanensis M4147/HYG were from Jean 
Patterson (Southwest Foundation for Biomedical Research, San Antonio, Texas). L. braziliensis 
LEM2780, L. guyanensis M4147, and L. guyanensis M4147/HYG were previously transfected 
with SwaI-linearized B6367 pIR2SAT-LUC(B), and clonal lines were used in these experiments. 
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L. braziliensis LEM2780 was also separately transfected with SwaI-linearized B6386 pIR2SAT-
LUC(B)-LUCStL(A), and clone 71 was used in this work. 
Parasites were grown in fresh Schneider’s Insect Medium supplemented with 10% heat-
inactivated fetal bovine serum, 100 μM adenine, 5 x 10-5% hemin, 2 μg/mL biopterin, 2mM L-
glutamine, 500 units/ml penicillin and 50 ug/mL streptomycin. Selective agents used were 
nourseothricin sulfate (Gold Biotechnology) and hygromycin B (Hygro99, Gold Biotechnology). 
Constructs and transfections 
B7061 pIR2HYG-LRV1_Lbr2780_CapsidStL(A) and B7062 pIR2HYG-
LRV1_Lbr2780_RDRPStL(A) were described previously (2). To generate the popout CapsidStL 
construct used in L. guyanensis, Gateway cloning reactions were performed between B7059 
pCR8-LRV1_LgyM4147_Capsid and B7405 pIR3HYG-GW(A)-GFP+(B) using LR Clonase II 
(Thermo Fisher Scientific) in an overnight reaction at room temperature (RT); the reaction was 
terminated by digestion with proteinase K for 1 hr at 37 ℃. This yielded B7416 pIR3HYG-
LRV1_LgyM4147_CapsidStL(A)-GFP+(B). 
Transfections were performed as previously described (1, 11). For L. braziliensis 
transfections, cells were plated on semisolid media containing 15 µg/mL hygromycin B.  
Colonies were picked and grown to stationary phase in 1 mL of media and passaged thereafter in 
5 mL of media containing 10 µg/mL (L. braziliensis) hygromycin B. For L. guyanensis, 
transfected cells were diluted to 105 cells/mL in Schneider’s media containing 50 µg/mL 
nourseothricin and 75 µg/mL hygromycin B. They were diluted 1:10 daily for three days and 
GFP-expressing cells were obtained by single-cell sorting. 
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Flow cytometry 
Flow cytometry using the anti-capsid antibody (12) was performed as previously 
described (2, 13).  
For single-cell sorting, log-phase cells were resuspended in phosphate-buffered saline, 
passed through a CellTrics 50 µm filter (Partec) to remove clumps, and single cells were 
recovered on the basis of GFP expression using a Beckman Coulter MoFlo cell sorter. Individual 
cells were placed into wells of a 96-well plate containing 200 µL of Schneider’s Insect Medium 
and incubated at 27 ℃ for 8 days before parasite growth was scored. Wells were expanded to 5 
mL with selection and passaged thusly. 
Luciferase activity assay 
106 log phase cells in 200 μL of Schneider’s Medium were added to a 96-well plate 
(Black plate, Corning Incorporated, NY, U.S.A.). D-luciferin (Biosynth AG) was added to a final 
concentration of 150 μg/mL and plates were incubated for 1 min. Plates were imaged using a In 
Vivo Imaging System (IVIS) photoimager (Perkin Elmer), and luciferase activity quantified as 
photons/s. Each sample was run in duplicate.  
StL construct popout 
Cells containing a popout StL construct were split to 105 cells/mL in Schneider’s medium 
lacking selection and GFP expression monitored by flow cytometry. Parallel cultures under drug 
selection were used as a comparison. When a GFP-negative population appeared in the cultures 
lacking selection, clonal lines were obtained by single-cell sorting. 
Log-phase cells were resuspended in phosphate-buffered saline, passed through a 
CellTrics 50 µm filter (Partec) to remove clumps, and single cells were recovered on the basis of 
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GFP expression using a Beckman Coulter MoFlo cell sorter. Individual cells were placed into 
wells of a 96-well plate containing 200 µL of Schneider’s Insect Medium containing no selective 
antibiotic (GFP-negative cells) or 10 µg/mL hygromycin B (GFP-positive cells) and incubated at 
27 ℃ for 10 days before parasite growth was scored. Wells were expanded to 5 mL with or 
without antibiotic, as appropriate, and passaged thusly. 
RNA preparation and cDNA synthesis 
2.5-3x108 cells were pelleted and dissolved in 1mL Trizol reagent (Ambion, Thermo 
Fisher Scientific). 250 µL of dissolved cells were used to isolate total RNA with the RNA 
miniprep kit (Zymo Research). RNAs were digested with 20 Units of DNaseI (Ambion, Thermo 
Fisher Scientific) in a 200 µL reaction using the supplied buffer and purified using the RNA 
Clean & Concentrator kit (Zymo Research) and eluted in 50 µL of nuclease-free water.  
cDNA was synthesized by random hexamer-primed reverse transcription using the 
Superscript III First-Strand Synthesis kit (Thermo Fisher Scientific) in 20 µL reactions 
containing 0.25 µg RNA. Control reactions contained an equal amount of RNA but omitted the 
reverse transcriptase enzyme. 
RT-PCR and qPCR 
RT-PCR reactions were performed using 1 µL of ten-fold diluted cDNA in 25 µL 
reactions to amplify 94 bp of LRV1 or ~400 bp of beta-tubulin sequence. Primer sequences are 
located in Table 1. PCR products were run on 2% agarose gels and visualized using ethidium 
bromide. 
qPCR reactions were performed using 5 µL of ten-fold diluted cDNA in a 20 µL reaction 
containing 10 µL of 2x Power SYBR reaction mix (Applied Biosystems, Thermo Fisher 
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Scientific) and primers to a concentration of 0.2 µM each in MicroAmp Optical 96-well plates 
(Thermo Fisher Scientific). Primer sequences are located in Table 1. Reactions were run on the 
ABI PRISM 7000 Sequence Detection System. PCR amplifications were as follows: 50 °C for 2 
min and 95 °C for 10 min followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. PCR 
products were confirmed to be specific by melt curve analysis. +RT reactions were performed in 
triplicate and –RT control reactions in duplicate. 
On each plate, 5-fold dilution series were performed for each primer set to calculate 
primer efficiencies, and relative RNA level calculated using the Pfaffl method (14) using 
amplification of KMP-11 as an internal control. The data are averages and standard deviations of 
2-3 independent clones, and significance was calculated by ANOVA followed by the Tukey post 
hoc test. 
RNA sequencing and bioinformatics analysis 
RiboZero RNA libraries were generated from total RNA as described (15). Briefly, 
sample integrity was assessed by Agilent Bioanalyzer 2100 (Santa Clara, CA). rRNA was 
depleted from 1 mg input RNA with the Ribo-Zero™ rRNA Removal Kit (“RiboZero”) from 
EpiCentre (an Illumina company, Madison, WI). RiboZero-depleted RNA was chemically 
fragmented to generate fragments ranging from 200-600 nt in length, then made into cDNA with 
Superscript III (Life Technologies, Thermo Fisher) and random hexamers followed by a second 
strand reaction. cDNA was then end-repaired, A-tailed, and standard Illumina adapters were 
ligated on. Libraries were amplified with primers to incorporate a unique index to each sample. 
Equal masses of each library were pooled and sequenced on an Illumina HiSeq2500 platform, 
with 2 × 100 base pair paired end reads (Illumina Inc., San Diego, CA). 
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Data were analyzed using CLC Genomics v9.5.3. Briefly, 5’ and 3’ adaptors were 
removed and trimmed reads were mapped to annotated genes and transposable elements from the 
L. guyanensis M4147 genome, as well as to LRV1 genes (KX808487) using default RNA-Seq 
parameters. Reads mapping to multiple locations were aligned randomly. 
S1 nuclease digestion 
15 µg of total RNA was digested with S1 nuclease in a 20 µL reaction containing 1x 
reaction buffer, 0.6M NaCl, and enzyme at a final dilution of 1:400. Samples were heated to 65 
℃ for 5 min prior to addition of the enzyme, then incubated at 37 ℃ for one hour. 
Statement on Institutional and Licensing Committee Approval of Animal Experiments 
Animal handling and experiments were carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals (16) of the US 
National Institutes of Health. Animal studies were approved by the Animal Studies Committee at 
Washington University (protocol 20090086) in accordance with the Office of Laboratory Animal 
Welfare’s guidelines and the Association for Assessment and Accreditation of Laboratory 
Animal Care International. 
Mouse infections 
Female C57/B6 mice were obtained from Jackson Laboratories. Parasites were grown to 
day 2 stationary phase and collected at 1x106 cells/50 μL DMEM. Mice were injected 
subcutaneously in the left hind footpad with 1x106 parasites using a 30 gauge needle. Luciferase 
activity was monitored weekly by imaging using the IVIS (Perkin Elmer). Briefly, mice were 
injected intra-peritoneally with 150 mg/kg D-luciferin, potassium salt (Gold Biotechnology) 10 
minutes before imaging. Five minutes before imaging they were anaesthetized with isofluorane, 
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and anesthesia was continued throughout the procedure. Emitted photons were quantified using 
Living Image v2.60.1 software (Perkin Elmer). Lesion size was measured weekly using calipers. 
IFN-γ-/- mice were monitored for the development of metastases, and any located on the 
uninjected foot were measured using calipers. 
E5 – Table Legends 
Table E1: RT-PCR and qPCR primer sequences. 
E6 – Figure Legends 
Figure E1: Integration of a CapsidStL or RDRPStL construct into L. braziliensis LEM2780 
previously transfected with a LUCSR construct results in loss of LRV1.  
Transfectants (blue, CapsidStL; green, RDRPStL) were evaluated by flow cytometry 
using an anti-capsid antibody. WT L. braziliensis LEM2780 (red) and L. braziliensis 
M2903 (black) were used as positive and negative controls, respectively. 
Figure E2: Integration of a second StL construct impairs knockdown of luciferase.  
The luciferase activity of WT, untransfected luciferase-expressing and LUCSR, and 
luciferase-expressing and LUCSR parasites carrying a second StL were measured. 
 A) Parasites transfected with an LRV1-targeting StL Averages and standard deviations 
are of six to seven clones of the LRV1StL lines.  
B) Parasites transfected with a GFP-targeting StL. Averages and standard deviations are 
of three to five clones. 
Figure E3: LRV1 is eliminated by transfection of CapsidStL(A)-GFP+(B) into L. guyanensis.  
cDNA from two clones of each of the indicated lines was used as template for the PCR 
amplification of a fragment of LRV1 (top) or β-tubulin (bottom). 
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Figure E4: The levels of RNAseq and sRNAseq reads mapping to TEs is altered in 
SSU:CapsidStL(A)-GFP+(B) parasites.  
A) RNA was sequenced for the indicated lines and mapped to the L. guyanensis M4147 
and LRV1 genomes. The levels of housekeeping genes were not affected by the presence 
of the StL construct, but levels of TATE elements increased.  
B) Reads mapping to LRV1 mapped to the entire viral genome in SSU:GFP+(B) 
parasites, but only to the stem region in SSU:CapsidStL(A)-GFP+(B) parasites.  
C) sRNAs were sequenced for the indicated lines and mapped to the L. guyanensis 
M4147 and LRV1 genomes. Reads mapping to SLACS and TATE fell 10-fold in 
SSU:CapsidStL(A)-GFP+(B) parasites. Levels of LRV1-mapping reads increased 20-
fold in SSU:CapsidStL(A)-GFP+(B) parasites and fell 400-fold in PO:CapsidStL(A)-
GFP+(B) parasites compared to SSU:GFP+(B).  
D) sRNA reads mapping to LRV1 mapped to the entire viral genome in SSU:GFP+(B) 
parasites, but only to the stem region in SSU:CapsidStL(A)-GFP+(B) parasites. 
Figure E5: Lines with an integrated CapsidStL(A)-GFP+(B) construct have elevated levels of 
TATE RNA.  
cDNA from the indicated lines was used as template in qPCR reactions with SLACS- and 
TATE-specific primers. Averages and standard deviations are of two clones of 
SSU:GFP+(B) and three clones each of SSU:CapsidStL(A)-GFP+(B) and 
PO:CapsidStL(A)-GFP+(B).  ** p<0.01; all other comparisons NS. 
Figure E6: Lines with an integrated StL construct accumulate stable dsRNA.  
15 µg of total RNA from two clones of each of the indicated lines was digested with S1 
nuclease, the reaction run on a 1.8% agarose gel and stained with ethidium bromide. 
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LRV1 genome is indicated by a white arrowhead; stable StL-dependent dsRNA is 
indicated by a black arrow. 
Figure E7: Tests of the effect of StL constructs on parasite virulence were inconclusive.  
A) Luciferase activity of lines containing integrated GFP+(B) or CapsidStL(A)-
GFP+(B) constructs.  
B) Lesion size of lines containing integrated GFP+(B) or CapsidStL(A)-GFP+(B) 
constructs.  
C) Luciferase activity of lines containing popped out GFP+(B) or CapsidStL(A)-
GFP+(B) constructs.  
D) Lesion size of lines containing popped out GFP+(B) or CapsidStL(A)-GFP+(B) 
constructs. Plotted are the geometric means and standard deviations of luciferase activity 
and the arithmetic means and standard deviations of lesion size for two independent 
experiments. Significance was determined by two-way ANOVA. 
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Table E1 
Target Primer 
ID 
Orientation Sequence 
LRV1 6423 Forward 5’-GGTAATATCACGCAGTGTAAGC 
6424 Reverse 5’-GACACCACCTCTAAGACACG 
Β-tubulin 5023 Forward 5’-AACGCTATATAAGTATCAGTTTCTGTACTTTA 
2110 Reverse 5’-GACAGATCTCATCAAGCACGGAGTCGATCAGC 
SLACS 7900 Forward 5’- GTACATACGCAAACGACTCCG 
7901 Reverse 5’-GGTGACATTCCGAATCTTCG 
TATE 7906 Forward 5’- ACCTGCCGCTCTACTCGAC 
7907 Reverse 5’- GGCACCGACTCCTTCATG 
KMP-11 5023 Forward 5’-AACGCTATATAAGTATCAGTTTCTGTACTTTA 
7412 Reverse 5’- GGTGACGATGCGGGTACC 
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Preface 
The experiments described here were conducted as part of a rotation project and will be 
incorporated into a future larger publication. I performed experiments designed by Stephen M 
Beverley and Lon-Fye Lye. L-FL assisted in data analysis. I wrote the first draft of this 
Appendix, and the final version here incorporates comments by SMB. 
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F1 – Introduction  
The flagellar pocket is the sole site of endo- and exocytosis in trypanosomatids such as 
Leishmania (1, 2), and components of sensory pathways such cyclic nucleotide (3, 4) and 
calcium signaling (5) are localized to the flagellum. Additionally, the axoneme of the amastigote 
flagellum exhibits a microtubule architecture more similar a pattern characteristic of sensory cilia 
than of the promastigote flagellum and other motile flagella (6). Finally, Gluenz et al. observed 
that the L. mexicana amastigote flagellar tip was frequently in close contact with the 
parasitophorous vacuole membrane (6). Because of these observations, it has been hypothesized 
that the flagellum of Leishmania could serve an important role in host-parasite interactions. 
The Leishmania flagellum is maintained by the collective action of Intraflagelar 
Transport (IFT), the mechanism by which flagellar components are shuttled from the cell body to 
the tip of the flagellum (anterograde) and back (retrograde). To investigate the role of the 
Leishmania flagellum in parasite biology and virulence, we attempted to disrupt its assembly by 
knocking down IFT in in a clone of L. braziliensis M2903 adapted for in vitro differentiation into 
the amastigote life cycle stage. Inducible RNAi knockdown of IFT in T. brucei disrupted 
flagellum formation, reduced cell body size, and induced cell cycle arrest (7). There are 
structural differences between Leishmania and Trypanosoma flagella, however, that decrease the 
likelihood that IFT disruption in Leishmania will be lethal. The Trypanosoma flagellum is 
attached along the length of the cell body, whereas the Leishmania flagellum protrudes freely 
from the anterior tip (8). The Trypanosoma flagellum plays crucial roles in defining cell polarity 
and directing organelle segregation and cell size during mitosis (9). While there is evidence that 
the mitochondrion-kinetoplast-basal body-flagellum complex in Leishmania also plays a role in 
directing organelle segregation(10), the different morphology of Leishmania during cell division 
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makes it unlikely that the flagellum plays a crucial role in directing cell division (10). Further, 
there appears to be some species-specific variation among Leishmania in the timing of flagellar 
replication during cell division (10–12), lessening the likelihood that the flagellum serves a 
crucial role in cell division. 
In our experiments, RNAi knockdown of IFT genes in L. braziliensis failed to generate 
viable mutants, whereas transfection of the same knockdown constructs in a Δago1 line yielded 
many viable transfectants. Later work in the lab pursued this project further, and the combined 
results paint a more complete picture of the role of IFT and the parasite flagellum in biology and 
virulence. 
F2 – Results  
We transfected constructs into L. braziliensis strain M2903 (SA2) to knock down four 
different IFT genes: IFT88, IFT122, IFT140, and IFT172. Two genes, IFT88 and IFT172, 
belonged to the anterograde pathway, moving cargo from the base of the flagellum to the tip, 
while the other two, IFT122 and IFT140, belonged to the retrograde pathway, returning cargo 
from the tip of the flagellum to the cell body. In parallel, we transfected the following positive 
controls: 1) a construct that enabled luciferase expression (“LUC”); a construct that 
simultaneously expressed and knocked down luciferase (“LUCSR”); and constructs that knocked 
down the paraflagellar rod proteins (“PFR1StL” and “PFR2StL”), which are known to be not 
essential for viability (13, 14). Positive control transfections yielded viable transfectants (Table 
1) with the expected phenotypes. Namely, LUC-transfected cells had high luciferase activity, 
while LUCSR-transfected cells had activity levels 130-fold lower (Figure 1). PFR1StL- and 
PFR2StL-transfected cells were defective in swimming (data not shown). In contrast, no colonies 
grew for cells transfected with any IFT StL construct (Table 1). 
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To confirm that this inability to recover transfectants was RNAi-dependent, we 
transfected IFT122StL, IFT140StL, and IFT172StL, as well as control LUC and LUCSR 
constructs, into an Argonaute1 knockout mutant (Δago1) of L. braziliensis M2903. Viable 
transfectants were recovered for each construct (Table 2). 
F3 – Discussion  
While positive control transfections into L. braziliensis M2903 (SA2) were successful, 
we were unable to recover viable transfectants after knockdown of IFT genes. This suggested 
that parasites were not viable in the absence of these gene products. This was not entirely 
unexpected, as IFT knockdown cells in T. brucei are likewise inviable. The essentiality of these 
genes was confirmed by transfection of the IFT knockdown constructs into Δago1 cells, which 
have a non-functional RNAi pathway, and therefore are insensitive to StL constructs. In this cell 
line, we easily obtained transfectants containing the IFTStL constructs, suggesting that the 
lethality seen in the SA2 line required an active RNAi pathway, and therefore was due to 
knockdown. Because knockdown of four separate genes gave an identical phenotype, this was 
unlikely to be due to off-target effects, but rather to loss of IFT, specifically.  
Later research in the lab, however, showed this not to be the case. Tiffanie Fowlkes 
demonstrated in her dissertation that IFT140 could be knocked out in L. donovani parasites if an 
ectopic copy was first provided episomally. After replacement of both chromosomal copies with 
drug resistance cassettes, the antibiotic maintaining selection of the episome was removed, 
allowing it to be segregated out. Using this technique, she showed that Δift140 promastigote cells 
were viable, lacked flagella, and accumulated vesicles in the flagellar pocket. In addition, in vitro 
differentiation of Δift140 cells was impaired and the lines were avirulent in a mouse model of 
visceral leishmaniasis (15). An analogous essentiality test for RNAi experiments would require 
252 
 
temporary ectopic expression of the IFT target, recoded to be resistant to knockdown by the StL 
construct, such as from a popout construct (see Chapter 4). After integration of the IFTStL 
construct, the RNAi-resistant ectopic copy could be removed, and if the gene is essential, no 
viable cells would be obtained; if not essential, IFT knockdown cells would be obtained. 
Further, Lon-Fye (George) Lye in the lab has been able to recover parasites with some 
IFT genes knocked down in L. braziliensis by using shorter “stems” in the StL constructs, which 
reduces knockdown efficiency (unpublished data). This approach yielded mutants with shortened 
flagella and vesicle accumulation, similar to the Δift140 mutant in L. donovani. 
While somewhat unusual, it is not unprecedented for a gene at first to appear essential in 
Leishmania, only to prove otherwise using a “gentler” approach such as an episome sort. Efforts 
to knock out the hexose transporter GT2 from L. mexicana required the transient overexpression 
of a suppressor gene, but after Δgt2 mutants were obtained, the suppressor was no longer 
required for viability(16). Similarly, work in our lab investigating LPG4A failed to yield viable 
mutants without the expression of the gene from an episome; after knockout of chromosomal 
copies of the gene, episomal expression was no longer required for viability (Guo and Beverley, 
unpublished data).  
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F5 – Materials and Methods 
Parasites and in vitro culture 
A variant of L. braziliensis strain M2903 adapted to differentiate in culture was obtained 
from the laboratory of S.C. Alfieri(17) and plated to generate clonal lines; clone SA2 was used in 
the following experiments. The Δago1 line of L. braziliensis was described previously(18). 
Parasites were grown in fresh Schneider’s Insect Medium supplemented with 10% heat-
inactivated fetal bovine serum, 100 μM adenine, 10 μg/mL hemin, 2 μg/mL biopterin, 2 mM L-
glutamine, 500 units/ml penicillin and 50 μg/mL streptomycin, and selective drugs as indicated 
below. 
Stem-loop constructs 
Stem-loop constructs were constructed as described previously (19). Specifically, regions 
of each IFT gene to be knocked down were amplified by PCR using the primers listed in Table 3 
to ultimately generate B6613 pIR2HYG-IFT88StL(A), B6664 pIR2SAT-IFT122StL(A), B6666 
pIR2SAT-IFT140StL(A), and B6674 pIR2HYG-IFT172StL(A). B6386 pIR2SAT-LUCStL(A)-
LUC(B), B6282 pIR1SAT-PFR2StL(A), and B6294 pIR1SAT-PFR1StL(A) were described 
previously(14).  
Transfection 
Stable transfections were performed as previously described(14, 20). After overnight 
recovery, ⅙ of the transfected cells were spread per plate on semisolid media with 100 μg/mL 
nourseothricin or 30 µg/mL hygromycin B. Transfectants were grown to stationary phase in 1 
mL media without selection and passaged thereafter in 10 mL media with 100 µg/mL 
nourseothricin or 30 µg/mL hygromycin B. 
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Luciferase activity assay 
106 log phase cells in 200 μL of Schneider’s Medium were added to a 96-well plate 
(Black plate, Corning Incorporated, NY, U.S.A.). D-luciferin (Biosynth AG) was added to a final 
concentration of 150 μg/mL and plates were incubated for 1 min. Plates were imaged using an In 
Vivo Imaging System (IVIS) photoimager (Perkin Elmer), and luciferase activity quantified as 
photons/s. Each sample was run in duplicate. One clone of WT, three clones of LUC-transfected, 
and eight clones of LUCSR-transfected cells were evaluated. 
F6 – Table Legends 
Table F1: Colonies per µg of DNA obtained from transfection of StL constructs into WT L. 
braziliensis strain M2903 (SA2). 
Also indicated are the number of plates scored, each of which represents 1/6 the total 
number of cells from a transfection. The IFT172StL transfection was attempted twice. 
Table F2: Colonies per µg of DNA obtained from transfection of StL constructs into Δago1 L. 
braziliensis M2903.  
Indicated in parentheses are the number of plates scored, each of which represents 1/6 the 
total number of cells from a transfection. 
Table F3: Primers used in the cloning of StL constructs for the knockdown of IFT genes.  
XbaI site underlined. 
F7 – Figure Legends 
Figure F1: Cells transfected with the positive control LUC and LUCSR constructs displayed the 
expected luciferase activity.  
Error bars are standard deviation. 
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Table F1 
Construct Colonies per µg DNA 
LUC 54.6 
LUCSR 25.9 
PFR2StL 3.5 
PFR1StL 3.9 
IFT122StL 0 
IFT140StL 0 
IFT88StL 0 
IFT172StL 0 
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Table F2 
Construct Colonies per µg DNA 
LUC 36.0 
LUCSR 24.3 
IFT172StL 28.9 
IFT140StL 26.5 
IFT122StL 46.0 
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Table F3 
Target Primer ID Sequence 
IFT88 B4177 5’ – CGCTAGTCTAGATCGTCGAGCAGATCAATGTC – 3’ 
B4178 5’ – CGCTAGTCTAGAGTAGATGGCCTCCACGTTGT – 3’ 
IFT122 B4181 5’ – CGCTAGTCTAGATTCACCATTTTGGAGAAGGC – 3’ 
B4182 5’ – CGCTAGTCTAGATTCAAAATGTCTGCTGACGC – 3’ 
IFT140 B4179 5’ – CGCTAGTCTAGATTGTTTTCGAGACGATGCAG – 3’ 
B4180 5’ – CGCTAGTCTAGACTTCAGTCCCTCAAAGTCGC – 3’ 
IFT172 B4175 5’ – CGCTAGTCTAGAGCGCCATCAATATGTACGTG – 3’ 
B4176 5’ – CGCTAGTCTAGACACCCAGTTGTTCACCTCCT – 3’ 
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Figure F1 
 
